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Abstract 
 
Adverse drug reactions (ADRs) are common in children. They contribute significantly 
to patient morbidity, mortality and hospitalisation costs. There is limited data on 
the avoidability of ADRs in children and wide variation in avoidability rates has been 
reported. There is currently no standardised method for determining avoidability 
and many of the established tools are not suitable or designed for use in 
paediatrics. The aim of this thesis was to develop and test a new avoidability 
assessment tool that is suitable for use in paediatrics. The stimulus for this work 
was difficulty using other tools including the one developed by Hallas et al. (1990). 
Ideally the new tool should also be applicable and generalisable to a variety of other 
settings. A secondary objective was to identify potential strategies for clinical 
practice that might reduce the incidence of ADRs. Three key themes for avoidability 
have been established through a review of existing literature these are: 
inappropriate or suboptimal prescribing, inadequate monitoring and inadequate 
patient or parent education. 
 
The development of the LAAT was a multistep process which involved a 
multidisciplinary team (MDT). Individual and group assessments were conducted 
and qualitative and quantitative analyses of the assessments were carried out. The 
LAAT has undergone validity and reliability testing for groups and individuals. The 
newly validated LAAT was used to assess 249 ADR case reports from a prospective 
paediatric admissions study by one individual and compared to existing avoidability 
assessments conducted using the Hallas scale. Assessment of these ADR case 
reports using the LAAT found that 19.3% were either possibly or definitely 
avoidable. This was similar to results using the Hallas scale where 22% of the 
reactions were either possibly or definitely avoidable. Overall percentage exact 
agreement (%EA) between LAAT and the Hallas scale was 90%; when 
subcategorised into oncology and non-oncology cases the %EA was found to be 94.2 
and 86% respectively. The kappa score between LAAT and Hallas scale assessments 
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was 0.71 (95% CI 0.60 - 0.82) for all cases, 0.54 (95% CI 0.40 - 0.68) for the oncology 
cases and 0.73 (95% CI 0.58 - 0.88) for the non-oncology cases. The most common 
avoidability theme detected in this study was inappropriate or suboptimal 
prescribing. 
 
Assessing the avoidability of ADRs is a complex process which requires taking into 
account a number of factors. Strategies to avoid ADRs can be applied at different 
levels including: patient, ward, departmental institutional, professional, and 
national. A common theme that emerged from this work was the lack of available 
guidelines that could be used to assess whether ADRs were avoidable. Where 
guidelines were available few contained information about ADRs or their 
prevention. The majority of clinicians relied on their experience and tacit knowledge 
rather than on guidelines. Some of the ADRs categorised as either possibly or 
definitely avoidable may have been avoidable with improved prescribing, more 
frequent monitoring or improved education of patients and/or parents. Other 
possible prevention strategies include creating an awareness of ADRs in general and 
their prevention throughout a clinician’s training. Improved communication and 
documentation in patient records is a simple but effective method of ADR 
reduction.  
 
In summary, we have designed a novel avoidability assessment tool, developed by a 
multidisciplinary team, and have  shown that the new tool is comparable to an 
existing avoidability tool, can be used by individuals and most importantly is 
suitable for use in paediatrics or other areas where clinical conditions extend 
beyond the expertise of individuals. The LAAT refers to guidelines and patient 
history rather than to abstract concepts such as ‘present-day knowledge of good 
medical practice’ and ‘effort exceeding the obligatory demands’ as per Hallas. 
Further work to identify potentially avoidable ADRs and strategies to prevent them 
is needed. 
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Chapter 1 Introduction 
1.1 Background 
 
Adverse drug reactions (ADRs) contribute significantly to patient morbidity, 
mortality and hospitalisation costs. ADRs are a major patient safety issue and they 
can have significant consequences both for the patient and health care system 
(Lövborg et al. 2012). A recent systematic review of ADRs in children reported 
incidences of ADRs in hospitalised children ranging from 0.6 to 16.8% among studies 
(Smyth et al. 2012). This is similar to the incidence rate in hospitalised adults of 
14.7% (Davies et al. 2009). The annual cost of drug related morbidity and mortality 
has been estimated in the United States at more than $136 billion and ADRs 
contribute significantly to these costs (McDonnell et al. 2002). Davies et al. (2009) 
estimated that in the United Kingdom (UK) ADRs in adults cost the National Health 
Service (NHS) in excess of £637 million a year; this figure represents an 
extrapolation from a single NHS hospital to the NHS as a whole. Children are 
considered to be particularly susceptible to ADRs (Le et al. 2006, Gallagher et al. 
2012).  
 
Medicines are commonly prescribed to children, but many have limited data 
available on their safety and efficacy in children. Prior to the Paediatric Regulation 
coming into effect a survey conducted by Conroy et al. (2000) in five European 
hospitals showed that almost half of the medicines prescribed (46%) for use in 
children had not been tested for use in this specific age group. Over half of the 
children (67%) in the study received a prescription for an unlicensed or off-label 
medicine during their inpatient stay (Conroy et al. 2000). The prescribing habits in 
the five centres varied; but analgesics and bronchodilators were among the top five 
most frequently prescribed off-label medicines in four out of five centres (Conroy et 
al. 2000). In 2006 roughly 75% of the 317 centrally licensed medicines were relevant 
for children but only half (34%) had a paediatric indication (European Medicines 
Agency 2012). As a result medicines are often prescribed to children off-label 
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and/or unlicensed. The reported incidence of off-label and unlicensed use of 
medicines in children ranges from 36 to 100% in paediatric wards (Cuzzolin, Atzei & 
Fanos 2006). The use of unlicensed and off-label medicines is common, as 
traditionally clinical trials have not been conducted in children. Some studies have 
reported the contribution of unlicensed or off-label medicines in the development 
of ADRs. According to Cuzzolin, Atzei and Fanos (2006) the percentage of off-label 
or unlicensed medicines involved in ADRs ranged from 23 to 60%.  
 
There is a lack of safety and efficacy data on many medicines used in paediatrics 
and prescribing in children is often based on extrapolation from clinical trials in 
adults. The information available to clinicians regarding unlicensed or off-label 
medicines may not always be as detailed as when prescribing a medicine that is 
licensed for an approved indication (Langerova, Vrtal & Urbanek 2014). Due to the 
lack of studies designed to evaluate drug dosing in children, clinicians are often at a 
disadvantage to make informed therapeutic decisions potentially placing patients at 
increased risk for adverse drug effects (Kearns 2000). Children are a heterogeneous 
group and have complex needs. Clinicians may have to take extra steps to consider 
the potential risks and the potential benefits of treatment.  
 
New legislations were introduced in the European Union (EU) and United States 
(US) to improve research into paediatric medicines. In 1997 the US initiated 
legislative changes to encourage more clinical trials in children; the Food and Drug 
Administration Modernisation Act (FDAMA) was passed (FDA U.S Food and Drug 
Administration 1997). The FDAMA offered a financial incentive to pharmaceutical 
companies, an additional six months of market exclusivity if they conducted 
paediatric trials in line with a Food and Drug Administration (FDA) request. In 2002 
the Best Pharmaceuticals for Children Act (BPCA) was implemented. It extended the 
provision from the 1997 FDAMA, offering an additional 6 months of patent 
exclusivity for medicines tested for paediatric use. In 2003 the Paediatric Research 
Equity Act (PREA) was enacted. The introduction of PREA required paediatric 
assessments of new drug and biologic licensing applications for all new active 
ingredients (Patrick E. Clarke, Office of Communications 2011). Under PREA the FDA 
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can request paediatric studies of a drug submitted in a new drug application if the 
product is likely to be used in a substantial number of paediatric patients, or if the 
product would provide a meaningful benefit in the paediatric population over 
existing treatments. This does not delay the availability of drugs for adults.  In 2007 
the Paediatric Regulation came into effect in the EU. It aimed to improve the 
availability of medicines for children, to ensure medicines were of high quality, 
researched and authorised for use in children without subjecting children to 
unnecessary clinical trials or delaying the approval process of medicines for use in 
children (European Medicines Agency 2012). Following this the Paediatric 
Committee (PDCO) was established to assess paediatric investigation plans (PIPs), 
waivers and deferrals (European Medicines Agency 2012). The Paediatric Regulation 
also introduced a Paediatric-Use Marketing Authorisation (PUMA) for medicines 
exclusively used in paediatrics which are not protected by a patent or a 
supplementary protection certificate (SPC) (European Medicines Agency 2011b). 
These legislative changes have resulted in an increase in the number of paediatric 
trials (Joseph, Craig & Caldwell 2015). A report to the European Commission (EC) 
published in 2012 by the EMA outlined the experience gained as a result of the 
Paediatric Regulation (European Medicines Agency 2012). By 2011, the European 
Medicines Agency (EMA) and the PDCO had agreed more than 600 PIPs and the 
number of clinical trials in children has increased to approximately 10%. Also, as a 
result of the Paediatric Regulation more information on the use of medicines in 
children has resulted in updates to Summaries of Product Characteristics (SmPCs) 
(European Medicines Agency 2013). Despite these advances ADRs in children 
remain under-studied. 
 
The Adverse Drug Reactions in Children (ADRIC) programme was funded by the 
National Institute of Health Research (NIHR) to conduct research into ADRs in 
children. It was a five year programme which consisted of a series of studies 
investigating ADRs including an admissions study and an inpatient study. The ADRIC 
admissions study was a prospective observational study carried out over a one year 
period which examined ADRs causing admission to hospital (Gallagher et al. 2012). 
The ADRIC inpatient study was a prospective observational cohort study which was 
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carried out over a one year period and examined ADRs occurring in hospital 
(Thiesen et al. 2013). A series of qualitative studies described the experiences of 
parents whose children had experienced an ADR, clinicians’ experience of ADRs and 
developing communication strategies and information leaflets about ADRs for 
parents (Arnott et al. 2012, Smyth et al. 2014). A systematic review was also 
conducted. During the course of the programme, it was found that none of the 
commonly used tools to assess causality and avoidability of ADRs were sufficiently 
reliable to be used in these studies (the reliability issues of commonly used causality 
and avoidability tools are discussed in more detail later in this chapter in Section 1.8 
(Evaluation of adverse drug reactions). This led to the development and validation 
of new assessment tools - the Liverpool causality assessment tool (LCAT) (Gallagher 
et al. 2011b) and the Liverpool avoidability assessment tool (LAAT) (Bracken et al. 
2014a). 
 
This chapter will firstly look at how ADRs are defined and classified, the incidence of 
ADRs in children, risk factors and characterisation. It will go on to focus on the 
avoidability of ADRs; the methodology of assessing avoidability and finally, it will 
review previous studies which have examined the avoidability of ADRs in children. 
 
1.1 Definitions 
 
There is an issue regarding terminology used in the area of pharmacovigilance and 
this can make the comparison of studies difficult (Hakkarainen et al. 2012a). 
Aronson and Ferner (2005) produced a paper on the terminology used in drug 
safety in an attempt to clarify this complex area. Consistent terminology is essential. 
A clear definition of adverse drug reactions is needed so that data on ADRs can be 
consistently reported and reliably interpreted.  
 
There are a number of definitions of ADRs. The two definitions below have been 
widely used in ADR studies. The World Health Organisation (WHO) definition (1972) 
of an adverse drug reaction has been in existence for over 40 years: 
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‘A response to a drug that is noxious and unintended and occurs at doses normally 
used in man for the prophylaxis, diagnosis or therapy of disease, or for modification 
of physiological function’. 
 
This definition is widely accepted. However, the use of the word ‘noxious’ has been 
criticised in the past for being vague. It raises the question; does it include all 
adverse reactions irrespective of how minor they are? In which case it may lead to 
the reporting of large numbers of common minor ADRs to the regulatory bodies 
(Edwards, Aronson 2000) 
 
 
This led to Edwards and Aronson (2000) proposing their own definition of an ADR: 
 
‘An appreciably harmful or unpleasant reaction, resulting from an intervention 
related to the use of a medicinal product, which predicts hazard from future 
administration and warrants prevention or specific treatment, or alteration of the 
dosage regimen or withdrawal of the product’.  
 
The two definitions above do not include responses or reactions resulting from drug 
errors or from poisoning (deliberate or accidental). In 2010 the European 
Parliament and Council of Ministers adopted a new directive on the community 
code relating to medicinal products for human use. The definition of the term 
‘adverse reaction’ was updated to include noxious and unintended effects resulting 
from medication errors (MEs) and use outside the marketing authorisation (MA), 
including misuse and abuse of the medicinal product in addition to the effects 
resulting from the authorised use of a medicine (The European Parliament and the 
Council of the European Union 2010). New pharmacovigilance legislation came into 
effect in July 2012 (The European Parliament and the Council of the European Union 
2012).  
 
EU definition of ADR 
Definition of Adverse Reaction Directive 2001/83/EC - Article 1(11)  
Prior to July 2012:  ‘A response to a medicinal product which is noxious and 
unintended and which occurs at doses normally used in man for the prophylaxis, 
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diagnosis or therapy of disease or for the restoration, correction or modification of 
physiological function’.  
After July 2012:  ‘A response to a medicinal product which is noxious and  
unintended ‘. 
 
Following the EU Directive 2010/84/EU1 that came into force in July 2012, the 
MHRA define the term ADR as,  
‘A response to a medicinal product that is noxious and unintended effects resulting 
not only from the authorised use of a medicinal product at normal doses, but also 
from medication errors and uses outside the terms of the marketing authorisation, 
including the misuse, off-label use and abuse of the medicinal product.’ 
 
The definitions and terms used depend on the country of origin of the article. There 
is overlap between the terms. For example all ADRs are adverse events (AEs), but 
not all AEs are ADRs. An adverse event is any undesirable event experienced by a 
patient whilst taking a medicine, regardless of whether or not the medicine is 
suspected to be related to the event (Aronson, Ferner 2005). Some studies have 
included ADRs alongside drug errors under the term ‘adverse drug event’ (Bates et 
al. 1999). The revised definitions of ADRs outlined above now also include drug 
errors. 
 
An adverse drug event (ADE) is defined as ‘an injury resulting from medical 
intervention related to a drug’ (Bates DW, Cullen DJ, Laird N,et al 1995). The 
definition was intended to encompass harms that arise from medication errors in 
addition to ADRs (Aronson 2011). 
 
The WHO define an adverse drug event as ‘Any untoward medical occurrence that 
may present during treatment with a medicine but which does not necessarily have 
a causal relationship with this treatment’ (World Health Organisation 2002).  
 
Aronson and Ferner (2005) stated that the term ‘adverse drug event’ could be 
confusing depending on the usage of it. The term ADE includes harms arising from 
medication errors and ADRs. If the term were confined to this context, there would 
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be no problem, the problems arise from its wider use. They also criticised the above 
definition for being unclear particularly the use of the words “injury” and “medical” 
(Aronson, Ferner 2005).  
 
The Edwards and Aronson (2000) definition of an ADR is the one used in this thesis. 
It excludes prescribing errors, administration errors and intentional drug overdoses. 
The use of the word ‘appreciably’ rules out trivial effects but includes clinically 
relevant ADRs that the patient detects (Edwards, Aronson 2000). This definition has 
been used in several studies since its publication; it was the definition used in the 
ADRIC programme and is the one used in this thesis. 
 
1.3 Adverse drug reaction classification by mechanism 
 
ADRs were formally classified as type A and type B by Rawlins and Thompson 
(1977). Type A reactions - dose dependent and predictable from the known 
pharmacology of the drug; and type B reactions - not dose dependent and 
unpredictable in nature. This classification is simple and has been widely used in the 
literature. However, not all ADRs can be classified using this system. It has been 
gradually extended to include type C - dose and time-related, type D - time-related, 
type E - withdrawal and type F - unexpected failure of therapy. These changes have 
eliminated some of the issues with the system but have also introduced others 
(Aronson, Ferner 2003, Aronson, Ferner 2005). They suggested there is overlap 
between some of the categories. They gave the example of category F (failure) 
which is an outcome rather than a mechanistic category and could therefore arise 
from reactions in some of the other categories. They also criticised the fact that 
dose relatedness had not been considered for the additional categories, whilst Type 
A and Type B had been classified as dose related or not dose related (Aronson, 
Ferner 2005). 
 
Aronson and Ferner (2003) proposed an alternative classification system Dose-time-
susceptibility (DoTS): which is based on dose-relatedness, timing and patient 
susceptibility. DoTS is a ‘three dimensional approach’ that considers not only the 
properties of the medicine implicated in the ADR but also the characteristics of the 
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reaction and of the individual who experienced the reaction. They describe how 
dose-relatedness is actually relevant to all reactions inclusive of immunological 
reactions although it is traditionally thought of in the context of non-immunological 
reactions. They give examples of dose-dependent immunological reactions including 
the immunogenic response to hepatitis B vaccine and type IV hypersensitivity skin 
reactions. They suggest dividing ADRs into those that occur at supratherapeutic 
doses (toxic effects), at standard therapeutic doses (collateral effects) or at 
subtherapeutic doses in susceptible patients (hypersusceptibility reactions). The 
concept of timing takes into consideration when the reaction becomes apparent in 
relation to when the dose was given and a reaction can be classified as either rapid, 
first dose, early, intermediate, late or delayed. Finally, the risk of an ADR differs 
among the population. Susceptibility specifically relates to the patient and is 
dependent on a number of factors including; genetic variation, age, sex, 
physiological variation, exogenous factors, and disease (Aronson and Ferner, 2003). 
This system allows an ADR to be profiled and can perhaps improve drug 
development and patient care (Cox 2008, Aronson, Ferner 2003).  
 
Ferner and Aronson (2010a) proposed a mechanistic adverse effect classification 
system (EIDOS) which considers five factors and complements the DoTS system. The 
five elements considered are: an extrinsic chemical species (E) initiates the effect; it 
interacts with an intrinsic chemical species (I). In order for the interaction to occur 
the two species must be co-distributed (D) in the body and this interaction produces 
an outcome (O) the adverse effect which leads to sequela (S) the adverse drug 
reaction (Aronson, Ferner 2010). 
 
Example of a classification using the EIDOS system (Ferner, Aronson 2010a): 
 
 Extrinsic species (E) - the chemical species that initiates the effect for 
example glucocorticoid 
 Intrinsic species (I) - the chemical species that it affects; calcium 
homeostasis, osteoblasts 
 Distribution (D) - sites of calcium transport, bone 
 Outcome (O) - Atrophy: osteoporosis  
 Sequelae (S) - Fracture 
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However, the Rawlins and Thomson (1977) classification is still widely used in ADR 
studies today perhaps due to its simplicity. It was the one used in the ADRIC studies 
and in this thesis. 
 
1.4 Changing pharmacology and ADRs in children 
 
The continuous development during childhood presents a challenge to developing, 
prescribing and administering age appropriate medicines. The paediatric population 
is very diverse ranging from pre-term neonates to adolescents. Infants and children 
undergo significant developmental changes over relatively short time periods which 
have dramatic effect on pharmacokinetics and pharmacodynamics. The most 
dramatic pharmacokinetic changes take place in the first year of life (Kearns 2000). 
Challenges include the production of appropriate formulations and the 
determination of appropriate dosing regimens. It is vital to appreciate that children 
cannot be viewed simply as small adults (Kearns 2000). It is not always possible to 
translate what is known about medicine use in adults into recommendations for 
medicine use in children. According to Mulla (2010) understanding the 
pharmacokinetic (PK)/pharmacodynamic (PD) relationship is important for clinical 
practice, particularly where factors such as age, genotype, co-morbidities and co-
medications can affect the nature of this relationship.  
 
Children are not only different from adults but differ within their own age groups as 
they develop. Pharmacokinetics of drugs in children may differ from adults for 
several reasons: variability due to age, body composition, functionality of liver and 
kidneys and maturation of enzymatic systems (Cella et al. 2009). Developmental 
changes in children affect drug disposition. Examples of this include differences in 
gastric pH and gastric emptying, changes in circulating plasma proteins, increased or 
decreased expression of the enzymes involved in drug metabolism and differences 
in glomerular filtration rate (GFR). These changes can affect the absorption, 
distribution, metabolism and elimination of drugs in children (Becker, Leeder 2010, 
Kearns 2000).  
 10 
 
During the neonatal period intragastric pH is higher (>4), changes in intraluminal pH 
can directly affect drug dissolution and has an impact on both drug stability and the 
degree of ionisation thus affecting the amount of drug available for absorption. 
Hence oral administration of acid labile compounds such as penicillin G have a 
higher bioavailability in neonates compared to older infants and children because of 
the relatively high gastric pH in neonates (Kearns et al. 2003). The gastric pH 
gradually declines after birth and hence the rate of penicillin degradation in the 
stomach increases, leading to a reduction in drug absorption. Conversely, drugs that 
are weak acids such as phenobarbital, may require higher oral doses in neonates 
that in older infants or children to achieve therapeutic plasma levels (Kearns et al. 
2003, Kearns 2000, Samardzic, Allegaert & Bajcetic 2015).  
 
Neonates have a thinner stratum corneum which can lead to an increased rate of 
absorption of a drug through the skin (Samardzic, Allegaert & Bajcetic 2015). The 
ratio of total body surface area to body mass in infants and young children is far 
greater than that in adults hence children are potentially exposed to higher levels 
for topically applied drugs; for example topical corticosteroids and therefore may 
be exposed to toxic effects (Kearns et al. 2003).  
 
Renal function needs to be considered particularly when using medicines which are 
renally cleared. The GFR increases rapidly during the first two weeks of life and then 
rises steadily reaching adult values at between 8 and 12 months of age; the GFR is 
reduced in pre-term neonates (Kearns et al. 2003). Neonates and young infants 
have a decreased level of active tubular secretion for the first 12 months. Adult 
values are achieved by the age of two (Samardzic, Allegaert & Bajcetic 2015). 
Developmental changes in renal function can greatly affect the plasma clearance of 
renally excreted medicines and hence need to be considered when prescribing 
drugs which are predominantly cleared by the kidneys. For example, 
aminoglycoside dosing regimens need to be adjusted to account for the ontogeny of 
renal function. Neonates and young infants require an increased dosage interval 
and/or reduced maintenance dose for a three month period (Samardzic, Allegaert & 
Bajcetic 2015). 
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Neonates and young infants have reduced hepatic metabolism of many drugs and 
subsequently may require increase in dosage interval to account for the increased 
half-life (Samardzic, Allegaert & Bajcetic 2015). Drugs metabolised in the liver have 
shown an age-dependent increase in plasma clearance in children under the age of 
ten years compared with adults which requires higher weight-based dose 
requirements (Kearns et al. 2003). According to Samardzic, Allegaert and Bajcetic 
(2015) children aged one to six have an apparent increased level of certain enzymes 
over adult values. This leads to increased clearance and a decreased half-life 
resulting in higher dose requirements for certain medicines. 
 
The majority of age specific dosing requirements are based on the known influence 
of ontogeny on the disposition of drugs (Kearns et al. 2003). For specific drugs there 
are dramatic differences in the dose and the dosing interval used in children and 
those used in adults for example certain antibiotics including, gentamicin, 
ceftazidime and clindamycin all require higher doses on a milligram per kilo basis in 
neonates, infants and children compared to adults (Kearns et al. 2003). For example 
aminoglycoside antibiotics require a higher dose due to the distribution volume but 
they also require an extended dosing interval as the lower rate of clearance 
requires an extended interval in order to reach a safe trough level. Aminoglycoside 
clearance reflects GFR and neonatal clearance is reported to be between 1-5% of 
adult clearance (Allegaert, Langhendries & van den Anker 2013). 
 
Developmental changes are also present in the drug metabolising enzymes which 
highlight the need for age-appropriate dosage regimens. The expression of phase 1 
enzymes (primarily oxidation) changes during development, for example the 
cytochrome P-450 enzymes. CYP3A7 is the predominant form in foetal liver. It peaks 
shortly after birth and declines rapidly to almost undetectable levels in adults. 
Within hours after birth CYP2E1 activity rises and CYP2D6 becomes detectable 
thereafter. CYP1A2 is the last to appear between one and three months of age. Two 
medicines commonly prescribed for neonates caffeine and theophylline are both 
substrates for CYP1A2. In infants over four months of age the clearance of caffeine 
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from plasma primarily reflects demethylation activity by CYP1A2 (Kearns et al. 
2003). 
 
In a paper on the identification of genomic and developmental causes of ADRs in 
children Becker and Leeder (2010) concluded that a vital first step is the recognition 
and characterisation of the differences between children and adults so we can 
systematically approach personalised therapeutics in children. An understanding of 
developmental changes in drug disposition informs appropriate dosing regimens 
but also contributes to an explanation of why children’s susceptibility to ADRs may 
vary. 
 
Clinical experience has shown that children differ from adults in terms of risk for 
particular ADRs for example; delayed maturation of drug metabolising enzymes may 
be a particular problem in newborns and contribute to concentration dependent 
drug toxicities. An example of this is cardiovascular collapse due to accumulation of 
chloramphenicol (parent compound) associated with delayed maturation of 
glucuronidation. Drug clearance pathways undergo vast changes throughout 
development; at birth the activity of many enzymes involved in biotransformation 
are limited or absent which may increase susceptibility to concentration dependent 
drug toxicity (Becker, Leeder 2010).  
 
Hepatotoxicity associated with sodium valproate (valproic acid) has been reported 
as more common in children under six. It has been suggested that young children 
have an increased risk due to their abnormal metabolism of valproic acid (Star, 
Edwards & Choonara 2014). Epidemiological studies have shown that the risk of 
fatal hepatotoxicity is highest in children under two receiving polytherapy (Becker, 
Leeder 2010).  
 
Codeine is metabolised in the liver via both Phase I and Phase II pathways. Codeine 
is de-methylated by the enzyme CYP2D6 to produce morphine. Codeine metabolism 
by CYP2D6 typically only accounts for 5% of the dose; further metabolism is via 
glucuronidation (Rieder, Carleton 2014). Koren et al. (2006) described the risk of 
opioid toxicity in breastfed infants. They outlined details of a case of a breastfed 
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baby who died as a result of opioid toxicity. The mother was an ultra-rapid 
metaboliser for CYP2D6 who metabolized significantly more codeine to morphine 
than expected which resulted in high concentrations of morphine in the blood 
(Koren et al. 2006). CYP2D6 has been recognized as a polymorphic enzyme for some 
time. There are three phenotypes: extensive metabolisers, poor metabolisers and 
ultra-rapid metabolisers. These polymorphisms show variable expression in 
different populations. The case of codeine has highlighted the importance of 
pharmacogenomics for safe and effective drug therapy (Rieder, Carleton 2014). 
 
The EMA and the MHRA have made changes to the guidance on the use of codeine 
in children for both pain relief and use in the treatment of coughs and colds. The 
latest guidance from the MHRA on use of codeine on pain relief is that it should 
only be used to relieve acute moderate pain in children over 12 and only if pain 
cannot be relieved by alternatives (paracetamol or ibuprofen) alone. The risk of 
serious and life-threatening ADRs has been highlighted following reports of serious 
and fatal respiratory depression in children with obstructive sleep apnoea who 
received codeine after tonsillectomy and/or adenoidectomy. As a result codeine is 
now contraindicated in all children younger than 18 years who undergo these 
procedures for obstructive sleep apnoea. Some of the children who suffered severe 
ADRs had evidence of being ultra-rapid metabolisers of codeine. In these patients, 
codeine is converted into morphine in the body at a faster rate than normal. This 
results in high levels of morphine in the blood that can cause toxic effects such as 
respiratory depression.  
 
There are many genetic variations of CYP2D6, which affect the extent of this 
conversion in individuals. The review also concluded that codeine is not suitable for 
all patients known to be CYP2D6 ultra-rapid metabolisers and that codeine should 
not be used by breastfeeding mothers due to the risk (Medicines and Healthcare 
Products Regulatory Agency 2013). In 2010 the UK Commission on Human 
Medicines advised that over-the-counter liquid medicines that contain codeine 
should not be used for cough suppression in children under 18. A European review 
has been conducted of the benefits and risks of using codeine to treat cough and 
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cold symptoms in children. Although impact of age on codeine metabolism is not 
fully understood, current evidence suggests children under 12 are at a higher risk of 
serious side effects than children over 12 (Medicines and Healthcare Products 
Regulatory Agency 2015). 
 
1.5 Pharmacovigilance – detection and monitoring of adverse drug 
reactions  
 
Pharmacovigilance is defined as ‘the science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects or any other medicine-
related problem’ (World Health Organisation 2004a). 
 
Following the thalidomide disaster in 1961 international efforts were initiated to 
address drug safety. The WHO established a pharmacovigilance programme in 
response to the thalidomide tragedy. Legislation regarding pre-marketing efficacy 
and safety data for medicines was introduced in the UK with the 1968 Medicines 
Act. Before a medicine is marketed, any experience of its safety and efficacy is 
limited to its use in clinical trials. A medicine will only have been tested in a 
relatively small number of patients for a limited time period. Also, the conditions 
under which patients and medicines are studied in clinical trials do not necessarily 
reflect the way the medicines are used in hospitals or general practice once they are 
marketed. Some ADRs may not be seen until a very large number of people have 
received the medicine. Therefore it is vital that the safety of all medicines is 
monitored throughout their marketed life. Effective pharmacovigilance post-
marketing helps to develop a full drug-safety profile for medicines.  
 
A formal system to monitor the adverse effects of medicines was set up in the UK in 
1964. The Yellow Card Scheme (YCS) collects spontaneous reports of ADRs; it is run 
by the Medicines and Healthcare Products Regulatory Agency (MHRA) and the 
Commission on Human Medicines (CHM) (MHRA 2013).  It has evolved over the 
years and it recently celebrated its 50th anniversary. Initially only doctors were 
allowed to report ADRs but it was later expanded to include pharmacists, nurses 
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and other healthcare professionals and in 2008 it was extended to allow patients to 
report ADRs. It receives about 25,000 reports of possible side effects each year. 
Since the YCS was set up in 1964, over 600,000 UK Yellow Cards have been received. 
It began as a paper based reporting system and in 2002 the introduction of the 
yellow card (YC) website saw the inclusion of an electronic YC reporting form 
(MHRA 2013). The scheme has helped to identify numerous important safety issues. 
There have been many successes with the YCS which have led to changes to SmPCs, 
changes to the legal status of a medicine, for example, from over-the-counter to 
prescription only; domperidone is a recent example of this and withdrawal of the 
medicine in rare cases where, the risks of a medicine are found to outweigh the 
benefits (MHRA 2014a).  
 
The MHRA no longer requires all suspected adverse drug reactions (ADRs) in 
children and adolescents to be reported. This change was made in response to 
feedback that mandatory reporting of all suspected ADRs in children was 
impractical and deterred reporting. The advice for reporting adverse reactions is 
now the same for adults and children. The scheme asks that all suspected ADRs to 
Black triangle drugs (▼) are reported and for established drugs and vaccines all 
serious ADRs are reported. The aim was to encourage reporting (MHRA 2014b).  
 
The system is hindered by under-reporting. A systematic review of 37 studies from 
twelve countries on under-reporting of ADRs estimated its incidence to be between 
6 and 100% with a median under-reporting rate of 94% (Hazell, Shakir 2006).  Some 
of the reasons for under-reporting include lack of time, different care priorities, 
uncertainty about the medicine causing the ADR and difficulty accessing reporting 
forms (Hazell, Shakir 2006). Reminding clinicians to report suspected ADRs can 
improve reporting rates.  
 
In July 2012, new pharmacovigilance legislation came into effect across the 
European Union (EU) (The European Parliament and the Council of the European 
Union 2010), including centralised reporting by industry of ADRs to the 
EudraVigilance database at the European Medicines Agency (EMA) and the inclusion 
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of reports from patients as valid, reportable ADRs.  Since July 2012, drug companies 
in the EU have been required to submit a risk management plan (RMP) at the time 
of application for a MA for new medicinal products (European Medicines Agency 
2014). The RMP includes information on the safety profile of the medicine, how 
risks will be minimised or prevented, any studies planned to find additional 
information about the safety profile and identifies potential risk factors and how 
they should be managed. The introduction of RMPs is intended to address the 
deficit of information regarding safety available at the time of MA. It is recognised 
that at the time of authorisation, information on the safety of a medicine can be 
limited due to a number of contributing factors including the relatively small 
numbers of people involved in clinical trials compared with the intended treatment 
population. Also there is often a restricted population in terms of age, gender and 
ethnicity (European Medicines Agency 2014).  
 
1.6 Incidence of adverse drug reactions in children 
 
There have been four main reviews in this area to date and they are discussed here 
in more detail. Firstly, a systematic review and meta-analysis published in 2001 
which included seventeen prospective studies found the overall incidence of ADRs 
in hospitalised children to be 9.53% (95% CI 6.81, 12.26). The overall rate of 
admissions due to ADRs was 2.09% (95% CI 1.02, 3.77) and the overall incidence of 
ADRs in outpatients was 1.46% (95% CI 0.7, 3.03). The reported ADR incidence in 
hospitalised children ranged from 4.37% to 16.78% among the different studies 
(9/17) (Impicciatore et al. 2001). The review aimed to explore the usefulness of data 
derived from observational studies in defining and preventing the risk of 
pharmacological interventions in children. The review found that polypharmacy was 
a potential risk factor of ADRs. There was substantial variability in the reported 
incidences of ADRs which the authors stated was only partly explained by the 
different number of drugs. The lack of consistent reporting of other variable such as 
patient age, diagnosis and prescription patterns meant they could not be 
considered in the analysis. 
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A review conducted by Clavenna and Bonati (2009) aimed to assess the incidence of 
ADRs in children and examine safety alerts issued by international drug regulatory 
agencies since 2001. The review included eight prospective studies published 
between 2001 and 2007. The estimated the incidence of ADRs at 10.9% (95% CI 4.8, 
17.0) in hospitalised children, 1.8% (95% CI 0.4, 3.2) causing admission and 1% (95% 
CI 0.3, 1.7) in outpatients. The review by Aagaard, Christensen and Hansen (2010) 
included 33 studies which looked at ADRs in general paediatric populations. The 
average incidence rate of ADRs in inpatients was 42%, the figure for ADRs causing 
admission was 9% and for outpatients it was 14%. The review also provided 
information on the methods and reports types. 
 
However Smyth et al. (2012) stated that there were a number of limitations with 
the three previous reviews. Firstly, the reviews were conducted using a limited 
number of keywords and were limited to two electronic databases MEDLINE and 
EMBASE this may have resulted in the exclusion of relevant studies. Two of the 
reviews excluded studies that included ADEs as well as ADRs (Aagaard, Christensen 
& Hansen 2010, Clavenna, Bonati 2009).  
 
The most recent of these systematic reviews was published by Smyth et al. (2012). 
It aimed to provide a more comprehensive assessment of ADRs in children and to 
gain an understanding of how ADRs are detected, assessed and avoided. The review 
included data from 102 studies and was the largest review of ADRs in children to 
date, although incidence data was not reported by all studies. The incidence rate of 
ADRs causing admission to hospital ranged from 0.4% to 10.3% with a pooled 
estimate of 2.9% (95% CI 2.6%, 3.1%) and the incidence of ADRs in hospitalised 
children ranged from 0.6 to 16.8%. There is wide variation in the incidence of ADRs; 
Smyth et al. (2012) suggested this may be due the differences between studies such 
as study duration, population characteristics and clinical setting. Also, the absence 
of clear definitions in some studies may have affected the results as not all studies 
provided a definition of the term ‘adverse drug reactions’ and it was not always 
clear if their definition of ADRs included prescribing or medication errors (Smyth et 
al. 2012).  
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The incidence of ADRs causing admission in the ADRIC study was 2.9% (95% CI 2.5, 
3.3); with 240/8345 admissions thought to be related to an ADR (Gallagher et al. 
2012). The study by Gallagher et al. (2012) is the largest of its kind in children and 
the only study to provide information regarding causality, severity, type of reaction, 
risk factors and avoidability. The ADRIC inpatient study reported an incidence rate 
of 17.7% in 6,601 admissions (Thiesen et al. 2013). It is the largest study to date; it 
characterised ADRs in terms of their type, causality and severity. It also identified 
risk factors which are discussed in more detail below.  
 
1.7 Risk factors for adverse drug reactions 
 
Children are thought to have a higher risk of developing ADRs than adults due to 
their physiology and their ability to handle medicines. Previously reported risk 
factors for ADRs in children include gender, number of medicines, use of unlicensed 
or off-label medicines and age. Polypharmacy is an established risk factor; previous 
studies have shown that in both children and adults there is an increased risk of 
developing an ADR. Patients with five or more medicines prescribed had the highest 
risk of developing an ADR (Rashed et al. 2011). A study in adults by Zopf et al. (2008) 
found polypharmacy to be a risk factor (Zopf et al. 2008). Rational prescribing and 
minimising the number of medicines prescribe d can potentially help to avoid ADRs. 
 
It has been reported that older children are more at risk of ADRs than their younger 
counterparts (Gallagher et al. 2012, Rashed et al. 2011, Thiesen et al. 2013) which is 
perhaps the opposite of what might be expected. With the changing physiology and 
differences in handling of drugs among the different age groups it may have been 
reasonable to expect younger children to be more at risk. Rashed et al. (2011) 
stated that the question remains whether the incidence is higher in older children 
because more high risk drugs are given to older children? Thiesen et al. (2013) have 
suggested that perhaps the difference may be due to lack of detection and 
underreporting in younger children as it can be difficult to distinguish ADRs from 
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common clinical issues in children for example loose stools and vomiting may be 
more ‘normal’ in younger children thus making it difficult to establish causality. 
 
A study by Turner et al. (1999) of 1046 inpatients which examined ADRs associated 
with unlicensed and off-label medicines found the overall incidence of ADRs to be 
11%.  6% of these were due to unlicensed or off-label medicines. They found an 
association between the number of medicines administered and the risk of an ADR. 
The study also showed a potential higher risk of an ADR with unlicensed or off-label 
medicines and suggested further studies were needed to determine the risk (Turner 
et al. 1999). Work conducted by Bellis et al. (2013) found that unlicensed and off-
label prescribing was a risk factor for ADRs as was the number of medicines 
irrespective of licensing status (Bellis et al. 2013).  
 
The ADRIC admissions study, a large prospective study of 8345 admissions, reported 
an ADR incidence of 2.9%. The medicine types most frequently implicated in ADRs 
were antineoplastic agents, non-steroidal anti-inflammatory drugs, vaccines, 
immunosuppressants and corticosteroids. Risk factors identified in the admissions 
study were number of medicines, oncological treatment and increasing age 
(Gallagher et al. 2012). The ADRIC inpatients study included a total of 5118 children 
in 6601 admissions. They reported the ADR incidence rate of 17.7% with opioid 
analgesics and drugs used in general anaesthesia accounting for over 50% of the 
medicines implicated in ADRs (Thiesen et al. 2013). Risk factors identified were 
number of medicines, oncological treatment, increasing age and receipt of a general 
anaesthetic. Thiesen et al. (2013) found children who had received a general 
anaesthetic (GA) were six times more likely to develop an ADR (hazard ratio (HR) 
6.40; 95% CI 5.30-7.70). The risk of experiencing an ADR in patients receiving a GA 
has not been assessed previously.  Most previous paediatric inpatient studies were 
carried out in general paediatric settings in which only a small number of patients 
will have undergone GAs. Rashed et al. (2012) reported that anaesthetic drugs were 
among the drugs most commonly implicated in ADRs, but accounted for only 1% of 
all prescriptions in their study which was conducted on general medical wards. 
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The ADVISE study (Adverse Drug Reactions in Children- International Surveillance 
and Evaluation) was a prospective multicentre cohort study conducted on 
paediatric general medical wards in five different countries (two European and 
three non-European sites). ADRs were identified by intensive chart review and were 
evaluated by the research team, which included at least one clinical pharmacist and 
one paediatrician and/or paediatric pharmacologist. They assessed causality, 
avoidability, severity and seriousness using standardised criteria. They used a 
system introduced by Schumock and Thornton (1992) to assess avoidability.  They 
included a total of 1253 patients in their study and of these, 1115 (89%) received 
prescribed medicines during their stay. They used the WHO (1972) definition of an 
ADR. They identified a total of 328 ADRs and reported an overall ADR incidence rate 
of 16.7% (95% CI 14.5, 19.0) (Rashed et al. 2011).  They investigated the following 
risk factors: age, gender, number of medicines (high and low risk drugs), length of 
stay and diagnoses. They concluded that number of medicines, older age, presence 
of certain diseases, disorders or conditions were all independent predictors of 
ADRs. They found that gender did not appear to have the same effect on ADR 
epidemiology as in adults. They defined high-risk drugs as analgesics, antiepileptics, 
antibactericals and antimycotics for systemic use, corticosteroids for systemic use 
and immunosuppressants. All other medicines were classified as low risk for the 
study purposes. They found that the use of five or more low risk drugs or three or 
more high risk drugs were strong predictors of ADRs. 
 
1.8 Evaluation of adverse drug reactions 
 
This review will focus on the three main areas of ADR assessment, causality, severity 
and avoidability. 
 
1.8.1 Causality assessment 
 
Causality assessment examines the relationship between the ADR and the 
suspected medicine and the likelihood that the medicine caused the ADR. In order 
to conduct this assessment several questions must be answered: 
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1 Are there previous reports of the ADR? 
2 Did it appear after the suspected medicine was administered? 
3 Did it resolve when the medicine was stopped?  
4 Could there be another plausible explanation for it e.g. underlying disease? 
5 If the medicine was given again, did it reoccur? 
6 Was there any objective evidence of the ADR? 
7 Did the patient have a similar reaction in the past to the same or any similar 
medicines? 
 
There are numerous methods for assessing the causality of ADRs. A recent 
systematic review found 34 different methods and acknowledged that there is 
currently no ‘gold standard’ method (Agbabiaka, Savovic & Ernst 2008). The 
methods fall into three categories: expert judgement/global introspection, 
algorithms and probabilistic methods (Bayesian approaches). The assessment 
methods however different share some common features. Algorithms were the 
most common method found in the review.  
 
1.8.2 Expert judgement/global introspection 
 
This method of causality determination is based on the personal judgement of each 
ADR report by the investigator, following careful consideration of the available data. 
It involves the application of clinical opinion. This can be carried out by a single 
investigator or by a group, who then compare their evaluations to arrive at a 
consensus opinion. Although this method is widely used, several reports have 
shown that expert judgement is not a reliable method for causality assessments 
(Agbabiaka, Savovic & Ernst 2008). Due to the subjectivity of this method there is no 
guarantee of a consistent approach. Despite these issues it remains popular for ADR 
assessments, perhaps because it is straightforward. 
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1.8.3 Algorithms 
 
Algorithms provide a systematic approach for ADR assessment using structured and 
standardised methods. Several algorithms have been developed to assess the 
causality of ADRs. Three of these algorithms, Karch and Lasagna (1977), Kramer et 
al. (1979) and Naranjo et al. (1981) are discussed. 
 
Karch and Lasagna (1977) developed an algorithm based around three decision 
tables intended to assess potential ADRs, the certainty of the link between the 
event and the agent and evaluate the underlying causes of the identified adverse 
events. If the possibility of a link was established, it was categorised as definite, 
probable, possible, conditional or unrelated. These criteria include knowledge of 
the reaction, the temporal relationship, presence of known alternative causes, 
information about dechallenge and rechallenge. The algorithm still requires the 
investigator to make certain judgements therefore, results may not always be 
reproducible. 
 
Kramer et al. (1979) expanded on the work of Karch and Lasagna (1977) and 
produced a set of diagnostic criteria providing specific rules for the assessment of 
ADRs. The algorithm is comprised of six axes of decision tables, each with a scoring 
system. The axes are as follows: previous general experience with the drug, 
alternative etiologic candidates, timing of events, drug levels and evidence of 
overdose, dechallenge and rechallenge. As the assessor moves through the axes 
they accumulate points, individual scores from each of the axes are added together 
to give a total score, which in turn gives the probability of an ADR. The ADR is 
classified as definite, probable, possible or unlikely depending on the score. 
Individual judgement is still required to make decisions at each of the six stages of 
assessment. Levels of expertise and experience of the assessor may affect the 
results (Karch, Lasagna 1977). 
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The Naranjo tool (1981) (Table 1.1) is widely used for the assessment of causality. It 
consists of ten questions that are answered and a scoring system is applied to 
categorise ADRs as definite, probable, possible or doubtful. It classifies the 
likelihood that a reaction is related to a drug using concepts such as timing, 
evidence, history, dechallenge and rechallenge. Each question is weighted and the 
total score is used to categorise the reaction. 
 
ADR cases are assigned a total score which determines the category as follows: 
>9 = definite ADR 
5-8 = probable ADR 
1-4 = possible ADR 
0 = doubtful ADR 
 
Table 1.1 The Naranjo tool for ADR causality assessment (Naranjo et al. 1981) 
Question 
number 
Question Yes No Don’t 
know 
1 Are there previous conclusive reports on this reaction? 
 
+1 0 0 
2 Did the adverse event appear after the suspected drug 
was administered? 
+2 -1 0 
3 Did the adverse reaction improve when the drug was 
discontinued or a specific antagonist was administered? 
 
+1 0 0 
4 Did the adverse reaction reappear after the drug was 
readministered? 
 
+2 -1 0 
5 Are there alternative causes (other than the drug) that 
could on their own have caused the reaction? 
 
-1 +2 0 
6 Did the reaction reappear when a placebo was given? 
 
-1 +1 0 
7 Was the drug detected in the blood (or other fluids) in 
concentrations known to be toxic? 
 
+1 0 0 
8 Was the reaction more severe when the dose was 
increased, or less severe when the dose was decreased? 
+1 0 0 
9 Did the patient have a similar reaction to the same or 
similar drugs in any previous exposure? 
 
+1 0 0 
10 Was the adverse event confirmed by any objective 
evidence? 
 
+1 0 0 
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During the ADRIC admissions study Gallagher et al. (2011) experienced some 
difficulties using the Naranjo tool. They found some questions were not appropriate 
which led to ‘don’t know’ being selected which affected the scoring system used. As 
a result of this they set out to develop a new causality assessment tool that would 
overcome these problems and be easy to use. The team developed and validated a 
new tool the Liverpool Causality Assessment Tool (LCAT) (Gallagher et al. 2011a, 
Gallagher et al. 2011b). The LCAT tool (Figure 1.1) is a flow diagram which classifies 
ADRs as one of the four categories ‘unlikely’, ‘possible’, ‘probable’ or ‘definite’. The 
LCAT was used to assess the causality in the two ADRIC observational studies 
(Gallagher et al. 2012, Thiesen et al. 2013) 
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Figure 1.1 The Liverpool adverse drug reaction causality assessment tool taken from (Gallagher et al. 2011a) 
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1.8.4 Bayesian methods 
 
Bayesian approaches use specific findings in a case to transform a prior into a 
posterior probability of drug causation (Hutchinson 1991). A number of methods for 
diagnosis of ADRs use Bayes’ theorem. The Bayesian Adverse Reaction Diagnostic 
Instrument (BARDI) which applies logic of uncertainty to causality assessment it was 
developed to overcome some of the limitations associated with the other methods. 
It is a decision analysis tool that calculates the posterior odds that a drug caused a 
particular event. The method has been found to be reproducible but the complex 
calculations are one of its limitations (Agbabiaka, Savovic & Ernst 2008). 
 
1.8.5 Severity assessment 
 
The severity of an ADR relates to the effect it has on the individual it is distinct from 
seriousness which is the extent to which the reaction causes harm. A severe 
reaction may not necessarily be serious. Severity assessments describe the clinical 
impact of ADRs. The terms ‘mild’, ‘moderate’ and ‘severe’ have been used to 
describe ADRs but these terms are rather subjective as they rely on the judgement 
of the assessor (Aronson, Ferner 2005). The Hartwig (1992) scale (Table 1.2) has 
been used in both the ADRIC observational studies to determine severity (Gallagher 
et al. 2012, Thiesen et al. 2013). The severity levels range from Level 1 (where the 
ADR required no change in treatment with the suspected drug); to Level 7 (the ADR 
was fatal). The scale is easy to use with clear definitions.  
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Table 1.2 Hartwig ADR severity assessment scale taken from (Hartwig, Siegel & 
Schneider 1992) 
 
Level Description 
Level 1 An ADR occurred but required no change in treatment with the suspected drug. 
 
Level 2 The ADR required the treatment with the suspected drug be held, discontinued or 
otherwise changed. No antidote or other treatment required. No increase in 
length of stay (LOS). 
Level 3 The ADR required that treatment with the suspected drug be held, discontinued or 
otherwise changed, and/or an antidote or other treatment was required. No 
increase in LOS. 
Level 4 a) Any level 3 ADR which increase LOS by at least 1 day. 
Or 
(b) The ADR was the reason for admission. 
 
Level 5 Any level 4 ADR which requires intensive medical care. 
 
Level 6  The adverse reaction caused permanent harm to the patient. 
 
Level 7 The adverse reaction either directly or indirectly led to the death of the patient 
 
 
 
Aronson and Ferner (2005) proposed a classification which asks specific questions 
about the ADR and the dosage regime of the suspected drug. It classifies severity by 
grade (1-3). It focuses on what needs to be done to manage the ADR by asking 
whether any change in the patient’s treatment was required as a result of the ADR 
and whether the treatment was effective (Table 1.3). 
 
Table 1.3 Proposed classification of ADR intensity (Aronson, Ferner 2005) 
 
Grade Change in dosage regimen of the 
offending drug 
 
Treatability of the reaction 
 
1 No change in dosage regimen 
required 
 
A. No treatment required 
B. Relieved or partly relieved by treatment 
C. Not relieved by treatment 
 
 
2 Altered dosage regimen required or 
desirable 
 
A. No other treatment required 
B. Relieved or partly relieved by treatment 
C. Not relieved by treatment 
 
 
3 Withdrawal required or desirable 
 
A. No other treatment required 
B. Relieved or partly relieved by treatment 
C. Not relieved by treatment 
 28 
 
Dormann et al. (2000) devised an ADR severity score. It classifies ADRs as mild, 
moderate or severe depending on the numerical score obtained when the algorithm 
is applied. It incorporates quality of life assessment. A score of 1 to 4 indicates a 
mild, a score of 5 to 8 a moderate, and a score of >8 a severe adverse drug reaction. 
 
1.9 Avoidability assessment 
 
1.9.1 Avoidability of adverse drug reactions – overview of the literature  
 
Avoidability is an important concept in the study of ADRs (Ferner, Aronson 2010b). 
There is no universally accepted definition of avoidability or preventability as it is 
also called. The terms are often used interchangeably but for the purpose of this 
thesis the term avoidability has been used. There have been many attempts to 
devise tools or scales to help determine avoidability. As yet there is no ‘gold 
standard’. 
 
Definitions  
Prevent: ‘keep (something) from happening’ (Oxford Dictionaries a) or to ‘stop 
(something) from happening’ (Merriam-Webster a). 
Avoid: ‘prevent from happening’ (Oxford Dictionaries b) or to ‘prevent the 
occurrence of’ (Merriam-Webster b) 
 
A systematic review carried out by Ferner and Aronson (2010) identified eight 
different approaches to defining avoidability in the literature:  
 
1. analysis without explicit criteria 
2. assessment by consensus 
3. preventability linked to error 
4. preventability linked to standards of care 
5. preventability linked to medication-related factors 
6. preventability linked to information technology 
7. categorisation of harmful treatments in explicit lists 
8. combinations of more than one of these approaches 
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These approaches rely on two general methods, judgement of one or more 
investigators or the use of pre-defined criteria. Both methods have limitations. In 
terms of consensus, it is possible for experts to agree but still be wrong. With 
avoidability related to standards of care, if the standards are poorly defined, it is 
difficult to determine avoidability (Ferner, Aronson 2010b). 
 
They stated that nothing is absolutely avoidable but any intervention that reduces 
the probability of harm can be said to have made a contribution to prevention 
(Ferner, Aronson 2010). In a follow up paper, they outlined a novel method for 
determining avoidability (Aronson, Ferner 2010). This novel method involves 
classifying ADRs by mechanism and clinical manifestation to inform judgement 
about theoretical avoidability (Aronson, Ferner 2010). According to Ferner and 
Aronson complete analysis requires consideration of pharmacodynamic and 
pharmacokinetic mechanisms of the ADR, its time course, its dose-responsiveness 
and individual susceptibility factors (Ferner, Aronson 2010b, Aronson, Ferner 2010).  
 
A systematic review conducted by Hakkarainen et al. (2012a) which looked at 
methods for assessing the avoidability of adverse drug events included 134 articles, 
27% of these investigated avoidability of ADRs exclusively (excluding other ADE 
types). They found eighteen unique instruments for determining avoidability, which 
fell into four groups: 
 
1. Instruments using a definition of avoidability  only 
2. Instruments with a definition of avoidability and an assessment scale for 
determining avoidability 
3. Instruments with specific criteria for each avoidability category 
4. Instruments with an algorithm for determining avoidability 
 
Group 1: instruments using only a definition of avoidability, included three 
instruments (Dubois and Brook (1988), Bates et al. 1993 and Bates et al. 1995) 
which had no specific criteria for determining the type of preventability.  
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Group 2: instruments with a definition of avoidability and a scale for determining 
preventability category, five unique instruments were identified. In these 
instruments preventability of AEs was determined using a confidence scale or a 
Likert scale. Four out of the five were developed to assess preventability of AEs. 
 
Group 3: included three instruments with specific criteria for each preventability 
category including Hallas et al. (1990). Two instruments had more than one 
category for preventable events. All three instruments in this group were developed 
for drug related AEs.  Unlike any other instrument Hallas (1990) and colleagues 
included an unevaluable category for cases which data was not available or 
evidence was conflicting.  
 
Group 4: instruments with an algorithm for determining preventability, seven 
instruments were found. All seven were developed for drug related AEs. Several of 
the instruments were modified from Schumock and Thornton (1992). 
 
There is no standardised method for determining avoidability of an ADR, commonly 
used scales include Hallas (1990) (Figure 1.2) and Schumock and Thornton (1992) 
(Figure 1.3). 
 
Figure 1.2 The Hallas Scale taken from (Hallas et al. 1990) 
 
Hallas Scale 
Definitely avoidable: The event was due to a drug treatment procedure 
inconsistent with present-day knowledge of good medical practice or was 
clearly unrealistic, taking the known circumstances into account 
Possibly avoidable: The prescription was not erroneous but the event could 
have been avoided by an effort exceeding the obligatory demands  
Not avoidable: The event could not have been avoided by any reasonable 
means, or was an unpredictable event in the course of a treatment fully in 
accordance with good medical practice 
Unevaluable: The data for rating could not be obtained or the evidence was 
conflicting 
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Schumock and Thornton (1992) categorise avoidability based on a series of 
statements concerning possible contraindications, inappropriate dose, 
inappropriate monitoring, not considering previous history of a reaction to the drug, 
drug interactions, toxic drug levels and compliance. Answering yes to one or more 
of the statements categorises the ADR as preventable.   
 
Figure 1.3 The Schumock and Thornton avoidability tool, taken from (Schumock, 
Thornton 1992) 
 
Schumock and Thornton 1992 
Yes to one or more indicates ADR may have been preventable 
 
1. Was the drug involved in the ADR not considered appropriate for the  
patient’s clinical condition? 
2. Was the dose, route, and frequency of administration not appropriate for the 
patient’s age, weight and disease state? 
3. Was required therapeutic drug monitoring or other necessary laboratory testing not 
performed? 
4. Was there a history of allergy or previous reactions to the drug? 
5. Was a drug interaction involved in the reaction? 
6. Was a toxic serum drug level documented? 
7. Was poor compliance involved in the reaction? 
 
Actions taken to standardise the assessment process were rarely described; 18/143 
studies reported the use of an operational manual, guidelines or protocol for 
avoidability assessments. Physicians were reported to have conducted the 
assessments in 60% of the studies and pharmacists in 29% of studies, often a 
combination of both. 66% of articles had more than one assessor and an 
independent assessment was reported in 51% of studies. There is no consensus or 
guidance on the number of assessors required and whether assessments should be 
conducted by individuals or by groups. The hypothesis that group assessments are 
superior to individual assessment is tested in Chapter 3 of this thesis.  Reliability of 
the assessments were reported in 27% of the articles overall and in three of the 
articles which looked at ADR avoidability (Hakkarainen et al. 2012a). 
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The ADRIC admissions study used the Hallas scale (1990) to assess avoidability 
(Gallagher et al. 2012). However, during the ADRIC inpatient study the need for 
developing a new avoidability assessment tool (AAT) was identified (Thiesen et al. 
2013, Smyth et al. 2014). Difficulties were encountered answering certain questions 
as some of the questions cover consistency with ‘good medical practice’ which in 
paediatrics is difficult to answer due to the lack of guidelines available and deemed 
not appropriate; therefore this led to ‘unevaluable’ being selected regularly. Whilst 
the Hallas scale can be used in paediatrics as seen in the ADRIC admissions study it 
is sometimes difficult to apply for example the ADRIC inpatient study cases due the 
complex language and types of ADR cases being assessed. The Hallas scale may be 
easier to use in the assessment of adult cases due to the number of guidelines 
available in the adult setting and therefore making the assessment of what 
constitutes “good medical practice” easier or less subjective than the assessment of 
paediatric cases.  
 
A “good” avoidability assessment tool should be less subjective, easy to use and 
appropriate for use by less experienced reviewers. The criteria specified above are 
relevant to both adults and paediatrics. The LAAT although designed and tested for 
use in paediatrics is generalisable and applicable to other settings including adults. 
Our decision to develop a novel tool that was a flow diagram aimed to reduce or 
minimise the subjectivity involved in avoidability assessments. The difficulties 
encountered and the development of the LAAT is discussed in more detail in 
Chapter 2.   
 
The systematic review by Smyth et al. (2012) highlighted the lack of studies 
performing an avoidability assessment. Out of 101 studies included in the review 
only nineteen assessed avoidability and there was wide variation in avoidability 
with 7-98% of ADRs being deemed as either possibly/definitely avoidable. Ten out 
of fourteen studies used a recognised avoidability tool with half using Schumock 
and Thornton (1992). Smyth et al. (2012) stated that further studies were required 
to determine which ADRs are potentially avoidable. However, they did not 
comment on specific requirements for assessing avoidability unlike Hakkarainen et 
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al. (2012a) who made recommendations for future studies which are discussed in 
more detail in Chapter 2. However, both studies commented on the importance of 
clear terminology and the importance of definitions to reduce heterogeneity and to 
allow comparisons between different studies.  
 
A meta-analysis of the avoidability of ADRs in adults found that between 45-52% of 
ADRs were avoidable (Hakkarainen et al. 2012b). This study demonstrated that 
ADRs are a significant cause of morbidity and that effective intervention strategies 
are needed to prevent ADRs. The early detection of ADRs is important to avoid 
unnecessary harm to patients and knowledge of risk factors predisposing patients 
to ADRs is important to developing appropriate prevention strategies (Rashed et al. 
2011). 
 
1.9.2 Overview of paediatric studies that assessed avoidability  
 
The ADRIC systematic review highlighted that few studies conducted an avoidability 
assessment (19/102). Data were only available for 14/19 studies as child only data 
were not available for four studies and ADR specific data was not provided by one 
study the studies are outlined in Table 1.4. 
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Causing admission studies 
Study Country Study duration/design Clinical setting  Population Causality Avoidability assessment 
Easton  
2004 1 
 
Australia 22 weeks Prospective 
 
Specialist 
paediatric teaching 
hospital and 
general regional 
teaching hospital  
Children 
Not reported – 17 
years 
 
Dartnell et al. 1996 Schumock and Thornton 1992 
127 DRPs,  29/127 were ADRs 
10.3% ADRs preventable 
46.9% DRP preventable 
Gallagher 2011  UK 2 weeks Prospective 
 
Large tertiary - 
paediatric hospital 
Children 
<18 years 
 
Naranjo Hallas et al. 1990 
33% Possibly avoidable 
67% Unavoidable  
 
Gallagher 20112 UK 12 month Prospective 
 
Large tertiary - 
paediatric  hospital 
 
Children 
<18 years 
 
Liverpool ADR 
Causality Assessment 
Tool (LCAT) 
Hallas et al. 1990 
22.1% 
 
 
Al-Olah 2008 Saudi Arabia 28 days Prospective  Causing admission 
Emergency 
department 
Children and adults 
Not reported in 
publication/unable 
to obtain from 
author 
Naranjo Definite preventable and definite 
non-preventable 
defined as 3 evaluators in 
agreement; possible preventable 
and 
possible non-preventable 2 in 
agreement 
 
 
                                                          
1 Easton (2004) cited in Table 4 of systematic review by Smyth et al. (2012) as Easton-Carter but referenced as Easton (2004) in their reference list 
 
2 Gallagher (2012) cited in Table 4 of systematic review by Smyth et al. (2012) as Gallagher (2011) as unpublished at time of publication of the systematic review 
Table 1.4 Studies reporting avoidability data taken from systematic review by Smyth et al. (2012) 
 35 
 
In hospital studies 
Choonara 1984 UK 6 months Prospective 
 
General paediatric 
ward 
 
Children Not 
reported in 
publication/unable 
to obtain from 
author 
Seidl et al. 1966 6/15 ADRs were avoidable (40%) 
 3 dose prescribed was too high, 1 
treatment not necessary, 2 
application of pharmacological 
principles would have prevented 
reactions  
Easton-Carter 2003b 
 
Australia 39 weeks Prospective & 
prospective 
 
General paediatric 
ward 
 
Children 0–17 years 
 
Naranjo Score 
 
Schumock and Thornton 1992 
9.8% avoidable 
Gonzalez-Martin 
1998 
 
Chile 1 year Prospective 
 
Paediatric wards  Children 5 days–15 
years 
 
Naranjo Score 
 
Naranjo and Busto 1989 
93% dose dependent 
Neubert 2004 Germany 8 months Prospective 
 
Paediatric isolation 
ward 
 
Children 
5 days–17 years 
 
Naranjo Score 
 
Adapted version Schumock and 
Thornton 1992 
Preventable 21.7% 
Not preventable 50% 
Tolerated 28.3% 
Community Studies 
Easton-Carter 2003a 
 
Australia 18 weeks Prospective 
 
Emergency 
department 
 
Children < 17 years 
 
Dartnell et al. 1996 Schumock and Thornton 1992 
280 DRPs 118/280 were ADRs 
51.3% preventable for all DRPs 
36.9% not preventable for all DRPs 
30.5% for ADRs 
Table 1.4 Studies reporting avoidability data taken from systematic review by Smyth et al. (2012) (continued) 
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Kramer 1985 Canada 1 year Prospective 
 
Private group 
practice 
 
Children 2 days–18.9 
years 
 
Kramer 1979 Highly preventable - realistic 
nondrug alternative available; 
Probably preventable - safer 
alternative drug available/lower 
dosage; Possibly preventable - 
Dose might have been modified; 
Unpreventable - would not have 
changed the choice/dose of drug. 
77% highly/probably/possibly 
avoidable 
Planchamp 2009 France 6 months Prospective 
 
Emergency 
department 
 
Children 0–18 years 
 
Begaud et al. 1985 Olivier et al 2005 
7% 
Combined settings (causing admission and in hospital) 
Baniasadi 2008 Iran 12 month prospective Multidisciplinary 
hospital 
 
Children and adults 
0–18 years 
 
Naranjo Score Schumock and Thornton 1992 
22.3% both adults and children 
Oshikoya 2007 Nigeria 3 years both  General paediatric 
ward 
Children 4 months–
12 years 
 
 
Jones 1982 
 
Done but no reference provided 
44 ADRs detected and 43/44 
deemed preventable (98%) 
Van der Hooft 
2008 
 
Netherlands 1 year Retrospective 
 
 Children and adults 
Not reported -16 
years 
 
WHO Hallas et al. 1990 
115 ADRs total, 1 detected <16s  
30% over 17s- adults 
0%  ADRs avoidable <16s 
Table 1.4 Studies reporting avoidability data taken from systematic review by Smyth et al. (2012) (continued) 
 
  
1.9.2.1 Studies of ADRs causing admission 
 
A prospective study of drug related problems (DRPs) causing admission over 22 
weeks to two hospitals (a specialist paediatric teaching hospital and a general 
regional teaching hospital) in Australia (Easton KL, Chapman & Brien 2004). DRPs 
were classified according to the eight categories defined by Strand et al. (1990) 
which include ‘resulting from an adverse drug reaction’ (category 5). DRPs were 
assessed by a multidisciplinary panel. The panel consisted of seven independent 
members from a variety of disciplines including paediatric medicine, pharmacy, 
paediatric clinical pharmacology and nursing. Two members of the panel reviewed 
each case on an independent basis. At least one was required to be a medical 
practitioner. In cases where discrepancies arose, the reviewed cases were discussed 
by panel members to reach a consensus. The consensus opinions were recorded as 
the final DRP category, causality and preventability classifications. Schumock and 
Thornton (1992) algorithm was used to assess avoidability. One hundred and 
twenty seven cases were deemed to be caused by a DRP of these, twenty nine were 
categorised as ADRs. Three out of the twenty nine ADRs (10.3%) were assessed as 
avoidable.  
 
A pilot study which looked at ADRs causing admission conducted by Gallagher et al. 
(2011a) was conducted over a two week period. The Edwards and Aronson (2000) 
definition of an ADR was used. All unplanned admissions to the main hospital and to 
the accident and emergency observation ward were included. The study team 
collected information for each patient including any medication taken in the 
preceding two weeks. Over the two week period there were 822 acute admissions 
to the hospital, 473 to the main hospital wards and 349 to the observation ward 
subsequently discharged home. There were 27 admissions identified as being 
complicated by an ADR which occurred in 25 patients. There were 19 admissions to 
the main hospital and 8 to the observation ward. The estimated incidence of 
admissions to the main hospital wards related to an ADR was 4% and 2.3% for the 
observation ward. The ADRs were assessed for causality, severity and avoidability. 
The Hallas scale (1990) was used to determine avoidability 33% of the ADRs were 
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classified as ‘possibly avoidable’ and 67% were deemed unavoidable. No ADRs were 
found to be ‘definitely avoidable’. The study team reported that Hallas classification 
was easy to use but due to its broad classification terms it was likely to be user-
dependent (Gallagher et al. 2011a). 
 
Gallagher et al. (2012) conducted a prospective study in a large tertiary children’s 
hospital over a one year period. All unplanned admissions were prospectively 
screened for ADRs. Patients admitted to the accident and emergency department 
short-stay observation ward were not included. The Edwards and Aronson (2000) 
definition of an ADR was used. The incidence of ADRs causing admission was 2.9%. 
They detected 249 ADRs and assessed them for causality, severity and avoidability. 
The Hallas scale (1990) was used for assessing avoidability; this was done via a 
consensus group. 22.1% of the ADRs were classified as possibly or definitely 
avoidable. 
 
Al-Olah and Al Thiab (2008) undertook a 28 day prospective, observational study 
which looked at DRPs causing admission to the emergency department. The study 
included adults and children. The study team was made up of two clinical 
pharmacists and one physician. They defined a DRP as ‘an event or circumstance 
involving drug treatment that actually or potentially interfered with the patient 
experiencing an optimum outcome of medical care’. They included ADRs in DRP and 
they defined an ADR as ‘a medical problem resulting from an adverse effect(s)’ (Al-
Olah, Al Thiab 2008). A definite DRP was defined as three reviewers in agreement, a 
possible DRP was defined as two reviewers in agreement following a consensus 
meeting. The same applied to avoidability of DRPs, definite preventable and definite 
non-preventable were defined as three reviewers in agreement and possible 
preventable and possible non- preventable DRPs were defined as only two 
reviewers in agreement. A total of 557 patients were admitted during the study 
period, 82 (14.7%) were due to a DRP. The adult to paediatric ratio was 50:32. ADRs 
were the second most common DRP accounting for 24.5%. Six ADRs occurred in 
children, 17% were deemed possibly preventable and 83% were deemed definitely 
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no-preventable. The reason provided for the possibly preventable ADR was the drug 
not being prescribed as per treatment protocol.  
  
1.9.2.2 Studies of ADRS among in-patients  
 
Choonara and Harris (1984) conducted a 6 month study investigating ADRs in 
medical inpatients in a paediatric hospital (Choonara, Harris 1984). Medical and 
nursing staff prospectively looked for ADRs on the daily ward round. An ADR was 
defined according to the criteria used by Seidl et al. (1966). Over the six month 
period 268 children were admitted and 15 suffered a probable or definite ADR. Six 
of the fifteen ADRs were deemed avoidable, in three cases the dosage prescribed 
was too high and in two cases application of pharmacological principles could have 
prevented the ADRs and in the final case the treatment was deemed not necessary.  
 
A study investigating the frequency of ADRs in the inpatient population of three 
Australian hospitals (Easton-Carter, Chapman & Brien 2003a) considered all 
paediatric patients admitted to wards of three hospitals for inclusion, excluding 
oncology patients. ADRs were identified using two methods: spontaneous 
monitoring and retrospective intensive monitoring. An independent panel reviewed 
information collected on reactions and established the causality, clinical significance 
and preventability of ADRs arising amongst inpatients. Of the 17,432 eligible 
patients, 41 (0.2%, 95 % CI 0.1-0.3%) were determined by an independent panel to 
have experienced ADRs. Avoidability was assessed using the Schumock and 
Thornton (1992) criteria and 9.8% of the ADRs were considered preventable.  
 
A prospective study which aimed to determine the frequency and characteristics of 
ADRs in hospitalised children conducted in Chile between January and December 
1997. The study included children aged 0 to 16 years receiving drug treatment. Data 
were collected by a clinical research pharmacist on a daily basis. Medication 
histories including past and present medicines were gathered by the pharmacist by 
interviewing the parent or guardians on admission. ADRs were defined according to 
the WHO definition. Suspected ADRs were evaluated by the pharmacist and then 
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discussed with a clinical pharmacologist. 13.7% of 219 patients experienced one or 
more ADR(s) during their hospital stay. In total 46 ADRs were detected; 13.6% were 
definite, 54.2% probable and 32.2% were possible. The mechanisms of ADRs were 
classified as dose-dependent: ‘the frequency and severity of the ADRs are directly 
proportional to the administered dose and therefore can be prevented and/or 
treated by adjusting the dose, and not dose related: a reaction due to an increased 
susceptibility of the patient’ (Naranjo CA 1989). 93% of ADRs in the study were 
classified as dose dependent. Twenty four drugs were involved in the ADRs, 38/46 
ADRs were due to a single drug and the remaining eight involved two drugs. No 
further details were reported on the assessments. 
 
Neubert et al. (2004) conducted a prospective study in Germany over eight months 
in 2001. The setting was a ten-bed paediatric ward, patients <18 years were 
included and the WHO (1972) definition of an ADR was used. ADRs were identified 
by a weekly review of patient charts; this was conducted by a team comprised of a 
clinical pharmacologist, a pharmacist and a paediatrician. Forty-six ADRs were 
detected in 31 patients, representing an ADR incidence of 17.4%. Suspected ADRs 
were assessed using an adapted version of the Schumock and Thornton (1992) 
avoidability criteria. All preventable ADRs with a benefit greater than risk were 
classified as tolerated. Overall 21.7% were classed as preventable, 50% were not 
preventable and 28.3% were categorised as tolerated (Neubert et al. 2004). 
 
1.9.2.3 Community studies 
 
A prospective multicentre study carried out over 18 weeks in Australia (Easton-
Carter, Chapman & Brien 2003b). The study included children aged seventeen and 
under attending the emergency department of one of the three sites (a specialist 
paediatric teaching hospital, a general suburban teaching hospital and a general 
regional teaching hospital. They considered DRPs according to the eight categories 
defined by Strand et al. (1990). An emergency department attendance was 
considered a study case if the association between the attendance and a DRP was 
established. Over the data collection period 280 cases were assessed by the 
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multidisciplinary panel to have had a DRP. Of these 118 were categorised as ADRs. 
Causality and avoidability assessments were carried out by the panel. They used 
Schumock and Thornton (1992) to assess avoidability 36/118 ADRs were considered 
avoidable. Interestingly antibiotics were involved in 34 of the 36 ADRs. 
 
Kramer et al. (1985) carried out a prospective study over a one year period which 
employed active patient follow up to monitor for adverse drug reactions in a 
community setting. Patients visiting the practice were invited to take part in the 
study. Courses of therapy were classified as either short term ≤ 1 month or long 
term > 1 month. For short term courses, follow up monitoring was conducted at 2 
weeks or at the anticipated end of therapy and at completion of treatment. For long 
term courses monitoring calls were made at 2 weeks and 1, 3 and 5 months after 
starting treatment. No definition of an ADR was provided. The ADR incidence was 
11.1% in the study population. Two hundred ADRs were categorised as probable or 
definite. Avoidability assessments were carried out for all definite or probable ADRs 
by the senior author and prescribing physician. ADRs were classified as follows: 
Highly preventable - realistic nondrug alternative available; Probably preventable - 
safer alternative drug available/lower dosage; Possibly preventable - dose might 
have been modified; Unpreventable - would not have changed the choice/dose of 
drug (Smyth et al. 2012). Out of the 200 ADRs assessed by the senior author, 12 
were deemed highly preventable, 83 were probably preventable, 59 possibly 
preventable and 46 were deemed unpreventable and overall 77% were deemed 
preventable. The distribution of responses was similar when the prescribing 
physician conducted the assessments, although agreement on a case by case basis 
was reported as fair (Kramer, Hutchinson & Flegel 1985). 
 
Planchamp et al. (2009) conducted a six month prospective study of children 
attending the emergency department. The regional pharmacovigilance centre and 
the department of clinical pharmacology prospectively recorded all potential ADRs 
among patients under 18 years old in the paediatric emergency unit reported at the 
daily staff meetings. All cases were then screened and validated by the regional 
pharmacovigilance centre. Confirmed ADR cases were assessed for avoidability, 
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seriousness, and off-label use. Ninety children presented with potential adverse 
drug events and ADRs were confirmed in 43 patients. Avoidability was assessed 
using the algorithm from Olivier et al. (2005). Three ADRs (7%) were deemed 
avoidable (Planchamp et al. 2009).  
 
1.9.2.4 Combined Settings (causing admission and in hospital) 
 
Baniasadi et al. (2008) conducted a study in a 250 bed, tertiary care, 
multidisciplinary teaching hospital. The study included both children and adults. The 
aim was to establish an ADR reporting and monitoring centre. The study 
encouraged the reporting of ADRs over a 12 month period through ADR reporting 
yellow forms, via a rapid telephonic reporting system or direct reporting to the 
pharmacovigilance team. An ADR was defined according to the WHO (1972) 
definition. Each ADR was assessed for causality, severity and avoidability. The 
avoidability assessments were conducted using the criteria defined by Schumock 
and Thornton (1992). Over the study period a total of 6840 patients were admitted 
and 112 ADRs were reported. Thirty six patients aged 0-18 experienced an ADR. 
Overall 22.3% of the ADRs were classified as avoidable, the percentage breakdown 
of avoidable ADRs in children was not available (Baniasadi, Fahimi & Shalviri 2008).   
 
A study by Oshikoya et al. (2007) used data pooled from two studies; a 
retrospective medical record review of paediatric admissions and a prospective 
observational study of admissions. The prospective study included a six month data 
collection period which looked at all patients admitted to the paediatric ward with a 
stay greater than 24 hours.  The retrospective study was performed using the 
hospital admissions records which looked at a two year period from 2004 to 2006 
and identified children with an ADR whether it was present on admission or 
occurred during a hospital stay. ADRs were defined according to the WHO (1972) 
definition. Causality assessments were carried out using the criteria by Jones (Jones 
1982). The incidence of ADRs causing admission was 0.45% and 0.71% for ADRs in 
hospital. In total 44 children were reported to have experienced an ADR. Twenty 
eight ADRs were deemed definite, twelve probable and four possible. 98% of the 
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ADRs were categorised as avoidable however, no information was provided on the 
assessments and how they were conducted or what criteria were used. The most 
commonly reported ADRs during the study period were skin related with erythema 
multiforme and a pustular rash accounting for almost 55% of cases (Oshikoya KA et 
al. 2007).  
 
A study by van der Hooft et al. (2008) looked at ADR related admissions over a one 
year study period in 2003. The study was retrospective and included patients 
(adults and children) from an Integrated Primary Care Information (IPCI) database, a 
General Practitioner (GPs) research database which included data from electronic 
patient records of approximately 150 GP surgeries. Patient records and hospital 
discharge summaries were reviewed for ADRs. The research team was comprised of 
research assistants and four doctors. The team evaluated discharge letters each 
letter was reviewed independently by two doctors; where discharge letters were 
not available electronic patient records were used to gather the required 
information. Consensus meetings were held and where any disagreement occurred 
either in causality or avoidability assessments discharge letters were re-evaluated if 
agreement could not be reached then a third doctor was consulted and their 
decision was taken as definitive. Causality assessments were completed using the 
WHO criteria (World Health Organisation 1969) and avoidability assessments were 
conducted using Hallas et al. (1990). In total 3609 hospital admissions occurred in 
the study population during the study period however, 94 cases were excluded due 
to lack of information. Of the remaining 3515 admissions, 122 ADRs were detected 
and 115 were acute. One ADR occurred in children under 16 years of age, it was 
deemed not avoidable. 24 ADRs occurred in the 17-55 age group but the 
breakdown of how many occurred in patients under 18 was not available.  35/115 
ADRs were categorised as avoidable (van der Hooft et al. 2008). 
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1.9.2.5 Other paediatric studies which have assessed ADR avoidability identified 
from a systematic review of inpatient ADRs in adults and children by Khan (2013) 
 
The systematic review by Khan (2013) included 51 studies from 2000 to April 2013. 
The review aimed to investigate the comparative impact of hospital acquired ADRs 
in adults and children in terms of economic implications and to describe incidence, 
severity, morbidity, mortality and preventability of the ADRs. ADRs were defined 
using the WHO (1972) definition. In their description of studies which conducted 
avoidability assessments they cited the systematic review by Smyth et al. (2012) 
and stated that various individual studies of ADRs in hospitalised children have 
shown different avoidability rates. Two additional studies were mentioned Temple 
et al. (2004) and Priyadasini et al. (2011). The study by Banisaddi et al. which was 
included in the review by Smyth et al. (2012) was also mentioned although child 
specific data relating to avoidability was not available. It was not clear from the 
paper if they had included other studies which looked at avoidability but no others 
were mentioned (Khan 2013). 
 
Other studies 
A study conducted in the US by Temple et al. (2004) which looked at the frequency 
and avoidability of ADRs over a six year period from 1994 to 1999 found the 
incidence to be 0.85 ADRs per 100 admissions. 20.7% of the ADRs reported were 
avoidable. Avoidability was assessed using the Schumock and Thornton (1992) 
criteria and two assessors reviewed the cases for avoidability. 
 
An observational study conducted in the paediatric department of a tertiary 
hospital which included all children under 12 inpatients and outpatients. Inpatients 
included those who were admitted as a result of an ADR and those who 
experienced an ADR during their hospital stay. Over the study period July to 
September 2009, 30 ADRs were recorded. Causality, severity and avoidability were 
assessed for the ADRs. A modified version of the Schumock and Thornton (1992) 
criteria was used to assess preventability. The majority of ADRs were categorised as 
probable preventability (87%) and 3% were definitely preventable. Overall 90% of 
ADRs were deemed preventable (Priyadharsini et al. 2011).   
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1.9.2.6 Results from the Hakkarainen et al. (2012a) systematic review 
 
Hakkarainen et al. (2012a) conducted a systematic review of methods for assessing 
the avoidability of ADEs (described earlier in section 1.7.7). The review included 38 
studies which investigated the avoidability of ADRs. Of these eight studies used 
Hallas et al. (1990), three used Imbs et al. (1998) and fifteen used Schumock and 
Thornton (1992). Both adult and paediatric studies were included; details of the 
individual studies are outlined in table 1.5.  
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Table 1.5 Summary of studies included in the systematic review by Hakkarainen et al. 
(2012a) which assessed avoidability of ADRs in adults or children 
 
Authors Country Study design Population Avoidability 
Calderon-Ospina 
et al. 2010 
Colombia Cross-sectional  
Observational 
 
≥ 18 years Schumock and Thornton (1992) 
50% 
Farcas et al. 
2010 
Romania Prospective 
observational 
 
 25-92 years Imbs et al. (1998) 
50%  
Jonsson et al. 
2010 
Sweden Retrospective 
observational 
 
26-85 years Hallas et al. (1990) 
26% 
Lopez et al. 2010 Colombia Prospective 
observational 
 
≥ 18 years Dormann et al. (2003) 
Davies et al. 
2009  
United 
Kingdom 
Prospective 
observational 
 
 Hallas et al. (1990) 
53.3% 
Pourseyed et al. 
2009 
Iran Prospective 
observational 
 
13-91 years Schumock and Thornton (1992) 
50% 
Alexopoulou et 
al. 2008 
Greece Prospective 
observational 
 
15-100 years 
 
Chan et al. (2001) 
42.9% 
Al-Malaq et al. 
2008 
Saudi-
Arabia 
Retrospective 
observational 
 
1 month- 80 
years 
24.7% of 
cases were in 
children <18 
years 
Preventability by Type A, B, C 
60% (adults + children) Paediatric specific data 
not available 
Baniasadi et al. 
2008 
Iran Prospective, 
observational 
 
Adults and 
children 
Schumock and Thornton (1992) 
22.3% (adults + children) Paediatric specific 
data not available 
Franceschi et al. 
2008 
Italy Prospective 
observational 
 
≥65 years Hallas et al. (1990) and integrated by Gurwitz 
et al. (2000) 
76.5% 
Hopf et al. 2008 United 
Kingdom 
 
Prospective 
observational 
 
19-91 years Hallas et al. (1990) 
83.3% 
Joshua et al. 
2008 
India Prospective 
observational 
 
Adults Schumock and Thornton (1992) 
19.6% 
Mehta et al. 
2008 
South 
Africa 
Prospective 
observational 
 
>16 years Schumock and Thornton (1992) 
53% causing admission 
33.3%  hospital inpatients 
Ruiz et al. 2008 Spain Prospective 
observational 
 
Children 
were 
excluded 
Schumock and Thornton (1992) 
34.6% 
Subish et al. 
2008 
Nepal Retrospective 
observational 
 
Adults and 
children 
Modified Schumock and Thornton (1992) and 
Lau et al. (2003) 
9.09% (adults + children) Paediatric specific 
data not available 
Van der Hooft et 
al. 2008 
 
Netherlan
ds 
Retrospective 
observational 
 
Adults and 
children 
Hallas et al. (1990) 
30% for adults 
0% for children 
Grenouillet-
Delacre et al. 
2007 
France Prospective 
observational 
 
>15 years 48% 
(adults + children) Paediatric specific data not 
available 
Patel et al. 207  India Prospective 
observational 
 
>18 years Hallas et al. (1990) 
59.62% 
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Rivkin 2007 United 
States 
Prospective 
observational 
 
Not reported Schumock and Thornton (1992) 
86% 
Davies et al. 
2006 
United 
Kingdom 
 
Prospective 
observational 
 
Adults Hallas et al. (1990) 
59% 
Hanlon et al. 
2006 
United 
States 
Prospective 
intervention 
 
Male >65 
years 
37.63% 
Jose et al. 2006 India Retrospective 
observational 
 
Children and 
Adults 
Lau et al. (2003) 
28.7% 
(adults + children) Paediatric specific data not 
available 
Dormann et al. 
2004 
Germany Prospective 
observational 
 
18-97 years Schumock and Thornton (1992) 
44.3% 
Pirmohamed et 
al. 2004 
 
United 
Kingdom 
 
Prospective 
observational 
 
>16 years Hallas et al. (1990) 
72% 
Temple et al. 
2004 
United 
States 
Retrospective 
observational 
 
Paediatric Schumock and Thornton (1992) 
20.7% 
Dormann et al. 
2003 
Germany Prospective 
observational 
 
17-97 years Schumock and Thornton (1992) 
41.2% >65s 
65.7% <65s 
Easton-Carter et 
al. 2003b 
 
Australia Retrospective 
observational 
 
Paediatric Schumock and Thornton 1992 
9.8% 
Easton-Carter et 
al. 2003a 
 
Australia Prospective 
observational 
 
0-17 years Schumock and Thornton 1992 
30.5% 
McDonnell et al. 
2002 
 
United 
States 
Retrospective 
observational 
 
Children and 
adults ≤15 
Adapted from Schumock and Thornton (1992) 
62.3% (adults and children)  
Paediatric specific data available not available 
Olivier et al. 
2002 
France Prospective 
observational 
 
>15 years Imbs et al. (1998) 
34% Paediatric specific data available not 
available 
Letrilliart et al. 
2001 
France Prospective 
observational 
 
0-99 years Imbs et al. (1998) 
59% Adults 
0% for the 1 ADR detected in a child aged 15 
Wasserfallen et 
al. 2001 
 
Switzerla
nd 
Prospective 
observational 
 
16-93 years Livio et al. (1998) 
32% 
Lagnaoui et al. 
2000 
France Prospective 
observational 
 
15-94 years Dubois and Brook (1988) 
81.2% 
Gholami et al. 
1999 
Iran Prospective 
observational 
 
excludes 
children <10 
 
Criteria adapted from Schumock and Thornton 
(1992) 
58.8% 
5.9 % in ages 10-25 years 
Schumock et al. 
1995 
 
United 
States 
Prospective 
observational 
 
Not reported Mean rate 21.25% 
Pearson et al. 
1994 
United 
States 
Prospective 
observational 
 
Adults 19% 
Kramer et al. 
1985 
Canada Prospective 
observational 
 
0-18 years Highly preventable Probably preventable -
Unpreventable  77% 
 
Choonara et al. 
1984 
United 
Kingdom 
 
Prospective 
observational 
 
Paediatric Judgement  
40%  
Table 1.5 Summary of studies included in the systematic review by Hakkarainen et al. (2012) which 
assessed avoidability of ADRs in adults or children (continued) 
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1.9.2.7 Other studies which assessed avoidability  
 
The ADVISE study (previously described in Section 1.61) conducted avoidability 
assessments using the Schumock and Thornton (1992) criteria. All assessments of 
ADRs were carried out by the local research team in each country. Overall 16.6% of 
ADRs identified were categorised as avoidable. Avoidability rates ranged from 4.3% 
to 33.3% in the different countries; Australia reported the highest rate of avoidable 
ADRs and Malaysia reported the lowest rate of 4.3% (Rashed et al. 2012). 
 
An 8 month prospective study was conducted at a ten bed paediatric isolation ward 
of a University hospital (Weiss et al. 2002). Charts were reviewed once weekly by 
the study team. ADRs were defined according to the WHO (1972) definition. A total 
of 68 ADRs were detected in 46 of 214 patients. An adapted version of the Naranjo 
algorithm was used to assess causality. ADRs were classified as predictable or 
unpredictable, predictable ADRs may either be avoidable or tolerated, implying 
such events as toxicity, drug interactions, and secondary effects. Unpredictable and 
usually unavoidable ADRs include idiosyncratic or allergic reactions as well as 
intolerance. 24% of the ADRs were judged to be avoidable, 29% to be unavoidable, 
and the majority, 47% events to be tolerable. 
 
1.9.3 Incidence of avoidable ADRs in Adults 
 
A meta-analysis conducted in 2010 on preventable ADRs in adults showed that 
approximately half of ADRs among adult inpatients and outpatients may be 
avoidable (Hakkarainen et al. 2012b). The study also highlighted the lack of 
evidence on avoidable ADRs. The study confirmed that ADRs are a significant 
burden to healthcare among adults. No similar study has been done in paediatrics 
but studies suggest similar incidence rates.  
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1.10 Conclusion  
 
In summary, adverse drug reactions are a significant problem in children. The 
available instruments for the assessment of avoidability of ADRs vary in reliability 
and validity (Smyth et al. 2012). The assessment of avoidability is compromised by a 
lack of consensus on the definition of avoidability and associated heterogeneity in 
underpinning methodology for instrument development (Hakkarainen et al. 2012a). 
No instruments are available specifically for characterisation of ADRs in children and 
young people, and there is a requirement to develop such instruments.  There is a 
lack of data on avoidability of ADRs in children and there is wide variation between 
studies where data were available (Smyth et al. 2012). Given the burden of ADRs in 
children further work is needed to address how ADRs in children may be prevented 
in the future. Our experience with the Hallas approach indicated the need to 
develop a new method to assess avoidability in children. 
 
1.11 Aim and objectives of thesis 
 
1.11.1 Aim 
The aim of this thesis was to describe the avoidability of ADRs in children and 
methods used to assess avoidability. 
 
1.11.2 Objectives 
 
1 To develop and test a new avoidability assessment tool that is more suitable for 
use in paediatrics but which is also generalisable and applicable to a variety of 
other settings. 
2 To conduct reliability and validity testing on the new tool as per 
recommendations by Hakkarainen et al. (2012a) 
3 To test the hypothesis that group assessments are superior to individual 
avoidability assessments. 
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4 To assess the avoidability of the ADRIC admissions study cases using the newly 
developed Liverpool avoidability assessment tool and to compare the results to 
the existing Hallas assessments carried out as part of the ADRIC programme. 
5 To identify potential strategies for clinical practice that might reduce the 
incidence of ADRs. 
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Chapter 2: Development of the Liverpool Adverse Drug 
Reaction Avoidability Assessment Tool (LAAT)  
 
2.1 Introduction  
 
The prevention of avoidable harm due to ADRs is a prime clinical motivation for 
studying drug safety. According to the World Health Organisation (WHO), ADRs rank 
among the top ten leading causes of mortality in some countries (World Health 
Organisation 2004b). Patient and medication safety is high on the agenda of the 
European Medicines Agency (EMA) (European Medicines Agency 2011a), the 
Council of Europe (Expert Group on Safe Medication Practices 2006) and the WHO 
(World Health Organisation 2004b). The WHO has identified some key areas 
including measuring harm, understanding causes, identifying solutions, evaluating 
impact and translating evidence into safer care (World Health Organisation 2004b). 
A meta-analysis of avoidable ADR studies conducted by Hakkarainen et al. (2012b) 
concluded that avoidable ADRs are a significant burden to the healthcare system 
and a cause of morbidity among outpatients. They found that roughly half of all 
ADRs amongst adult inpatients (45%) and outpatients (52%) may be avoidable 
(Hakkarainen et al. 2012b).  
 
The importance of examining avoidability of ADRs became clear from two sources. 
Firstly, the ADRIC systematic review indicated that few previous studies (19/101) 
had examined avoidability and those that had, used inconsistent methods (Smyth et 
al. 2012). The review concluded that the available instruments for assessment of 
avoidability of ADRs vary in reliability and validity (Smyth et al. 2012). Secondly, 
difficulties were encountered during the assessment of avoidability using existing 
tools in the ADRIC inpatient study (Thiesen et al. 2013). The study of avoidability is 
complex. A key factor for this complexity is that there is no universally accepted 
definition for avoidability (Ferner, Aronson 2010b). Ferner and Aronson (2010) 
stated there are two aspects to avoidability: whether or not in principle an event is 
avoidable, in the absence of error and, if it is, whether or not we can, in fact, 
prevent it. They gave the example of penicillin hypersensitivity reactions, which, in 
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principle, can be avoided in patients who are known to be susceptible, by not giving 
the drug; however, in practice these reactions can still occur owing to lack of 
information available to the prescriber (Ferner, Aronson 2010b). Ferner and 
Aronson (2010) concluded in their systematic review that several definitions exist 
and none fits all circumstances.  
 
There have been many attempts to devise tools or scales to help determine 
avoidability including those by Hallas (1990), Schumock and Thornton (1992), 
Dormann et al. (2003), Ducharme et al. (2007) and Olivier et al. (2005). Commonly 
used scales include: Hallas (1990) and Schumock and Thornton (1992) which are 
based on appropriateness of prescribing or treatment choice.  
 
Hakkarainen et al (2012a) reported while there was wide variation in the methods 
used they all shared a common theme; the basis for defining avoidability whether 
an error or sub-standard care had resulted in an ADE (Hakkarainen et al. 2012a). 
Despite the importance of avoiding ADRs, this area remains under-researched. This 
may be attributable to the methodological problems in the area, which Hakkarainen 
et al (2012a) have summarised in a systematic review on methods for assessing the 
avoidability of ADEs. They listed inconsistent terminology as one of the problems; 
there is wide variation in the terms and definitions used (ADRs, ADEs etc.) and this 
hinders the interpretation and comparison of studies. In their review they used the 
term ADE which included ADRs and other AEs related to medications (Hakkarainen 
et al. 2012a).  
 
In the ADRIC admissions study Gallagher et al. (2012) used the Hallas scale (1990) 
(Figure 1.2) to determine avoidability and found that 78% of ADRs were 
unavoidable, and 22% were either possibly or definitely avoidable. They suggested 
some potential prevention strategies for ADRs based on their assessment of the 
ADRs they classed as  ‘definitely avoidable’- that more careful attention to practical 
aspects of care, such as improved monitoring, following prescribing guidelines and 
improved patient education, could lead to a reduction in the frequency of ADRs 
causing admission (Gallagher et al. 2012). The Hallas scale was chosen for the ADRIC 
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admissions study as it has been used previously in ADR studies by other 
investigators (Smyth R et al. 2014). Assessment of avoidability was undertaken by 
consensus approach using the definitions by Hallas et al. (1990) (Gallagher et al. 
2012). The Hallas criteria are less prescriptive than some other avoidability tools. 
The definitions, which are based on avoidability linked to standards of care, are 
wide and may lead to variability in assessor rating.  
 
The need for developing a new avoidability assessment tool (AAT) was identified 
during the ADRIC inpatient study when we tried to use the Hallas scale (1990) to 
determine avoidability (Thiesen et al. 2013). The Hallas scale (1990) is a series of 
four statements linked to standards of care (Figure 1.2). In particular we 
encountered difficulties with some of the language and mechanisms for judging 
avoidability. For example, the ADRIC team (comprised of a paediatrician, a 
paediatric research nurse and at least one paediatric research pharmacist) 
suggested that in some cases it was difficult to agree about the nature of ‘present 
day knowledge of good medical practice’. Specifically, Hallas was difficult to use in 
the inpatient study as treatment was often guided by tertiary paediatric specialist 
advice. ’Present day knowledge of good medical practice’ of treatments for 
paediatric diseases covers a vast range of information. Comprehensive awareness 
of the information required to assess avoidability of ADRs would require extensive 
reading and synthesis of information. Many paediatric conditions are rare or ultra-
rare which makes information difficult to locate. In contrast, the ADRIC admissions 
study predominantly involved a relatively small number of common acute 
conditions that the research team were familiar with, or, a relatively small number 
of acute complications of chronic illnesses that the research team were familiar 
with.  
 
Also, due to the much smaller number of ADR cases (249) detected in the 
admissions study it was possible to hold consensus meetings to discuss the 
avoidability of each ADR case report and using the Hallas (1990) tool assign an 
avoidability outcome. The consensus meetings involved senior members of the 
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ADRIC investigating group. It would not have been feasible in the inpatient study to 
hold consensus meetings due to the much larger number of ADR cases (1446). 
 
On other occasions, the study team found it difficult to agree on whether an event 
could have been avoided by ‘an effort exceeding obligatory demands’. This was 
partly because of different perceptions of the ‘obligatory demands’ in particular 
clinical settings and partly because there were a range of opinions about whether 
extra effort would have made a difference to the occurrence of an ADR. In the 
ADRIC admissions study, 17.7% of ADRs were associated with prescriptions 
originating from community, 34.1% originating from hospital for non-oncology 
related conditions and 48.2% were prescriptions originating from oncology 
(Gallagher et al. 2012). The most common ADRs in the ADRIC admissions study were 
oncology related and there was clarity about nature of standard practice. In the 
ADRIC inpatient study opioid analgesics and drugs used in general anaesthesia (GA) 
accounted for more than 50% of all drugs implicated in ADRs (Thiesen et al. 2013). 
Analgesia and anaesthesia are usually tailored to the needs of the child and the 
clinical context. The nature of obligatory demands and the effort required to meet 
or exceed obligatory demands depend on the circumstances of the individual case. 
The information about each ADR case was not sufficient to allow judgments about 
obligatory demands. It may not be feasible to gather this information in research or 
clinical settings. 
   
For example, a variety of anaesthetic‐related factors have been implicated in 
producing increased post-operative vomiting (POV) in children. However, few of 
these factors are included in any of the POV risk scoring systems for paediatric 
patients. The use of inhaled anaesthetic agents has been linked with an increased 
risk of emesis particularly in children who have other risk factors for POV. It is 
recommended that total intravenous anaesthesia is considered for children who are 
at high risk of POV undergo surgery that has a high risk of producing POV (The  
Association  of  Paediatric  Anaesthetists  of  Great  Britain  &  Ireland 2009). 
Also the use of opioid analgesia in theatre may be associated with an increased risk 
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of POV and the Association of Paediatric Anaesthetists (APA) recommend that 
anaesthetists try to minimise the use of opioid analgesia where possible in high risk 
patients.  Using the Hallas score to assess avoidability of POV cases proved difficult 
in the ADRIC inpatient study, as it was difficult to assess the nature of obligatory 
demands given the individual nature of these cases.  
 
Another factor was the issue of guidelines. Paediatric guidelines do not exist for 
many therapeutic areas included in the ADRIC in patient study. If a guideline could 
be identified, it rarely contained information about prevention of ADRs. This 
situation was different from the ADRIC admissions study in which almost half of the 
ADRs were oncology related. As there are well documented guidelines available in 
this area, it made the application of Hallas to these cases easier (Gallagher et al. 
2012). During the in-patient study trial protocols and guidelines for oncology cases 
were often available and contained information about ADR prevention for example, 
prevention of chemotherapy induced nausea and vomiting. In contrast, there were 
no guidelines available for the cardiac related ADRs for example fluid retention, 
cardiac failure, hyponatremia, or hypokalaemia. There were no clear guidelines 
available for the prevention of opioid related constipation although some of the 
treatment protocols referred to constipation and the co-prescription of laxatives 
the guidance was unclear and varied between different protocols and guidelines. 
Other examples where no guidelines were available included diarrhoea, 
hypomagnesaemia, and raised liver enzymes.   
 
The Hallas scale (1990) was used for the ADRIC admissions study but appeared 
unsuitable for the ADRIC inpatient study owing to difficulties relating to the need to 
have comprehensive knowledge of the optimal treatment for all conditions 
represented in the cohort, the need to assess the obligatory demands of a case and 
the incomplete coverage of guidelines. The ADR cases were divided into four main 
therapeutic areas surgical, medical, oncology and cardiology and covered a wide 
range of conditions. For some patients in the cohort their treatment was often 
guided by multiple specialists. With the lack of guidelines and the wide variation in 
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cases in order to have used Hallas to assess avoidability in the ADRIC inpatient study 
it would have required the study team consulting with experts for the specific areas 
and asking the clinical team involved to provide a rationale for treatment. This 
would not have been feasible. As a result of this it was decided by the study group 
that we would design a new AAT which would be more suitable for use in 
paediatrics by avoiding these difficulties and which could also be used in other 
settings. Ideally, the newly developed AAT should be generalisable to a variety of 
different patient groups, reproducible and easy to use.  
 
Hallas is not the only approach that we could have used for the inpatient study. 
However, other approaches such as Schumock and Thornton (see Figure 1.3) 
involved similar judgments about appropriate care particularly questions 1 and 2. 
Therefore, it was decided that the Schumock and Thornton tool was not 
appropriate for use in the ADRIC in-patient study either. 
 
2.2 Aim and objectives of this work 
The aim of this study was to develop a new avoidability assessment tool that was 
generalisable and met all of the criteria of a good tool as described by Hakkarainen 
et al. (2012a). The objectives were to develop an algorithm with dichotomous 
responses based on Hallas (1990) and to conduct reliability/validity testing on the 
new tool as per Hakkarainen et al. (2012a) recommendations.  To assess the 
avoidability of a selection of ADRs reported in the ADRIC inpatient study and to 
identify strategies for clinical practice that might reduce the incidence of ADRs.  
 
2.3 Methods 
 
2.3.1 Preliminary Work 
 
A modified version (Figure 2.1) of the Hallas Scale (1990) was used as the starting 
point for the development of the Liverpool avoidability assessment tool (LAAT) but 
the focus was on the available information sources. The study team included 
experienced paediatricians, clinical paediatric pharmacists, a paediatric research 
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nurse and research methodologists. In discussion, the study team defined a number 
of principles that would underlie the new tool. The team wanted to ascertain if the 
relevant information was available in sources that prescribers would be expected to 
use, and, if so, whether the recommended advice was followed. The intention was 
to keep the tool as generalisable as possible by asking if accessible management or 
treatment plans were available.  These could be local, national or international. We 
recommended that only high-quality guidelines were considered. A guideline that 
would be recognised as appropriate by a reasonable body of opinion for example, 
Scottish Intercollegiate Guidelines Network (SIGN), National Institute for Health and 
Care Excellence (NICE), Royal College of Paediatrics and Child Health (RCPCH) or 
other peer-reviewed guidelines (Brouwers et al. 2010). For example in the case of 
post-operative nausea and vomiting, examples of appropriate management plans 
could include: Alder Hey Children's NHS Trust guideline on post-operative nausea 
and vomiting or the association of paediatric anaesthetists of Great Britain and 
Ireland (APA) guideline on the prevention of post-operative vomiting in children.  As 
guidelines are not always available, or contain no information on prevention of 
ADRs, we added other information sources, for example British National Formulary 
for children (BNF-C), Summary of Product Characteristics (SmPC).  
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Figure 2.1 Modified Hallas scale  
Hallas Scale (Hallas et al. 1990) 
 Definitely avoidable: The event was due to a drug treatment procedure inconsistent with 
present-day knowledge of good medical practice or was clearly unrealistic, taking the known 
circumstances into account 
 Possibly avoidable: The  prescription was not erroneous but the event could have been avoided 
by an effort exceeding the obligatory demands  
 Not avoidable: The event could not have been avoided by any reasonable means, or was an 
unpredictable event in the course of a treatment fully in accordance with good medical practice 
 Unevaluable: The data for rating could not be obtained or the evidence was conflicting 
Problems  
Inconsistent evaluations due to difficulties around the definition of “effort exceeding the obligatory 
demands of present day knowledge of good medical practice”  
Numbers of reactions which are impossible to assess. 
 
Adapted Hallas Scale 
 Definitely avoidable  
 Treatment not used in accordance with relevant source documentation (SPC, BNFC, Local 
Guidelines or pathway) 
 
 Non-administration of a prophylactic treatment specified in the relevant source documentation 
which could have been given within a realistic time course 
 
Possibly avoidable 
 One or more alternative approaches are found in relevant source documentation 
 
 Prophylactic or mitigating treatment available in theory, but not part of source documentation 
  
Not avoidable 
 Idiosyncratic reaction 
o Anaphylaxis with penicillin in a patient with no previous history of allergy 
 Treatment used in accordance with source documentation 
 
Unevaluable 
 Lack of information about optimal care (no relevant source documentation) 
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Figure 2.2 Flow chart of the preliminary work on the development of a new AAT 
 
 
 
 
A pilot study was carried out in November 2011, where three reviewers (a research 
nurse, and two pharmacists, all members of the ADRIC Study team independently 
assessed fifty ADR cases using a modified version of the Hallas scale (Figure 2.1) and 
a second fifty cases using the original Hallas scale (1990). The results were 
compared and inter-rater reliability (IRR) testing was carried out on both groups. 
Kappa values were interpreted according to the guidance from Altman (1991). The 
kappa scores for both groups were low. The modified Hallas group scores were 
poor, with pairwise kappa scores ranging from 0.0597 to 0.159. The kappa scores 
for the Hallas group were fair with pairwise kappa scores ranging from 0.209 to 
0.357. The reason for slightly better kappa scores for the Hallas group may be due 
to the nature of the cases.  The problem appeared to be distinguishing between 
‘possibly avoidable’ and ‘not avoidable’. There was difficulty with the language 
‘effort exceeding obligatory demands’ and what constituted this.  
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It was agreed that the LAAT should be redesigned to a flow diagram in an attempt 
to make it more user friendly and consistent to use. It was decided that some 
questions required rewording and that this should be done by a consensus 
approach (Ferner, Aronson 2010b).  We achieved consensus by agreement among 
peers without pre-set criteria and the consensus group was a multidisciplinary team 
(MDT) comprising a research children’s nurse, paediatrician and a paediatric 
pharmacist. A research pharmacist observed the group process and gathered 
comments from the participants. The initial tool was modified at each stage based 
on feedback to improve functionality and remove inconsistencies (see figure 2.3 
Version 1 of the AAT). This version of the AAT was fed into the next stage of 
development. 
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* If the case is ‘Unassessable’ please specify if this is due to “lack of information about the case” or “lack of information about guidance” 
Is there sufficient information* 
available about the case and/or 
treatment and preventative 
measures to allow assessment? 
No 
Unassessable 
 
Yes 
Was the reaction 
predictable on the basis of 
pharmacology? 
No
Was there a known history of 
allergy or previous reaction to the 
drug? 
No 
Not 
avoidable 
Yes 
Were preventative measures used 
appropriately? 
No 
Were treatment or preventative 
measures easily available? 
No
Possibly 
avoidable 
Yes 
Definitely 
avoidable 
No 
Was the treatment or management 
plan followed? 
Yes 
Yes 
Was there an appropriate 
treatment or management 
plan available? 
Yes 
Yes 
No 
Figure 2.3 Version 1 of the AAT 
Figure 2.3 Version 1 of the AAT 
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2.3.2 Development of the LAAT 
 
Phase 1a: Define the tool 
It was agreed that the best way to develop a new tool was to take a consensus 
approach in reviewing ADR cases. The format of the new tool was a flow diagram 
with dichotomous responses to each question followed by a routing to the next 
relevant question (see Version 1 of the tool, Figure 2.3, which had been developed 
in preliminary work). It was decided this would differ from the specific criteria that 
Hallas et al. (1990) has for each avoidability category. Initially twenty cases 
(randomly selected) from the ADRIC inpatient study were reviewed to define the 
tool (see Appendix 1 for a sample ADR case). This was carried out by a MDT working 
together to discuss clinical practice and avoidability outcome and observed by a 
research pharmacist. It was an iterative process and each question in the newly 
modified avoidability flow diagram was reviewed by the investigators during the 
consensus meetings and any necessary changes were made (see figure 2.4 for the 
LAAT development process). Two out of twenty cases were classified as 
‘unassessable’ because of lack of information about the case. Both were 
constipation cases and were missing vital information, such as fluid balance charts 
making the cases unassessable.  
 
 
The MDT carried out an avoidability assessment on the twenty cases. 20% of the 
ADRs were categorised as either ‘possibly’ or ‘definitely avoidable’, 70% of ADRs 
were deemed ‘unavoidable’ and 10% were ‘unassessable’. It was felt that it was not 
appropriate to distinguish between guidelines, and, for the purpose of the ADRIC 
inpatient study cases, we accepted, any available guidance based on an acceptable 
body of opinion, for example SIGN, Alder Hey Trust guidance or NICE guidance. A 
glossary was prepared to further explain this and other terms (see Appendix 2). Any 
areas of disagreement or discrepancies were reviewed by a clinical pharmacologist, 
who also reviewed the iterations as they moved through the various stages of 
development.  
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The consensus group discussed the different levels of avoidability and came up with 
the following list: 
 
• Patient (vital source of information) 
• Ward (communication/handover/feedback) 
• Departmental (management plans for chronic patients/staff training) 
• Institutional (what guidelines are in place and how up to date are 
they?/electronic prescribing (EP)/root cause analysis (RCA)/audit) 
• Professional (Continuing professional development (CPD)/training/over the 
counter (OTC) medicines) 
• National (guidelines/standards/regulatory systems/off-label/unlicensed 
prescribing) 
 
Phase 1b: Modify the tool 
The flow diagram was modified using twenty randomly selected cases from ADRIC 
inpatient study, with rephrasing of questions and additional information sources. 
Consensus of opinion was reached for the design and this version of the tool (Figure 
2.4) was carried forward to the next phase.  
 
Phase 1c: Refine the tool 
Two MDT groups, the original plus a new group (paediatric nurse, pharmacist and 
paediatrician), reached consensus about a second set of twenty cases from the 
ADRIC inpatient study, which were a randomly selected stratified sample in order to 
reflect the breakdown of specialties and types of ADRs in the study. The breakdown 
of the probable and definite cases was as follows:  
 
 11 surgical 
 4 oncology 
 2 medical  
 3 cardiology  
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Figure 2.4 Flow chart of the development of the Liverpool ADR avoidability 
assessment tool  
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Probable and definite cases were selected in line with the analysis undertaken in 
the ADRIC inpatient study and therefore possible cases were not included in the 
ADR case selection (Thiesen et al. 2013).  Both groups reviewed the same twenty 
cases. The results were compared, kappa scores were calculated and the 
concordance of routes and the final avoidability categories assigned. Both MDT 
meetings were observed and the assumptions and approaches of the teams were 
recorded. The difference in approach taken by the two MDTs was interesting with 
the original MDT looking up more guidelines than the second MDT despite the same 
resources being available to both groups. The latter approach may be more 
reflective of what happens in clinical practice. The second MDT group classified 
3/20 cases as ‘unassessable’ whereas the other group assessed all 20 cases (see 
Table 2.1 for details of the cases). Further changes to the tool were made as a result 
of the findings with two of the questions being amended to include ‘known 
preventative strategies’- prophylactic or concomitant medicines or any necessary 
monitoring. This was due to the three constipation cases in the stratified sample 
which the groups disagreed on, with one group categorising the cases as either 
‘possibly’ or ‘definitely avoidable’ and the other categorising all three cases as ‘not 
avoidable’. 
 
This led to a change in two questions on the tool (see Figure 2.5 and 2.6 – amended 
questions are circled): 
‘Was there an appropriate treatment or management plan, with information about 
the ADR and its avoidance, available?’ was changed to ‘Were there known 
preventative strategies and/or appropriate management plan(s), with information 
about ADR avoidance available?’  
 
The second change was to ‘Was the drug(s) used in accordance with the treatment 
or management plan?’ which was amended to ‘Were the strategies and/or 
management plan(s) followed?’  
 
These changes were to allow for ADR cases where either, there is no management 
plan available or, there is a management plan available but it contains no reference 
about ADR avoidance but preventative strategies may be applicable; for example 
the constipation cases.  
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Table 2.1 Details of the cases categorised as unassessable by MDT 2 in phase 1c 
ADR Type Drug (s) involved in 
ADR 
Causality   Avoidability Rationale 
Drug withdrawal 
 syndrome 
Chloral Hydrate Probable Unassessable Lack of 
information 
about the case 
- query other 
reasons for 
patient being 
unsettled. 
More 
information 
needed to 
assess. 
 
 
Hypotension Clonidine 1mcg/mL 
& Levobupivicaine 
1.25mg/mL 
 
Probable Unassessable Lack of 
information 
about the case 
- need 
information 
about intra-op 
blood loss and 
fluids given to 
assess the case. 
 
 
Hypertension Methylprednisolone Definite Unassessable Lack of 
information 
about the case 
- would like 
additional 
information 
regarding rates 
of infusion and 
more frequent 
BP 
measurements. 
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Figure 2.5 Version 2 of the avoidability assessment tool (used in Phase 1c) 
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2.3.2 Phase 2: Testing and validation of the tool  
 
The refined tool (version 3, Figure 2.6) was then tested on a further set of ADRIC 
inpatient study cases with the aim being to improve inter-rater reliability (IRR). This 
phase involved the assessment of fifty cases by six individual reviewers using the 
newly refined tool. For further details on completing an avoidability assessment see 
the accompanying glossary and guide to the questions in the tool (Appendix 2). 
These 50 cases were a stratified sample of possible, probable and definite cases (26 
surgical, 9 oncology, 9 medical and 6 cardiology). The reviewers included two nurses 
(HM and JS), two pharmacists (JB and LB) and two paediatricians (DH, MT). These 
cases were assessed in terms of pairwise agreements between the investigators. 
Cases where extreme disagreement occurred i.e. where the avoidability assessment 
differed by more than one category for example ‘not avoidable’ and ‘definitely 
avoidable’ and any cases for which half of the raters differed in assigning a category 
were identified and the questions which caused the discrepancies were reviewed. 
 
2.3.3 Data analysis  
 
The results were presented as categorical scores from the newly developed tool and 
inter- rater agreements were calculated using kappa scores with 95% confidence 
intervals (CI). Pairwise kappa scores were compared with global kappa scores. The 
percentage extreme disagreement (%ED) where the avoidability scores between 
two raters of the same case are wider than one interval apart were calculated to 
measure extreme disagreement between pairwise kappa scores. Pairwise kappa 
scores were also calculated by speciality to investigate the differences between 
surgical, medical, oncology and cardiology cases.  
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Kappa values were interpreted according to the guidance from Altman (1991)  
(Table 2.2) (Altman 1991):  
 
Table 2.2 Interpreted kappa values according to Altman (1991)  
 
 
 
 
 
 
  
 
 
There was no preset level for Kappa acceptability for the development of the LAAT. 
It may have been useful to have assigned a minimum Kappa score for agreement.  
 
2.4 Results 
2.4.1 Phase 1c  
 
The assessment of 20 ADR cases was undertaken by two different MDT groups 
(Table 2.3) using LAAT version 2 and showed fair agreement with a kappa score of 
0.29 (95% CI -0.04 to 0.62). The two groups agreed on 65% of the ADR cases. Group 
members commented that a mixture of professions was needed to give a full 
assessment of avoidability. Changes to the tool were made as a result of the 
findings, with two of the questions being amended to include ‘known preventative 
strategies’. 
 
Agreement Kappa   
Poor  < 0.2 
Fair 0.21–0.40 
Moderate 0.41–0.60 
Good 0.61–0.80 
Very good 0.81–1.00 
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Figure 2.6 The Liverpool ADR avoidability assessment tool (LAAT) (version 3 as used in Phase 2)
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Table 2.3 Phase 1c results - ADR type and avoidability outcome 
ADR Type MDT 1 - avoidability outcome MDT 2 - avoidability outcome 
Surgical     
Diarrhoea Not avoidable Not avoidable 
Procedural vomiting Not avoidable Not avoidable 
Constipation Possibly avoidable Not avoidable 
Constipation Definitely avoidable Not avoidable 
Urinary retention post-
operative 
Not avoidable Not avoidable 
Constipation Possibly avoidable Not avoidable 
Hypotension Not avoidable Unassessable 
Somnolence Not avoidable Not avoidable 
Somnolence Not avoidable Not avoidable 
Procedural vomiting Definitely avoidable Definitely avoidable 
Drug withdrawal 
syndrome 
Possibly avoidable Unassessable 
Medical   
Hypertension Not avoidable Unassessable 
Hypomagnesaemia Not avoidable Not avoidable 
Cardiology   
Procedural vomiting + 
Vomiting 
Definitely avoidable Definitely avoidable 
Hypotension Not avoidable Not avoidable 
Melaena Not avoidable Not avoidable 
Oncology   
Nausea Not avoidable Not avoidable 
Vomiting Definitely avoidable Not avoidable 
Pain Not avoidable Not avoidable 
Hypokalaemia Not avoidable Not avoidable 
Overall results MDT 1 MDT 2 
Unassessable 0 (0%) 3 (15%) 
Not avoidable 13 (65%) 15 (75%) 
Possibly avoidable 3 (15%) 0 (0%) 
Definitely avoidable 4 (20%) 2 (10%) 
Total 20 20 
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2.4.2 Phase 2  
 
Six individual reviewers assessed 50 ADR case reports using version 3 of the LAAT. 
Pairwise kappa scores ranged from poor to good, 0.12 to 0.75 and percentage exact 
agreement (%EA) ranged from 52-90% (Table 2.4). 77% of cases were categorised as 
‘not avoidable’ and 23% were classified as either ‘possibly’ or ‘definitely avoidable’ 
(Table 2.5).  Stronger agreement was found within professions than between 
professions. Comparison of reviewers by specialty type highlighted that agreement 
was better for certain specialties particularly oncology and surgical. In 34% of all 
cases all six reviewers agreed on the avoidability assessment and this increased to 
68% for five reviewers. Agreement was better between the ADRIC study group team 
(HM, JB and LB). Some of the comments recorded for the cases with disagreement 
included: ‘no relevant experience in area’, ‘no access to the relevant guideline’ and 
‘unsure if this is even an ADR’; which perhaps underpins the need for a MDT to 
carry out the assessments. Or, if assessments are to be carried out individually this 
highlights the need for information or guidance on assessments to be provided. 
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Table 2.4 Avoidability assessment of ADR cases from phase 2 
 
 Assessor 2 
 LB JB HM MT JS DH 
A
ss
es
so
r 
1
 
LB % EA  90% 84% 78% 60% 70% 
Kappa 
(95% CI) 
 0.75 
(0.53  
to 
 0.97)  
0.60 
(0.42 
 to 
 0.79) 
0.49 
(0.26  
to 
0.72) 
0.23 
(0.07  
to  
0.38) 
0.34 
(0.11 
 to  
0.56) 
JB % EA   80% 68% 60% 60% 
Kappa 
(95% CI) 
  0.49 
(0.31 
 to 
 0.67) 
0.26  
(0.05  
to  
0.46) 
0.20 
(0.03  
to  
0.37) 
0.12 
(-0.09  
to  
0.32) 
HM % EA    70% 66% 64% 
Kappa 
(95% CI) 
   0.30 
(0.12  
to  
0.49) 
0.32 
(0.17 
to 
 0.47) 
0.21 
(0.03  
to  
0.39) 
MT % EA     58% 62% 
Kappa 
(95% CI) 
    0.23 
(0.08 
 to  
0.38) 
0.20 
(-0.02 
 to   
0.42) 
JS % EA      52% 
Kappa 
(95% CI) 
     0.18 
(0.03 
 to 
 0.33) 
DH % EA       
Kappa 
(95% CI) 
      
%EA - Percentage Exact Agreement 
 
 
Kappa Scores          Reviewer Key 
 
Kappa values were interpreted according to the guidance from Altman (1991) 
 
Initials Reviewer Type  Member of ADRIC  
LB Research Pharmacist Member of the ADRIC study team 
JB Research Pharmacist Member of the ADRIC study team 
HM Research Nurse Member of the ADRIC study team 
MT Paediatrician Member of the ADRIC Senior 
Investigator group 
DH Paediatrician No 
JS Nurse (Pain team) No 
Agreement Kappa   
Poor  < 0.2 
Fair 0.21–
0.40 
Moderate 0.41–
0.60 
Good 0.61–
0.80 
Very good 0.81–
1.00 
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Table 2.5 Possibly and definitely avoidable cases and explanation of assessment 
result 
 
ADR Type Frequency Avoidability 
assessment 
Drug Classes Rationale for 
potential 
avoidability 
 
Procedural 
vomiting 
3 Definitely  Drugs used in 
general 
anaesthesia, 
Opioid 
analgesia 
 
Appropriate 
prophylaxis not used 
Vomiting 1 Definitely Cytotoxics Appropriate 
prophylaxis not used 
 
Constipation 5 Definitely Opioid 
analgesia +/- 
Drugs used in 
nausea 
 
Appropriate 
prophylaxis not used 
Procedural 
vomiting & 
vomiting 
1 Definitely Drugs used in 
general 
anaesthesia, 
Opioid 
analgesia 
 
Appropriate 
prophylaxis not used 
Constipation 1 Possibly Opioid 
analgesia 
 
Appropriate 
prophylaxis not used 
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2.5 Discussion 
 
There have been many attempts to devise tools or scales to help determine 
avoidability. There is currently no standardised method for determining ADR 
avoidability and many of the established tools are not suitable for use in paediatric 
practice. The available instruments for assessment of avoidability of ADRs vary in 
reliability and validity (Smyth et al. 2012). The assessment of avoidability is 
compromised by a lack of consensus on the definition of avoidability and associated 
heterogeneity in underpinning methodology for instrument development. No 
instruments were available specifically for characterisation of ADRs in children and 
young people, and therefore there was a requirement to develop such instruments 
(Smyth et al. 2012). The LAAT was an attempt to develop and validate a new 
instrument to improve the assessment of avoidability of ADRs in children.  
 
The new AAT was developed for use in hospital settings by healthcare professionals 
involved in clinical care. Our immediate need was for a research tool that would be 
used to assess the avoidability of cases described prospectively using structured 
data collection instruments. Whilst it may be useful in a research setting to know 
whether an ADR is ‘possibly’ or ‘definitely’ avoidable; in clinical practice it is not 
really important to distinguish between the two. As when an ADR is categorised as 
possibly or definitely avoidable the end result and impact to the patient is 
ultimately the same. The action taken and the learning points or system changes 
which may be implemented as a result to minimise the risk of recurrence are the 
same; regardless of whether the ADR was possibly or definitely avoidable. ADRs 
categorised as avoidable should be treated in the same manner. If anything can be 
done to potentially avoid the ADR these steps should be taken regardless of the 
assigned avoidability category. The four avoidability categories were maintained on 
the LAAT to allow direct comparison to the ADR cases assessed using the Hallas 
scale. If the LAAT was to be further developed for use in a clinical setting the 
number of categories could be reduced to ‘avoidable’ and ‘not avoidable’. In the 
context of a clinical tool the “unassessable” category also becomes less relevant. As 
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when an ADR is categorised as “unassessable” it may be indicative that something 
was missed or not completed in the care of the patient. However a small number of 
“unassessable” cases in the research setting may have been due to information 
missing from the medical notes which was required for the completion of the ADR 
case report. It would be important to distinguish between those possibilities in 
further development of the LAAT in a clinical context. The ADR case reports for the 
ADRIC study were written using the medical notes, fluid balance charts, prescription 
charts, nursing notes on the inpatient system Meditech were also viewed and 
information added to the report where appropriate. The ADRIC study team 
endeavoured to include all relevant information where available. Occasionally, 
some information was missing for example fluid balance charts were not routinely 
kept by all wards. Table 2.1 shows the details of cases deemed “unassessable” by 
one of the MDTs in Phase 1c. If ADR avoidability assessments were conducted 
prospectively it may reduce the number of “unassessable” cases. The advantage of 
assessing avoidability using the ADRIC case reports was that it significantly reduced 
the amount of time taken to assess the case as the ADR case reports contained the 
information required to make the assessments rather than asking reviewers to 
search through the medical notes which may not have been feasible given the time 
constraints. The prospective avoidability assessments using medical notes may be 
more time consuming; depending on the team assessing the case and their 
familiarity of the patient which, in some cases may make the process quicker if they 
are very familiar with the patient’s history.    
 
If the LAAT had been designed for a clinical context it might have looked quite 
different. The number of avoidability categories could have been reduced down 
from four to two: ‘avoidable’ and ‘not avoidable’ for the reasons discussed above. 
This may have resulted in a tool that was less complex and perhaps easier to use. 
The reduction in the number of avoidability categories from four to two is likely to 
have improved inter-rater reliability as the number of variables would be reduced”. 
However, as the LAAT was designed as a research tool rather than a clinical tool the 
four avoidability categories used in the Hallas scale were maintained in the LAAT. 
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We anticipate that the tool will also be used to assess cases described 
retrospectively. For example, to summarise the investigation of high impact or 
sentinel cases during safety review by a medicines management committee.  
 
The results of the initial validation studies showed mixed IRR, which prompted a 
review of the appropriateness of the tool and its questions. A central theme of the 
review was the finding that the assessment of avoidability frequently required 
information or judgments that were not part of the routine expertise of particular 
professions. A comprehensive assessment required input from multiple 
professionals. It was thus hypothesised that MDT groups may be more consistent 
than individuals as groups are more representative of the ward setting where care 
is provided within teams. This gave rise to the next step in the development of the 
LAAT: to test the hypothesis that group assessments are superior to individual 
avoidability assessments.  
 
Following the completion of Phase 2 it was decided that further testing was needed 
and that perhaps the best way to assess avoidability is in a group setting. Pairwise 
kappa scores ranged from poor to good agreement; possible reasons for this may 
be due to lack of experience in certain specialty areas or a possible training effect. 
As mentioned in the Methods Section 2.3 it may have been useful to have assigned 
a minimum Kappa score for agreement. As the LAAT was designed as a research 
tool rather than a clinical tool the minimum value for Kappa might have been set at 
a lower value than if the LAAT was designed as a clinical tool.  For a clinical tool the 
minimum Kappa score might be set to a minimum of 0.80 which indicates good 
agreement according to Altman (1991) and for the LAAT it might be more 
reasonable to set a lower Kappa of 0.60 which indicates moderate agreement. A 
higher Kappa of 0.80 may not be realistic for the LAAT given the complex nature of 
avoidability assessments; depending on the expertise of the reviewers conducting 
the assessments. In any future testing of the LAAT or in re-development of the LAAT 
into a clinical tool for assessing ADRs “a priori” Kappa value of 0.6 could be set for 
the minimum level of agreement for reviewers. 
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The next stage in the development process will be to carry out group assessments 
of additional cases and look for an improvement in the results. This further testing 
in a group setting is required to develop and validate the tool. This is discussed in 
Chapter 3. 
 
We have conducted preliminary testing of the LAAT, it has face validity and is easy 
to use.  However, a number of issues were raised. These include the dependence on 
guidelines and variations in clinical practice. In phase 2, comparison of reviewers by 
specialty type highlighted that agreement was better for certain specialties 
particularly oncology and surgical. Unlike the Hallas score; using the LAAT to assess 
POV case proved relatively straightforward due to the nature of the questions on 
the LAAT particularly ‘were there known preventative strategies and/or appropriate 
management plan(s) with information about ADR avoidance available. The assessor 
was able to consult the available guidelines to answer the questions on the LAAT 
rather than being expected to know or consult the literature on the most 
appropriate type of anaesthetic and analgesia for a particular patient and a 
particular operation. 
 
This may be explained by the number of guidelines available in these areas. Many 
oncology cases have detailed protocols and treatment regimens although the level 
of detail varies amongst different protocols. Also, it became apparent that despite 
guidelines being available for some cases not all reviewers consult them. Some cited 
guidelines from memory correctly or incorrectly and some clinicians used 
experience or prior knowledge to assess the cases. The subtlety in definitions 
between prevention, management and amelioration of ADRs caused confusion with 
reviewers at times with the ADRIC study team appearing to have a good 
understanding of the differences. Agreement was stronger between the ADRIC 
study group team (HM, JB and LB). This raised the question of reviewer’s experience 
of ADR assessments and ultimately who is likely to use the tool. The LAAT is 
predominantly a research tool designed for use in the assessment of ADRs rather 
than a clinical tool per se. Reviewer type and experience of the assessor was also 
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found to affect the results and the way in which the tool was interpreted. In the 
systematic review by Hakkarainen et al. (2012a) the avoidability assessment was 
made by physicians in 60% of the articles and by pharmacists in 29%, and often a 
combination of them both. In 20% of the articles, the assessors were described as 
trained for, or experienced in, conducting avoidability assessments (Hakkarainen et 
al. 2012a). 
 
It may not be possible to define a generalisable tool, but it may be possible to 
define a tool that individuals can use consistently. However, the tool in itself may 
not be sufficient to develop consistent results between individuals or across 
settings. Consistent results may require a standard body of guidelines, or gold 
standards for acceptable care. Consistent results may require clinical experience 
relevant to the suspected ADR. Nevertheless, the tool may provide useful insights 
within an individual setting. A limitation of this study was the number of cases 
assessed in the different phases with 20 cases being used for some phases. This was 
due to the feasibility of assessments and the time taken for MDT meetings. The next 
step in the development process will be to investigate if group assessment improves 
agreement and reliability (Chapter 3).  
 
Hakkarainen et al. (2012a) have made some useful suggestions for future research, 
which we followed. They recommended that future studies include reliability and 
validity testing; take action to standardise the measurement process; provide 
information on the assessors in terms of training and experience in assessing 
avoidability; and describe how the assessments took place (i.e. whether cases were 
assessed independently or via consensus and how any disagreement is dealt with). 
They also stated that owing to the limitations and diversity of assessments it 
remains unknown if variation in avoidability rates in different settings and 
populations is due to the methodology used or actual differences in avoidability 
rates. They suggested that there is a need for modifying previous instruments or 
developing new ones for use in different settings, and that a starting point for 
developing a new instrument could be to begin with a clear definition for the 
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avoidability of different types of ADEs. They also recommended that any newly 
developed instruments should be compared with existing ones and that if one or 
more instrument gained rigorous evidence and became a gold standard it would 
facilitate comparisons of different studies (Hakkarainen et al. 2012a). The 
development of the LAAT followed these recommendations. Chapter 5 of this thesis 
describes the comparison of the LAAT to Hallas (1990) for the assessment of the 
ADRIC admissions study ADR case reports (Gallagher et al. 2012).  
 
 
 
2.6 Conclusion 
 
Avoidability assessment is feasible but needs careful attention to methods. The 
ADRIC systematic review (Smyth et al. 2012) highlighted the lack of avoidability data 
in paediatric ADR studies and the need to develop paediatric specific tools. We have 
developed the LAAT which showed mixed IRR in the individual assessment phase; 
therefore, further testing in a group setting is required to develop and validate the 
tool.  
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Chapter 3: Consensus meetings and individual testing 
 
3.1 Introduction 
 
Consensus is defined as ‘general agreement’ or ‘the judgement arrived at by most of 
those concerned’ (Meriam Webster ).  
 
‘Consensus is only one step beyond individual judgement it is possible for experts to 
agree and yet be wrong’ (Ferner, Aronson 2010b). 
 
As noted in Chapter 2 group assessment may be a way to improve the assessment 
of avoidability of ADRs. Here we consider ways in which groups could assess the 
avoidability of ADRs using the LAAT. While the LAAT was initially designed as a 
research tool, the intention was that it could also be used within clinical practice. 
Accordingly, our choice of method for group work needed to account for the 
demands of the “real world” as well as the research world.   
 
Consensus decision-making is a process used by groups seeking to generate 
widespread levels of participation and agreement. Consensus methods can also deal 
with conflicting scientific evidence (Murphy et al. 1998b). The aim of consensus 
methods is to determine the extent to which experts or lay people agree about a 
given issue (Jones, Hunter 1995). They range from formal to informal methods. The 
vast majority of collective decisions in healthcare are based on group meetings, 
such as committees, which have been largely unstructured with few formal rules or 
procedures (Murphy et al. 1998b). In general, consensus methods aim to enhance 
decision-making, synthesise expert opinion or provide some means of 
measurement where there is incomplete evidence or uncertainty (Jones, Hunter 
1995). Consensus work can also lead to buy-in when action must be taken despite 
imperfect evidence. There are three main types of formal methods for consensus 
development: Delphi method, Nominal group technique (NGT) and Consensus 
development conference. The research question and the planned model of 
participant interaction generally determine the method chosen. For example, 
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nominal group techniques are used initially to generate and then prioritise ideas, 
while the Delphi technique involves two or more postal or electronic rounds of 
questionnaires to prioritise predetermined categories (Campbell, Cantrill 2001). 
Consensus development conferences involve face-to-face discussion and debate 
between stakeholders (Halcomb, Davidson & Hardaker 2008). 
 
Delphi method: The Delphi method was developed by the Rand Corporation in the 
1950s and the aim was to synthesise expert opinion (Black et al. 1999). It has been 
used for a variety of purposes in the health care sector. Participants never meet or 
interact directly. Instead they are sent questionnaires and asked to record their 
views. The method has been criticised for diminishing the potentially positive 
aspects of interaction in the face-to-face meetings (Black et al. 1999). The Delphi 
process is a survey technique for decision-making among isolated respondents. On 
balance the Delphi method was not suitable for our study as experience shows that 
group interaction and discussion are valuable during the assessment of an ADR for 
avoidability. 
 
NGT: NGT was developed in 1971 by Delbecq and Van de Ven in the context of 
committee decision making (Black et al. 1999). The aim of NGT is to structure 
interaction within a group. Firstly, each participant is asked to record his or her 
ideas independently and privately. The ideas are then listed in a round-robin 
format. Each idea is then discussed in turn by the group; a facilitator oversees the 
process. The facilitator should be an expert on the topic for discussion, or a credible 
non-expert (Black et al. 1999). They ensure all participants have the opportunity to 
express their views and it reduces dominance by individuals. Conducting NGT is an 
efficient process for the participants. However, the data analysis, particularly the 
qualitative aspect, is a time consuming process due to the volume of information 
produced. On balance NGT was not suitable for our study as it would not be 
practical in real-world settings.  
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Consensus development conference: a selected group of about ten people is 
brought together to reach consensus about an issue. Most suggest that participants 
should ideally be experts in the field and have credibility with the target audience 
(Black et al. 1999, Halcomb, Davidson & Hardaker 2008). According to Black et al. 
(1999) the effect of heterogeneity on group decision-making can lead to a better 
performance; but there is also some evidence to suggest it could have an adverse 
effect as conflict may arise between the diverse group. Conference participants 
come together in an open meeting to hear evidence from various stakeholders or 
experts in the field who are not members of the decision making group (Black et al. 
1999). After hearing the evidence participants consider the key questions in the 
light of the evidence presented and attempt to reach consensus and produce a 
consensus statement (Black et al. 1999).  A key advantage of the consensus 
development conference method is that it fosters dialogue, debate and discussion 
between participants (Halcomb, Davidson & Hardaker 2008).  The development of 
consensus conferences has drawn on aspects of judicial decision-making. Although 
this method was developed from a need to make decisions in the public forum, 
rather than a response to research on group decision-making techniques, it has 
mostly been evaluated in terms of its decision making properties. On balance 
consensus development conference was not suitable for our purposes due the large 
number of participants required that would not be realistic in real practice. 
 
None of the available formal methods were suitable for our study because the 
target users of this tool do not work in large groups. Accordingly we elected to use 
an informal method that drew on some elements of the formal methods. The tool 
was designed for use in real-world clinical settings. Hence the consensus method 
chosen should be applicable in real-world settings. 
 
The main characteristic of the informal method was small MDT groups. Each group 
had 3 reviewers including nurse, pharmacist and doctor with experience of 
prescribing, administering, or dispensing medicines for children. It was anticipated 
that the small groups would work informally in line with standard practice that does 
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not include formal group processes. Accordingly, the evaluation was designed to 
measure the outcomes, and process, of informal group work. 
 
An alternative would have been to introduce formal group process and the LAAT. 
However, it was decided against this, as it would make it difficult to assess the 
impact of the LAAT because participants would be exposed to two novel things at 
the same time. Assessment of the LAAT was framed by a descriptive study of 
informal group process this is described in detail in Chapter 4. 
There are no clear guidelines to assist in optimal composition of consensus groups 
(Black et al. 1999). Campbell and Cantrill suggest that participants reflect the 
stakeholder group (Campbell, Cantrill 2001). Group composition is an important 
consideration. In judgements of clinical appropriateness, the most relevant 
background factor is medical speciality (Jones, Hunter 1995). Generally, having 
more group members will increase the reliability of a group judgement. However, 
where the group interacts, large groups may cause coordination problems within 
the group. It seems likely that below six participants, reliability will decline quite 
rapidly, while above twelve, improvements in reliability will be subject to 
diminishing returns (Murphy et al. 1998a).   
 
It was decided that our consensus groups should include a nurse, pharmacist and 
doctor. During the earlier stages of tool development it was found that including 
members of each of the three professions accounted for different perspectives and 
overcame lack of knowledge or areas of uncertainty within each profession. In 
terms of the feasibility of assessing a larger component of the ADRIC inpatient study 
cases in the future a smaller group size of three people was decided upon, also this 
was more representative of other ADR study teams in research who may perhaps 
be the end-users of the LAAT. Although Murphy et al. (1998a) suggest a group size 
of between six and ten participants this would not have been practical for this 
study. Fink et al. (1984) have reported that the number of participants is dependent 
on the particular type of consensus method being used and is also constrained by 
the resources available for the individual project (Fink et al. 1984). The number of 
  
85 
 
stakeholder groups requiring representation may also influence the group size 
(Halcomb, Davidson & Hardaker 2008). The consensus groups selected for this study 
included nurse, doctor and pharmacist representation. The quantitative evaluation 
of the consensus groups was supplemented by an ethnographic approach. Details of 
this are described in Chapter 4. Ethnography is ‘the study of social interactions, 
behaviours and perceptions that occur within groups’ (Reeves, Kuper & Hodges 
2008). Qualitative methods have become increasingly popular in healthcare 
research in recent years (Britten 2005). Ethnography can generate rich and detailed 
accounts of clinicians’ professional and inter-professional relationships (Reeves, 
Kuper & Hodges 2008).  
 
3.2 Aim and Objectives  
3.2.1 Aim 
 
To test the hypothesis that group avoidability assessments are superior to individual 
avoidability assessments. 
 
3.2.2 Objectives 
 
To determine:   
1. The extent to which individual and group assessments agree with the 
assessments made by the panel of ADRIC senior investigators. 
2. The extent to which agreement between groups is similar to agreement 
between individuals. 
The following explanatory analyses were conducted. 
3. Exploration of the factors that influenced decision making in a MDT consensus 
group. 
4. Nature of the areas of disagreement. 
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3.3 Study Description 
 
3.3.1 Study Design 
An observational study comparing the findings reported by assessors assigned to 
group or individual participation in a retrospective review of selected ADR case 
reports from the ADRIC inpatient study.  
 
3.3.2 Study Setting 
A paediatric tertiary referral centre in the UK. 
 
3.3.3 Sample size and selection of cases 
 
ADR cases 
A purposive sample of 25 ADR case reports was selected from the 1446 cases 
categorised as probable and definite ADRs in the ADRIC inpatient study to reflect 
different ADR types and avoidability classifications. ADRIC Senior Investigators, 
clinical pharmacologist (MP), paediatrician (MT) and pharmacist (AN), assessed the 
cases and reached consensus about avoidability status on the LAAT. This was 
recorded as the ‘gold standard’ (GS). Following the first ‘gold standard’ consensus 
meeting it was decided that a stratified sample (surgical, medical, cardiology and 
oncology cases reflecting the breakdown of ADRs) was not appropriate as it falsely 
magnified agreement. It was therefore important to ensure the ADR cases were 
independent of each other. It was decided that a highly selective purposive sample 
based on ADR type and avoidability classification was required. This involved pre-
screening of the cases by LB to check for a spread of avoidability classifications (not 
avoidable, possibly avoidable, and definitely avoidable). The cases were all assessed 
as probable or definite ADRs using the final causality classification assigned in the 
study (Thiesen et al. 2013).   
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Definition of ‘gold standard’ for each ADR 
A panel of two to three ADRIC senior investigators met to define the avoidability 
status of ADRs to be used in the study on two separate occasions.  The meetings 
were observed; the outcomes and any notes provided on the rationale provided 
were recorded. The meetings considered a sample of 25 ADR case reports from the 
ADRIC inpatient study in order to develop a sufficient number of cases for use in the 
study. Initially a stratified sample was selected as per the previous phases but it was 
then decided that a purposive sample based on the ADR type was more appropriate 
in order to fully test the tool. As the stratified sample contained several of the same 
ADR types such as post-operative nausea and vomiting (PONV) and pruritus cases, it 
was felt that these cases were not independent of each other and could magnify the 
appearance of agreement. It was important to make sure that the tool was being 
validated rather than people’s level of agreement on being able to interpret a 
guideline or pathway. From the sample of 25 cases with a ‘gold standard’ 
assessment, 20 were selected for the study in order to maximise the variety of gold 
standard assessments: see table 3.1 for details of the cases.   
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Table 3.1 Selected ADR case reports for the study with ‘gold standard’ outcomes 
ADRID ADR Type Suspected 
Medicine 
Causality Gold Standard 
avoidability 
outcome 
1554 Vomiting Cytarabine Definite Definitely avoidable 
383 Procedural vomiting Morphine 
Sulphate 
Probable Definitely avoidable 
138 Somnolence Codeine 
Phosphate 
Probable Definitely avoidable 
2103 Immunosuppressant 
drug level increased 
Tacrolimus Probable Definitely avoidable 
1294 Constipation Fentanyl citrate Probable Definitely avoidable 
630 Hallucination Morphine 
Sulphate 
Probable Not avoidable 
2105 Cardiac failure Bisoprolol 
fumarate 
Definite Possibly avoidable 
293 Respiratory depression Morphine 
sulphate 
Definite Possibly avoidable 
2015 Flushing Dexamethasone Definite Not avoidable 
252 Pruritus Fentanyl & 
Levobupivicaine 
Probable Not avoidable 
2258 Visual disturbance Morphine 
sulphate 
Probable Not avoidable 
9 Diarrhoea + Excoriation Cefotaxime Probable Not avoidable 
1518 Hypocalcaemia + 
Hypophosphataemia 
Pamidronate Probable Not avoidable 
2815 Haematemesis Aspirin Probable Not avoidable 
477 Hypertension Prednisolone Probable Not avoidable 
2844 Infusion associated 
reaction 
Rituximab Probable Not avoidable 
1224 Urinary retention Morphine Definite Not avoidable 
1263 Clostridium difficile 
colitis 
Teicoplanin Definite Not avoidable 
493 Stomatitis Clofarabine Probable Not avoidable 
1572 Hypoglycaemia Insulin detemir Probable Possibly avoidable 
  
Breakdown of avoidability categories 
 
Definitely avoidable 5 
Possibly avoidable 3 
Not avoidable 12 
Total  20   
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3.4 Methodology 
 
Participants were assigned either to assess a selection of ADR cases reports 
independently or to one of the three MDT groups. The ADR case reports (see 
Appendix 1 for a sample ADR case) contained anonymised demographic data for the 
patient, details of suspected drug(s) thought to be implicated in the ADR and 
concurrent medication, brief past medical history, and a description of the adverse 
reaction, treatment and outcome. The ADR case reports covered a range of 
therapeutic scenarios. The experience of the reviewers ranged from 2 to 31 years 
post qualification. Previous experience with formal ADR assessment ranged from 
none to minimal. None of the reviewers had any previous experience of assessing 
the avoidability of ADRs.  
 
This was an internal validation study in which the avoidability tool was applied 
either by individuals or by groups that employed an informal method to reach 
consensus. The ‘gold standard’ for each assessment was the avoidability status 
assigned by a panel of two to three ADRIC senior investigators. This ‘gold standard’ 
was used to test whether groups were better than individuals. The ultimate goal is 
to roll out the LAAT. In order to support that roll out, reasons for variability 
between the responses, between participants and for any differences between 
individual and group assessments were explored. 
 
 
A mixed methods approach was taken. Quantitative analysis examined the extent to 
which individuals and groups agreed with the ‘gold standard’ (the avoidability 
outcome set by a panel of senior investigators) using percentage exact agreement 
(%EA) (figure 1). An ethnographic approach, including non-participant observations 
of consensus meetings and post-consensus meeting semi-structured qualitative 
interviews, explored decision making and reaching agreement in consensus group 
meetings outlined in chapter 4. 
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3.4.1 Participants 
 
Participants (nurses, pharmacists and doctors with experience of prescribing, 
administering, or dispensing medicines for children) were recruited via Alder Hey 
Children's NHS Trust through direct invitation or invitation through relevant line 
managers. For recruitment of the doctors we used snowball sampling to identify 
study participants where one of the senior clinicians introduced the study to a 
number of colleagues (6) who were then contacted directly and provided with 
information about the study. For recruitment of the nurses we liaised with the 
Research Nurse Manager and obtained a list of all the research nurses in the trust 
and their email addresses who we then contacted directly. We aimed to recruit 19 
participants in total a mixture of nurses, doctors and pharmacists from a variety of 
specialities with varying levels of experience. All eligible participants received a 
written study information leaflet electronically and a consent form to confirm 
agreement to participate in the study with a request to reply within three weeks of 
receipt of the study information. Non-respondents were contacted for a second 
time and invited to participate.  
 
After experiencing a low response rate from pharmacists, I was invited to go and 
speak to a group of pharmacists in the pharmacy department to give a brief 
overview of the study, raise the study profile and explain what was involved in 
taking part. The search for doctors to take part was widened by contacting the 
paediatric trainees via email through Mersey Deanery and North West Deanery. 
Once reviewers agreed to take part they were assigned to either one of the three 
consensus groups (A/B/C) or to the individual assessment group (10 reviewers 
independently assessed the cases). This was based on clinician type and availability 
for meetings. Each consensus group was made up of a multidisciplinary team 
(nurse, pharmacist, doctor). Group consensus meetings were arranged with 
clinicians who agreed to take part and written consent was taken prior to the 
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meeting. Consensus meetings were scheduled using Doodle® polls to check 
availability with participants.  
 
The inclusion criteria for the study were: 
 Clinicians (nurse, pharmacist, doctor) all levels/grades working in paediatrics 
The exclusion criteria for the study were: 
 Members of the ADRIC study group, the rationale being that they may introduce 
bias or show the effects of “group learning”. 
 
The impact of using ST6-ST7 doctors and research nurses and their ability to 
contribute or participate in the consensus meetings may mean the results of the 
validation are not generalisable (results from ST6-ST7 doctors may be generalisable 
to other ST6-ST7 doctors but possibly not to other groups of medical staff). The 
groups may not have been the “ideal” makeup for validating an avoidability 
assessment tool due to lack of experience of familiarity/training in ADRs. On the 
other hand Consultant staff were more difficult to engage and would not 
necessarily have specific experience with assessing ADRs. A practical approach was 
taken to the allocation of reviewers to the consensus groups. It is likely that the 
impact of this was reduced inter-rater reliability. 
 
 
3.4.2 Individual assessments 
 
Nine reviewers (a mixture of nurses, pharmacists and doctors) independently 
assessed the selected 20 ADR case reports in their own time. Details of the 
individual reviewers are outlined below in Table 3.2. They were asked to plot their 
responses/selected pathway on the tool choosing one of the four possible 
outcomes on the LAAT (see Figure 2.5, Chapter 2) (‘Not avoidable’, ‘Possibly 
avoidable’, ‘Definitely avoidable’, ‘Unassessable’).  
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Table 3.2 Details of the individual reviewers 
 
Clinician type Specialty  Grade or number of 
years’ experience 
Doctors   
D1 Renal ST6 - ST7 
D2 Rheumatology ST6 - ST7 
D3 Respiratory ST6 - ST7 
Nurses   
N1 PICU/Research < 10 years paediatrics  
N2 Research >10 years paediatrics 
N3 Research/surgical >10 years paediatrics 
Pharmacists   
P1 Specialist paediatric pharmacist > 10 years qualified 
P2 Specialist paediatric clinical pharmacist < 10 years qualified 
P3 Specialist paediatric pharmacist < 10  years qualified 
 
3.4.3 Consensus Meetings 
 
At the start of each consensus meeting the groups were provided with a brief 
overview of how the meeting would proceed. They were given the opportunity to 
ask any questions about the process.  
 
The selected ADR case reports (Table 3.1) were assessed (see appendix 2 for the 
LAAT glossary and a guide to completing assessments) by each group. Groups were 
given 3 hours to assess the 20 ADR case reports. If they were unable to reach a 
consensus decision they recorded ‘no consensus reached’ for the particular case 
report.  
 
The group meeting was overseen by a facilitator who did not take part in the 
assessment process but moderated the meeting. The facilitator JD was a member of 
the ADRIC study team. The group consensus meetings were also observed.  
Nonparticipant observation of the meetings were performed by LB who acted as an 
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observer to monitor the group interactions and see how groups decisions were 
made, discussed in Chapter 4.  
 
3.4.4 Data analysis and statistical considerations 
 
The number of cases was limited in order to avoid asking the teams to meet on 
more than one occasion to complete assessments. More than one meeting was not 
feasible and could potentially contaminate the results. This was a sample of 
convenience taking account of the availability of potential participants and of the 
study team. The sample size ruled out the possibility of calculating kappa scores (as 
a minimum of 40 cases is required for this which was not feasible for this 
study). Percentage exact agreement (%EA) was calculated for comparison.  
 
 
The extent to which individual and group assessments agree with the assessments 
made by the panel of senior ADRIC investigators. Main outcome measure: For each 
individual or group, the percentage exact agreement with the panel of senior 
investigators. 
 
Analysis: The overall series agreement for individuals and groups was summarised 
using descriptive statistics, means with standard deviations alongside the exact 
agreement statistics. 
 
3.4.5 Ethics approval 
 
a) Clinical data. The study involved the use of existing data held in routine clinical 
records which was collected during the ADRIC programme. The ADRIC programme 
was conducted with Trust approval. The Chair of an LREC agreed that the extraction 
of the clinical data from routine records did not required ethics approval. 
Accordingly, the use of this anonymised dataset did not require approval from the 
integrated research application system (IRAS). Approval was sought from the 
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Research and Development (R&D) department at Alder Hey NHS Foundation Trust 
for the use of this data in this study. 
b) Participants. The participants in the study were all NHS employees who are 
recruited by virtue of their professional role and therefore this study did not need 
NHS REC approval. We sought management approval for the study from the R&D 
department at Alder Hey for employees to take part in the study. All participants 
consented to participate in the study and to take part in an interview where 
applicable (only those involved in the consensus groups). Sample participant 
information sheets and a consent form are shown in Appendix 3. 
c) University of Liverpool (UoL). As this project was part of a PhD thesis. We gained 
approval from the University of Liverpool Committee for Research Ethics and we 
also obtained sponsorship from UoL (Sponsor Ref: UoL001004). 
 
 
 
3.5 Results   
 
Qualitative and quantitative analyses were carried out. We examined the extent to 
which individuals and groups agreed with the 'gold standard' using %EA (Figure 3.1). 
Agreement ranged from 35-70%. The mean agreement for individuals was 54% (SD 
12.4) and 47% (SD 7.6) for the consensus groups. 
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Figure 3.1 Graph showing percentage exact agreement versus reviewer type 
 
 
 
 
 
 
 
 
 
 
Table 3.3 shows the distribution of avoidability categories using the LAAT. The 
majority of assessments were ‘not avoidable’ for all reviewers. Overall the 
consensus groups were more likely to attribute a ‘definitely’ or ‘possibly’ avoidable 
assessment to the cases than the individuals.  
 
 
 
Key 
 
Individuals: 
N: Nurse 1,2,3 
D: Doctor 1,2,3 
P: Pharmacist 1,2,3 
 
Groups: 
CG: Consensus group 1,2,3 
  
96 
 
Table 3.3 Distribution of avoidability categorisation using the LAAT 
 
Clinician/Group Definitely 
avoidable 
Possibly 
avoidable  
Not 
avoidable 
Unassessable 
Nurse 1 0 2 18 0 
Nurse 2                         4 4 11 1 
Nurse 3                            1 4 13 2 
Doctor 1                           6 1 12 1 
Doctor 2                           2 9 8 1 
Doctor 3 5 4 10 0 
Pharmacist 1 2 4 12 0 
Pharmacist 2 2 4 14 0 
Pharmacist 3 9 2 9 0 
Consensus group 1 7 2 10 1 
Consensus group 2 7 3 9 1 
Consensus group 3 5 3 11 1 
Gold standard 5 3 12 0 
 
 
 
Table 3.4 shows the results from the individual reviewers and the consensus groups 
compared to the ‘gold standard’ (GS). It shows that some cases lead to complete 
agreement. Other cases lead to wide divergence. This includes some groups or 
individual assessors saying definitely avoidable and others saying unavoidable. 
There was also complete agreement and complete divergence between groups and 
individual assessors and the gold standard. The cases where disagreement occurred 
are denoted in red.  
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ADRID ADR Type Gold 
standard  
N1  N2  N3  D1  D2  D3  P1  P2  P3  Consensus 
group 1 
(4/2) 
Consensus 
group 2 
(10/2) 
Consensus 
group 3 
(26/02) 
1554 Vomiting Definitely 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
(SPC) 
Not 
avoidable 
(AH chemo 
N+V) 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
383 Procedural 
vomiting 
Definitely 
avoidable 
Not 
avoidable 
Possibly 
avoidable 
Possibly 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
Not 
avoidable 
(AH PCA 
guideline) 
Definitely 
avoidable 
(AH PONV) 
Definitely 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
138 Somnolence Definitely 
avoidable 
Not 
avoidable 
(BNFC) 
Possibly 
avoidable 
Not 
avoidable 
Not 
avoidable 
Possibly 
avoidable 
Possibly 
avoidable 
Not 
avoidable  
Not 
avoidable  
Definitely 
avoidable 
Not 
avoidable 
Not 
avoidable 
Possibly 
avoidable 
2103 Immunosuppress
ant drug level 
increased 
Definitely 
avoidable 
Not 
avoidable 
Not 
avoidable 
Possibly 
avoidable 
Definitely 
avoidable 
Possibly 
avoidable 
Definitely 
avoidable 
Possibly 
avoidable 
(SPC) 
Possibly 
avoidable 
(BNFC) 
Definitely 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
1294 Constipation Definitely 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
Possibly 
avoidable 
Definitely 
avoidable 
Not 
avoidable 
(AH PCA 
guideline) 
Possibly 
avoidable 
(BNFC) 
Definitely 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
Not 
avoidable 
630 Hallucination Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Unassessab
le 
Not 
avoidable 
Not 
avoidable  
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
Unassessable 
2105 Cardiac failure Possibly 
avoidable 
Possibly 
avoidable 
Definitely 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable  
Not 
avoidable 
Not 
avoidable 
(SPC) 
Not 
avoidable 
Possibly 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
293 Respiratory 
depression 
Possibly 
avoidable 
Possibly 
avoidable 
Not 
avoidable 
Possibly 
avoidable 
Definitely 
avoidable 
Possibly 
avoidable 
Possibly 
avoidable 
Possibly 
avoidable 
(AH PCA) 
Not 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
Possibly 
avoidable 
2015 Flushing Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Unassessab
le 
Not 
avoidable 
Not 
avoidable  
Not 
avoidable 
Possibly 
avoidable 
Not 
avoidable 
Not 
avoidable 
Possibly 
avoidable 
Possibly 
avoidable 
Not 
avoidable 
252 Pruritus Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable  
Not 
avoidable 
Not 
avoidable 
(AH pain 
guideline) 
Not 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
2258 Visual 
disturbance 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Unassessab
le 
Not 
avoidable  
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
9 Diarrhoea + 
Excoriation 
Not 
avoidable 
Not 
avoidable 
Possibly 
avoidable 
Not 
avoidable 
Not 
avoidable 
Possibly 
avoidable 
(could have 
Not 
avoidable 
Possibly 
avoidable 
Possibly 
avoidable  
Possibly 
avoidable 
Definitely 
avoidable 
Definitely 
avoidable 
Possibly 
avoidable 
Table 3.4 Avoidability category assignments of individual reviewers and consensus groups - a comparison to the ‘gold standard’ 
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3
 For some reviewers % avoidability is out of 18 or 19 not 20 due  to unassessable cases 
used 
orobase 
paste 
following 
similar 
problem as 
neonate) 
1518 Hypocalcaemia + 
Hypophosphatae
mia 
Not 
avoidable 
Not 
avoidable 
Unassessab
le 
Possibly 
avoidable 
Not 
avoidable 
Possibly 
avoidable 
(could have 
checked Ca 
level after 
each 
infusion?) 
Possibly 
avoidable 
Not 
avoidable 
Possibly 
avoidable 
Definitely 
avoidable 
Possibly 
avoidable 
Not 
avoidable 
Not 
avoidable 
2815 Haematemesis Not 
avoidable 
Not 
avoidable 
Possibly 
avoidable 
Unassessab
le 
Possibly 
avoidable 
Possibly 
avoidable 
Definitely 
avoidable 
Possibly 
avoidable 
Not 
avoidable 
Not 
avoidable 
Unassessab
le 
Possibly 
avoidable 
Not 
avoidable 
477 Hypertension Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable  
Not 
avoidable 
Possibly 
avoidable 
Not 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
Possibly 
avoidable 
Definitely 
avoidable 
2844 Infusion 
associated 
reaction 
Not 
avoidable 
Not 
avoidable 
(BNFC) 
Not 
avoidable 
Definitely 
avoidable 
Not 
avoidable 
Not 
avoidable  
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
1224 Urinary 
retention 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable  
Not 
avoidable 
Possibly 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
1263 Clostridium 
difficile colitis 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Possibly 
avoidable 
(previous 
episode of 
C. diff) 
Possibly 
avoidable 
Not 
avoidable 
Definitely 
avoidable  
Definitely 
avoidable 
Not 
avoidable 
Unassessab
le 
Not 
avoidable 
493 Stomatitis Not 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
Possibly 
avoidable 
Not 
avoidable 
Possibly 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
1572 Hypoglycaemia Possibly 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
Not 
avoidable 
Not 
avoidable 
Not 
avoidable  
Not 
avoidable 
Not 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
Not 
avoidable 
Not 
avoidable 
Definitely 
avoidable 
    % 
Agreement 
70% 45% 45% 65% 50% 70% 35% 50% 60% 45% 40% 55% 
  Guideline 
consulted  
2 x BNFC Web MD BNFC   0  4 (2 x 
BNFC, 2 x 
AH) 
    
 % Avoidable 40% 10% 42%3 28%3 37%3 55% 45% 45% 30% 55% 45% 50% 42%3 
Table 3.4 Avoidability category assignments of individual reviewers and consensus groups - a comparison to the ‘gold standard’ (continued) 
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3.5.1 Examples of cases with complete agreement or divergence 
 
ADRID 1554 – Vomiting  
The GS assessment was ‘definitely avoidable’ and overall agreement for this was 
4/12. Among individual reviewers, 4/9 agreed with the ‘gold standard’. There 
appeared to be a pattern related to profession with all three of the doctors and one 
pharmacist categorising the case as definitely avoidable. The other two pharmacists 
and all three nurses deemed the case not avoidable. In contrast all three consensus 
groups thought the case was not avoidable. 
 
ADRID 383 – Procedural vomiting 
The GS assessment was ‘definitely avoidable’. Overall agreement for this case was 
8/12. There was complete agreement between the consensus groups and the GS. In 
terms of the individual assessors 5/9 agreed with the GS. Of the remaining four 
reviewers, two categorised the ADR as possibly avoidable and two reviewers 
assessed the ADR as not avoidable. All three consensus groups agreed with the 
‘gold standard’ and categorised the ADR as definitely avoidable. 
 
ADRID 252- Pruritus 
The GS assessment was ‘not avoidable’. All the individual assessors (9/9) agreed 
with the GS. In contrast, all three consensus groups categorised the ADR as 
definitely avoidable. 
 
ADRID 1572- Hypoglycaemia  
The GS assessment was ‘possibly avoidable’.  There was complete divergence 
between groups and individual assessors and the gold standard for this case.  
Overall, 9/12 assessments categorised the case as not avoidable and the remaining 
three as definitely avoidable. Seven individual assessors categorised the ADR as not 
avoidable and the remaining two categorised the ADR as definitely avoidable .Two 
of the three consensus groups categorised the ADR as not avoidable and the third 
group categorised the ADR as definitely avoidable. Again there was a pattern seen 
in terms of professions with all three doctors in agreement and categorising the 
ADR as not avoidable.  
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ADRID 630 - Hallucination 
There was almost complete agreement with the GS for this case with 9/12 
assessments categorising the ADR as not avoidable. Eight out of nine individual 
reviewers categorised the ADR as not avoidable and the ninth individual reviewer 
categorised the ADR as unassessable. Of the three consensus groups one group 
assessed the case as not avoidable, one consensus group CG2, categorised the ADR 
as definitely avoidable and the third consensus group deemed the ADR 
unassessable.  
 
ADRID 2815- Haematemesis 
Overall there was poor agreement with the GS for this case (4/12). There was 
divergence between individual assessors and the groups. In terms of the individual 
assessors 3/9 agreed with the gold standard, 4/9 categorised the ADR as possibly 
avoidable, one individual categorised the ADR as definitely avoidable and one 
individual deemed the ADR unassessable. Two of the three individual pharmacists 
were in agreement with the GS. All three doctors categorised the ADR as avoidable 
either possibly or definitely. Of the three consensus groups, one group agreed with 
the gold standard, one group categorised the ADR as possibly avoidable and one 
group deemed the ADR unassessable.  
 
ADRID 493- Stomatitis  
The GS for this case was not avoidable. There was complete agreement with the GS 
from the consensus groups. The individuals had mixed agreement with the GS. 4/9 
individuals agreed with the gold standard, 3/9 individuals categorised the ADR as 
definitely avoidable and the remaining two individuals categorised the ADR as 
possibly avoidable.  
 
Cases with poor agreement included the diarrhoea and excoriation case. It was 
categorised as ‘not avoidable’ by the ‘gold standard’ group with only 3/9 individuals 
agreeing with the ‘gold standard’, the remaining six individuals and the three 
consensus groups all classified the ADR as either ‘possibly’ or ‘definitely’ avoidable.  
It was noted at the time of assessment in the ‘gold standard’ consensus group that 
 
 
 
101 
 
this case had a learning point attached to it. The case involved two separate ADRs 
the effect of the antibiotic and then the effect of the diarrhoea. The Senior 
Investigators noted that if they were being presented as separate ADRs they might 
have classified the excoriation as ‘possibly avoidable’ but on balance the ADR was 
classified as ‘not avoidable’. They felt that if you’ve got two interactions one may be 
dependent on the other. 
 
3.5.2 Likert scale feedback 
 
The participants were asked to complete Likert scale feedback forms once they had 
completed their assessments. Table 3.5 shows the Likert scale summary results for 
the consensus groups (see Appendix 4 for details of feedback surveys and Appendix 
5 for the full results from the Likert scales). The majority of reviewers thought the 
tool was easy to use. However, there was strong agreement that some questions on 
the LAAT were harder to answer and almost all reviewers agreed that in some cases 
it was difficult to know whether guidelines were available. Overall the reviewers 
were undecided if they would have been able to answer the questions by 
themselves, three reviewers (one pharmacist, one nurse and one doctor) felt they 
would be unable to answer all the questions by themselves. Two reviewers a 
pharmacist and a doctor agreed that they could have answered all the questions by 
themselves. Almost all reviewers thought the tool could be useful in the future. 
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Table 3.5 Likert scale summary results for consensus groups 
 
 
 
 
 
Table 3.6 Likert scale summary results for individual assessments 
 
  Strongly 
Agree     
Agree   Undecided               Disagree  Strongly 
Disagree  
The LAAT was easy to use. 2 5 1 1  
I found some questions harder to answer (for 
some questions it was difficult to decide between 
a positive and negative response) 
2 6  1  
In some cases it was difficult to judge whether 
guidelines or information were available 
2 5 1 1  
It may have been easier to assess the cases in a 
group setting 
3 1 3 2  
The tool could potentially have some utility in the 
future 
5 3 1   
Additional comments from reviewers: 
 
"Not always easy to judge if other sources of info are available." 
 
"I had to use BNFC, nurses' dictionary and google for clarification of drugs and conditions" 
 
  Strongly 
Agree     
Agree   Undecided               Disagree Strongly 
Disagree  
The LAAT was easy to use  7 2   
I found some questions harder to answer 
(for some questions it was difficult to decide 
between a positive and negative response) 
3 6    
In some cases it was difficult to judge 
whether guidelines or information were 
available 
1 7  1  
I would have been able to answer all the 
questions by myself 
 2 4 3  
The tool could potentially have some utility 
in the future 
4 4 1   
 
Additional comments from reviewers: 
 
“Sometimes difficult to assess if a 'management plan' was adhered to!” 
 
“Perhaps the tool would have future potential value with modification to include consideration of ADR 
and deliberate decision to proceed in a certain course of action” 
 
“Useful tool” 
 
“Was appropriate action taken box- should include addendum to detail that side effect/ADR was 
considered but that benefit to patient outweighed risk. Were there known preventative strategies box 
should include footnote to list considerable guidance e.g. protocols/NICE/Journal” 
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Table 3.6 shows the Likert scale summary results for the individuals. Overall the 
individual reviewers agreed that the LAAT was easy to use with one reviewer, a 
doctor disagreeing and a second reviewer, a pharmacist undecided. Similar to the 
consensus group results the majority of individual reviewers felt that some 
questions were harder to answer with one reviewer, a pharmacist disagreeing. In 
terms of thoughts on assessing the cases as a group or individually three reviewers 
strongly agreed that it may be easier in a group setting (two nurses and one 
pharmacist). Two individuals (a pharmacist and a doctor) disagreed that it might be 
easier in a group setting and the others were undecided. Overall nearly all of the 
reviewers felt the tool could be useful in the future. 
 
3.6 Discussion 
 
Assessing the avoidability of ADRs is a complex process that requires taking into 
account a number of variables. The literature has shown that avoidability 
assessments are challenging. A variety of tools are available, ranging from the 
implicit to explicit. None of the available tools has been widely accepted 
(Hakkarainen et al. 2012a). There is currently no standardised method for 
determining ADR avoidability and many of the established tools are not suitable for 
use in paediatric practice. A systematic review found that several definitions exist 
for avoidability as a consequence of the variability in methodological approaches to 
assessment of avoidability, and none fits all circumstances (Ferner, Aronson 2010b).  
 
A recent systematic review on ADRs in children noted the absence of avoidability 
data; this highlighted the need for work in this area. We followed the 
recommendations outlined by Hakkarainen et al. (2012) They recommended that 
future studies include reliability and validity testing; take action to standardise the 
measurement process; provide information on the assessors in terms of training 
and experience in assessing preventability; and describe how the assessments took 
place (i.e. whether cases were assessed independently or via consensus and how 
any disagreement is dealt with) (Hakkarainen et al. 2012a). 
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Following our initial testing of the LAAT with individuals it was decided to 
investigate if group avoidability assessments were superior to individual avoidability 
assessments. It was hypothesised that MDT groups would be superior to individual 
assessments given the nature of the assessments. However, agreement with the 
‘gold standard’ was similar for individuals and groups. In terms of %EA individuals 
had marginally better agreement with the ‘gold standard’ than the consensus 
groups. Given the logistic difficulties with groups, individual assessments can be 
used in further work. Feedback from individuals was generally positive with most 
participants agreeing that the tool was easy to use and that it might have potential 
utility in the future. Differences were observed between the three professions with 
doctors on average having the best agreement with the ‘gold standard’. The 
perceived good agreement between nurse (N1) and the ‘gold standard’ at 70% may 
have been falsely elevated as when you look at the distribution of avoidability 
categories, N1 classified 18/20 ADRs as ‘not avoidable’. This was significantly higher 
than the other individuals and consensus groups and may have falsely magnified 
agreement with the ‘gold standard’. 
 
On reflection, the reviewers who took part in the consensus groups may not have 
been the “ideal” group members. As in order to assess avoidability there is a 
requirement to have an understanding of what an ADR as it becomes difficult to 
assess avoidability if the reviewer does not believe an ADR has occurred in the first 
place. Ideally, reviewers with some understanding of pharmacovigilance would be 
preferable and perhaps more senior clinicians would be more naturally placed to 
assess avoidability. For example, members of the Drug and Therapeutic Committee, 
staff from the Yellow Card centres or more experienced nurses, pharmacists and 
consultant level doctors may have been a more appropriate choice. This group 
might have shown improved inter-rater reliability. This could be investigated in 
future work; to look at the impact of having more experienced group members 
assess avoidability and compare inter-rater reliability between the different groups.   
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External validity testing using expert groups would overcome the lack of 
understanding about ADRs and confusion over terminology and is therefore likely to 
improve the tool’s IRR. 
 
 
In terms of the reviewers used in this study; on one hand Nurse Prescribers may 
have been a better choice for example if ADR cases were grouped by speciality and 
the aim was to have expert reviewers assessing the cases. However, if the ADR 
cases were more variable in nature as was the case in the consensus and individual 
testing phases (Chapter 3 and 4) then the use of Nurse Practitioners who are highly 
specialised with an in-depth knowledge of a particular area for example oncology or 
respiratory might be beneficial in some instances but possibly also have a downside. 
The downside of using Nurse Practitioners may be the loss of the perspective of the 
nurse into what happens at the ward level and in some ways this might result in the 
loss of the MDT effect. In terms of Junior Doctors conducting assessments the tool 
highlighted the need for further training in the area of ADRs and pharmacovigilance. 
Whilst it may have been more appropriate and indeed also resulted in improved IRR 
to use more senior doctors, the groups and individuals were made up of people 
who had volunteered to take part in the assessments. In terms of validation of the 
methodology the clinicians chosen may not have been the right group but in terms 
of application they may have been as this was a balance between expert validation 
of a tool and testing in a real-life practical setting. 
 
The consensus groups were more inclined to attribute a ‘definitely’ or ‘possibly’ 
avoidable assessment to the cases than the individuals. The consensus groups also 
consulted more guidelines than the individuals (or at least those individuals that 
specified if guidelines were consulted) this may have been because a laptop 
computer was made available to the groups. Other reasons for this including 
differences between professions will be discussed in the qualitative analysis in 
Chapter 4. 
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The cases were informative with marked divergences for some ADR types. Possible 
reasons for divergence might be evidence based, practice based or irreducible 
divergence. The small sample size means caution should be taken with over 
interpretation of the data but the divergences show what is possible for avoidability 
assessment within the parameters of this assessment. The cases denoted in red in 
Table 3.4 show some examples of divergences. There may be limits to the extent of 
agreement about avoidability that can be reached between individuals or groups. 
The LAAT appears to support consistent assessments by a single assessor or within a 
group. Given that 16/18 of assessors agreed, or strongly agreed that the LAAT was 
potentially useful in future, the LAAT has face validity for paediatrics. Thus LAAT is 
likely to provide an improvement on global introspection or unstructured reflection 
on a case. However, the process we describe involving the LAAT was not sufficient 
for consistency between assessors or between groups. Consistency between 
assessors and groups would require similar attitudes to accessing and interpreting 
guidelines. Furthermore, as discussed in Chapters 5 and 6, similar and additional 
differences to the assessment of avoidability were found between individuals (see 
divergent cases in Chapter 5). A preliminary finding, which will be developed in later 
chapters, is that consistent assessment of the avoidability of ADRs appears to need 
more than the provision of an assessment tool. In the Likert feedback results some 
individuals agreed that it may have been easier to assess the cases in a group 
setting however some were undecided and two disagreed. The feedback from the 
groups showed that most were undecided whether they would have been able to 
answer the questions themselves. Given that the individual assessors had not been 
exposed to the group assessments this could indicate that assessors would tend 
towards preferring a group process if that assessor had experienced both models. 
Alternative study designs are discussed in section 6.3 in Chapter 6. 
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3.7 Conclusion 
 
In assessing the avoidability of ADRs individual assessments had better agreement 
with a ‘gold standard’ evaluation than group assessments. Overall, the LAAT 
showed face validly for use in paediatrics. It showed that some cases lead to 
complete agreement. Other cases lead to wide divergence. There was also 
complete agreement and complete divergence between groups and individual 
assessors and the gold standard. Given the logistic difficulties with groups, 
individual assessments can be used in further work. Qualitative analysis of 
observations and participant interviews may help identify reasons for this and 
inform the optimisation of a tool for assessment of ADR avoidability. Chapter 4 
examines the qualitative aspects of the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
Chapter 4: Qualitative Work- group processes and decision 
making in MDT consensus meetings  
 
4.1 Introduction  
 
There has been an increased use of qualitative methods in healthcare research in 
recent years (Britten 2005). As defined by Hakim (1997), qualitative research 
provides the:  
 
Individuals’ own accounts of their attitudes, motivations and behaviour. It offers 
richly descriptive reports of individuals’ perceptions, attitudes, beliefs, views and 
feelings, the meanings and interpretations given to events and things, as well as 
their behaviour; displays how these are put together, more or less coherently and 
consciously, into frameworks which make sense of their experiences...(Hakim 
1997:26).  
 
Qualitative research can provide rich descriptions which cannot be generated 
through quantitative methods (Pope, Mays 1995) and can, therefore generate rich 
and detailed accounts of clinicians’ professional and inter-professional relationships 
(Reeves, Kuper & Hodges 2008) especially in exploring the complexities of clinical 
decision making; a phenomenon that cannot be explored using purely quantitative 
methods (Pope, Mays 1995). For example, Kidger et al (2009) used a qualitative 
approach to explore the factors that influence the clinical decision making in a MDT 
gynaecological cancer team. They used non-participant observations and semi-
structured interviews. It emerged from their observations that decision making 
tended to take one of three paths: discussion quick and decision clear, discussion 
long, ends with agreement and clear decision and finally, discussion long, no clear 
decision and unresolved questions (Kidger et al. 2009). 
 
 
 
The increased use and awareness of the contribution of qualitative research 
methods within healthcare research has led to scrutiny of qualitative research 
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(Murphy et al. 1998b). There has been considerable debate over whether 
qualitative and quantitative methods can be assessed according to the same quality 
criteria (Hannes K et al. 2011). However, such debates often fail to engage with the 
goals of qualitative research methods which are designed to construct an 
understanding rather than provide statistically significant generalisable findings. As 
Devine (2002) has argued, qualitative research is appropriate where “the goal of a 
piece of research is to explore people’s experiences, practices, values and attitudes 
in depth and to establish their meaning for those concerned” (Devine 2002:207). 
 
The aim of this research was to generate an understanding of how clinicians make 
decisions individually and within a MDT context and how those decisions lead to 
quantifiable outcomes. As such, both qualitative and quantitative approaches were 
taken here. This chapter provides a description and justification of the 
methodological approach taken in this research. It will firstly examine the different 
research paradigms. It will go on to explain the rationale for choosing a mixed 
methods approach and describe the approach taken here. It will also describe the 
method of analysis employed in this study. This will offer some personal reflection 
of the research process. Then the results will be presented and finally the 
discussion. 
 
Research paradigms 
A paradigm is a belief system or theory that guides the way we do things, or more 
formally establishes a set of practices. This can range from thought patterns to 
action. According to Guba (1990), paradigms can be characterised through their: 
ontology (what is reality?), epistemology (how do you know something?) and 
methodology (how do we go about finding out?) (Guba 1990). These characteristics 
create a holistic view of how we view knowledge: how we see ourselves in relation 
to this knowledge and the methodological strategies we use to discover it. Denzin 
and Lincoln (2003) described research paradigms as a ‘net’ that contains the 
researcher’s ontological and epistemological approaches. It is the choice of 
paradigm that sets down the intent, motivation and expectations for research 
(Mackenzie, N. & Knipe, S. 2006). The theoretical framework or paradigm influences 
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the way knowledge is studied and interpreted. In the absence of a paradigm from 
the start, there is no basis for subsequent choices regarding methodology or 
research design (Mackenzie, N. & Knipe, S. 2006) and it is difficult to assure the 
quality of the research. 
 
Guba and Lincoln (1994) break down research paradigms into three aspects. First of 
all many paradigms have an ontology, an assumption about the nature of reality. 
Secondly, each paradigm has an epistemology, a set assumptions about the 
relationship between the "knower" and the "known." A particular researcher's take 
on knowing is known as their epistemological stance. Finally each paradigm 
contains some assumptions about methods, though none are restricted to simply 
one way of gathering and analysing data. Table 4.1 outlines the different research 
paradigms.  
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Table 4.1 Research paradigms adapted from (Guba, E.G. and Lincoln, Y.S. 1994, 
Creswell 2009, Mackenzie, N. & Knipe, S. 2006) 
Paradigm Ontology Epistemology Methodology (?) 
Positivism  Realism. There is a "real," 
objective reality that is 
knowable 
Objectivist. The researcher 
can, and should, avoid any 
bias or influence on the 
outcome. Results, if done well, 
are true. 
Verification of hypothesis. Tends 
toward quantification and 
controlled experiments. 
Post-positivism Critical Realism. There is a 
"real," objective reality, 
but humans cannot know 
it for sure. 
Modified Objectivist. The goal 
is objectivity, but pure 
objectivity is impossible. 
Results are "probably" true. 
 
Includes both qualitative and 
quantitative methods. Modified 
experimental/manipulated. 
Seeks reduction of bias through 
qualitative validity techniques 
(e.g. triangulation) 
Critical Theory  Historical Realism. Reality 
can be understood, but 
only as constructed 
historically and connected 
to power. 
Knowledge is mediated 
reflectively through the 
perspective of the researcher. 
 
Focused on 
investigator/participant 
dialogue. Dialogic. 
Constructivism Relativist- local and 
specific constructed 
realities. All truth is 
"constructed" by humans 
and situated within a 
historical moment and 
social context. Multiple 
meanings exist of perhaps 
the same data. 
Researcher and participants 
are linked, constructing 
knowledge together. 
Transactional/subjectivist 
findings. 
 
Generally qualitative, research 
through dialogue. 
 
 Pragmatism Varied. Pragmatists may 
be less interested in what 
"truth" is and more 
interested in "what works" 
Accepts many different 
viewpoints and works to 
reconcile those perspectives 
through pluralistic means 
 
Focuses on a real world 
problem, by whatever methods 
are most appropriate, and tends 
toward changes in practice. 
Qualitative and /or quantitative 
methods may be employed. 
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Ontology is what one believes exists and is a view on the nature of reality. Are you a 
realist or, a relativist? Ontological assumptions are concerned with what constitutes 
reality, in other words what is.  Epistemology is our perceived relationship with the 
knowledge we are uncovering. Are we part of constructing that knowledge or does 
knowledge exist independently and external to us? It is concerned with how 
knowledge can be created, acquired and communicated or what it means to know. 
Guba and Lincon (1994, p. 108) explain that epistemology asks the question, what is 
the nature of the relationship between the would-be knower and what can be 
known? The researcher’s viewpoint will frame their interaction with what they are 
researching and is dependent on their ontological view. This in turn affects the 
methodology and the approach to gathering knowledge and conducting the 
research. According to Wainwright (1997) methodology is your strategic approach, 
rather than your techniques and analysis. Together the three (ontology, 
epistemology and methodology) constitute the philosophy of a paradigm. 
 
Positivist paradigm 
Positivist approaches are based on an ontology that the things we experience are 
things that exist. Studies are based on facts and consider the world to be external 
and objective. A deductive approach begins with theories that are tested against 
new data with an emphasis on the replication and generalisability of findings. 
Deduction is defined by Babbie (2013) as “the logical model in which specific 
expectations of hypotheses are developed on the basis of general principles” (Babbie 
2013). A deductive approach is informally known as the "top-down" approach as 
the reasoning works from general to more specific, narrowing down into specific 
hypotheses that can be tested thereby confirming or rejecting our original theories. 
It is often referred to as ‘scientific research’. Positivist research is typically aligned 
with quantitative methods (Mackenzie, N. & Knipe, S. 2006). According to Coffey 
(1999) strict scientific research requires the researcher to be objective but in ‘real 
life’ a researcher does not find out things by remaining distant. It is impossible to 
remove the influence of the researcher (Coffey 1999). 
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Interpretivist/constructivist paradigm 
Each individual constructs his/her own reality so there are multiple interpretations. 
It tends to rely on the “participants views of the situation being studied” (Creswell 
2003). Constructivists do not usually begin with a theory they develop, refine, 
amend or support theory throughout the research process (Mackenzie, N. & Knipe, 
S. 2006). An inductive approach begins with specific data out of which more general 
ideas or theories are generated. An inductive approach is also called the "bottom 
up" approach as the reasoning begins with specific observations and moves towards 
broader generalisations. Inductive reasoning, by its very nature, is more open ended 
whilst deductive reasoning is narrower and is concerned with testing or confirming 
hypotheses (Trochim 2006). 
 
According to Strauss and Corbin (1998) the concept of induction is often applied to 
qualitative research and although hypotheses may evolve from data there is 
interpretation of data to some extent which they class as a form of deduction. They 
acknowledge that there is a human element in analysis and there is overlap 
between induction and deduction (Strauss, Corbin 1998).  
 
Rationale for mixed methods approach 
Traditionally research was thought of as being either quantitative or qualitative 
however, over the past forty to fifty years mixed methods have increasingly been 
adopted into practice (Creswell 2003). According to Creswell 2003 p.4 “the situation 
today is less quantitative versus qualitative and more how research practices lie 
somewhere on a continuum between the two”. Mixed methods research is 
increasingly being conducted where the researcher combines quantitative and 
qualitative aspects (Anderson 2010). 
According to Creswell (2003) there are three key questions which are fundamental 
to the design of research: 
1. What knowledge claims are being made by the researcher (including a 
theoretical perspective)? 
2. What strategies of inquiry will inform the procedures? 
3. What methods of data collection and analysis will be used? 
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The research question and the aim of the study dictate the type(s) of method 
chosen. It is vital that the method or methods chosen relate directly to the research 
question and the aims of the study. Creswell (2003) therefore suggests 
consideration of these three elements in the design of a research study enables the 
researcher to identify whether a quantitative, qualitative or mixed methods 
approach is needed. In this study a mixed methods approach was taken as adopting 
a solely quantitative approach would not have answered the research question.   
 
This chapter is about the behaviour of groups when using the LAAT. Our motivation 
for this research was the need to optimise group performance when using the LAAT 
and the need to optimise the LAAT (setup, explanation and use). In particular we 
were interested in levels of agreement between groups and extent of similarity in 
pathway taken when the LAAT was used.  We were interested in the different 
approaches used by the consensus groups to assess the avoidability of the ADR case 
reports. Although we provided written instructions and a glossary relating to the 
use of the LAAT which contained information regarding the questions and their 
interpretation and provided practical examples the groups often chose not to 
consult the glossary even when they experienced problems with certain cases.  
 
Quantitative analysis examined the extent to which individuals and groups agreed 
with the ‘gold standard’ as outlined in Chapter 3. The qualitative approach was 
adopted in addition to quantitative methods as one of the aims of the research was 
to explore the factors that influenced decision making in MDTs this could not have 
been done using quantitative methods alone. From this perspective qualitative 
methods were also used to gain an insight into clinician’s thoughts, experiences and 
practices in relation to assessing the avoidability of ADRs.  
 
Some researchers believe that mixed methods research should be linked to one 
paradigm only and pragmatism has been suggested as the research paradigm of 
mixed methods (Johnson, Onwuegbuzie 2004). More recently it has been suggested 
that multiple paradigms relate to different phases of research design, thus linking 
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paradigms to research design (Creswell 2011). The central premise of mixed 
methods research is that the combination of both qualitative and quantitative 
approaches provides a better understanding of the research question than either 
method would alone (Creswell 2011). This study began with a quantitative phase 
which reflected an initial postpositivist paradigm (Chapter 3) and then moved on to 
a qualitative phase described here in Chapter 4 where the stance taken was 
interpretive and reflects the constructivist paradigm. So, the selected ontological 
framework was a mixture of constructivism and critical realism. The selected 
epistemological framework could be described as both transactional and modified 
objectivist. The selected methodological framework was quantitative and 
qualitative including participant observation, semi structured interviews. With 
respect to Table 4.1 the research paradigms were post-positivism and 
constructivism. 
 
Analysis was inductive and a thematic approach was taken in order to identify key 
themes that emerged from the data. According to Boyatzis (1998) thematic analysis 
is a process of "encoding qualitative information" (p. vii) where the researcher 
develops codes; words or phrases that serve as labels for sections of data (Boyatzis 
1998). Thematic analysis is a systematic approach to the analysis of qualitative data 
that involves identifying themes then classifying data, according to themes, and 
interpreting the resulting thematic structures by seeking commonalties, 
relationships, patterns, theoretical constructs, or explanatory principles (Mills, 
Durepos, G & Wiebe, E 2010). Thematic analysis is used by researchers as a way of 
getting close to their data and developing deeper appreciation of the content. Often 
it is used as a first step prior to conducting further analysis and aims to identify key 
themes rather than generate theory. The use of grounded theory was considered as 
a way of analysing the data further and generating theory but insufficient data, time 
and resources available to conduct grounded theory therefore thematic analysis 
was chosen. 
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4.2 Aims 
The study was designed to assess whether using the LAAT gave consistent results in 
the assessment of ADR cases. This part of the study aimed: 
1. To explore the factors that influence decision making in a MDT consensus 
meeting. 
2. To review group processes, such as turn taking, during a MDT consensus 
meeting 
3. To review use of guidelines during a MDT consensus meeting 
 
4.3 Ethical considerations 
4.3.1 Ethics approval 
As outlined previously in Section 3.4.4 in Chapter 3 
 
4.3.2 Consent 
All participants were given an information sheet to read. They had the opportunity 
to ask any questions before providing written informed consent see appendix 3 for 
the information sheet.  
 
4.4 Methods 
As described in Chapter 3, reviewers were either assigned to independently assess a 
selection of ADR cases reports or to one of the three MDT consensus groups. 
Participants were then notified as to which group they had been assigned to.  
4.4.1 Sample size and selection of cases 
 
ADR cases 
The ADR cases were selected as outlined in Chapter 3, Section 3.3.3. 
Definition of gold standard for each ADR 
As outlined in Chapter 3, Section 3.3.3 
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Sampling 
We used purposive and snowball sampling (non-probability sampling methods) to 
recruit participants as we wanted to explore a specific group of healthcare 
professionals.  Purposive sampling is where members of a sample are chosen with a 
‘purpose’ to represent a location or type in relation to a key criterion (Ritchie, J: 
Lewis, J (eds) 2003). Decisions about which criteria are used for selection are often 
made in the early design stages of the research and are informed by a range of 
factors including the principal aims of the study, existing knowledge about the area 
of work and hypotheses that the research may want to explore (Ritchie, J: Lewis, J 
(eds) 2003). The main decision regarding criteria for selection in this study was 
based on profession as we required a mixture of nurses pharmacists and doctors 
with experience of prescribing, administering, or dispensing medicines for children 
in order to facilitate MDT consensus groups. 
 
Individual assessments 
As outlined in Chapter 3, section 3.4.1 
 
Consensus groups 
Three MDT (nurse, pharmacist, doctor) consensus meetings were held. The group 
meetings were overseen by an independent facilitator (JD), a research pharmacist 
known to the team with experience in ADRs. JD was not involved in this study. JD 
moderated the meetings but did not take part in the assessment process and was 
not involved in the study analysis meetings. Prior to the meeting (48 hours before) 
reminder emails were sent to all participants; a copy of the avoidability tool glossary 
and a study information sheet were attached. On the day of the consensus meeting, 
JD provided a very brief overview of the ADRIC study programme to the group, 
explained the format of the session and introduced the LAAT. 
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The consensus groups were given 3 hours to assess the 20 selected ADR case 
reports from the ADRIC inpatient study. They were asked to map their responses 
and selected pathways on a copy of the tool for each case report selecting one of 
the four possible outcomes on the LAAT for each case (‘Not avoidable’, ‘Possibly 
avoidable’, ‘Definitely avoidable’, ‘Unassessable’) or if unable to reach a decision, to 
record an outcome of  ‘unsure’.  
 
Description of the MDT consensus meetings 
Meetings lasted up to 2.5 hours and took place in a dedicated meeting room at a 
paediatric medical and surgical secondary and tertiary referral centre in the 
Northwest of England (Alder Hey Children’s Foundation Trust) with members seated 
around a table. The mean meeting time was 2 hours and 21 minutes and the range 
was 2 hours and 7 minutes to 2 hours and 39 minutes. A description of the 
consensus group meetings is outlined below in Table 4.2. 
 
Table 4.2 Description of the consensus group meetings 
Consensus  Group Meeting Date Meeting  Duration  
Consensus  group 1 04/02/2014 2.07.00 
Consensus  group 2 10/02/2014 2.17.58 
Consensus  group 3 26/02/2014 2.39.12 
 
Nonparticipant observations of meetings  
Nonparticipant observations of the consensus meetings were conducted by LB.  
Observations were recorded by hand during the meetings and the notes were typed 
up immediately afterwards. 
 
Interviews 
Semi structured interviews with team members were conducted over a four week 
period in February 2014 (4th-27th February) by LB.  The consensus meetings took 
place on the 4th, 10th and 26th February. The post meeting interviews were 
conducted either immediately after the meeting or the following day for all 
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participants who took part. Before the study started potential participants were 
contacted by LB to inform them of the study and gain initial consent to be contacted 
again. Informed written consent was gained from each participant prior to the 
consensus meeting and interview. The nine reviewers involved in the consensus 
meetings were invited to take part in semi-structured interviews after the 
consensus meetings. The purpose of the interviews was to explore reviewers’ 
accounts of the consensus meetings, in particular their perceptions and views of the 
decision making process and their role in this and how future meetings could be 
improved. Topic guides were used to steer the interviews. The topic guide was 
developed by LB and reviewed and commented on by (JA and MT) (see appendix 6 
for a copy of the topic guide). The interview topic guide was piloted with two other 
interviewees prior to the study to ensure questions and follow-up prompts were 
appropriate and feasible. Some changes were made as a result of this including the 
addition of extra prompt questions and clarification of some questions.  
 
4.5 Recruitment of participants 
 
The recruitment of participants was outlined in Chapter 3 section 3.4.1 
 
4.6 The research process: personal reflections 
 
At the beginning of the recruitment stage I was aware that it might be challenging 
to recruit enough participants and that arranging MDT consensus meetings may be 
difficult. I soon learned that even with detailed planning and scheduling that last 
minute changes were sometimes necessary due to clinical commitments. The first 
consensus meeting ended up being rescheduled after sickness resulted in staffing 
issues. The second meeting went ahead as scheduled and the third one was almost 
cancelled but went ahead after a last minute swap of doctors. This exemplified the 
extent of social networks as after sending an email request we had several 
volunteers who were aware of the study.  We were able to go ahead with the third 
meeting as a doctor volunteered to attend at short notice to replace a colleague. 
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The role of reflexivity during data collection and analysis was also considered. 
Reflexivity addresses our subjectivity as researchers related to people and events 
that we encounter in the field. The process of reflexivity refers to the influence of 
the researcher’s own position, views, and responses, which may be conveyed to 
participants, and which in turn, may result in participants continually adjusting their 
responses as the interview continues (Corbin, J. & Strauss, A. 2008). With this in 
mind I’ve reflected on my position as a researcher. 
 
4.7 Reflections on interviewing and consensus groups 
 
Interviewing was a new experience for me and whilst I had completed a two day 
introductory course on qualitative interviewing I was a bit apprehensive at first 
about conducting interviews myself. Being a pharmacist I guess somewhat helped 
prepare for this process as in clinical practice I would have gained some informal 
experience, practiced my listening skills and interpreted information provided. 
However, there were some differences between research and clinical practice for 
example; interviews conducted in the research setting were based on a topic guide 
whereas interviews in a clinical setting would not be based on a topic guide. Also in 
the case of this study, the interviews were conducted with other clinicians where 
typically in practice they are more likely to be with patients rather than clinicians 
and are probably conducted in a less structured and formal way.  The first two 
interviews were conducted immediately after the first consensus meeting and they 
went well which gave me some confidence.  Overall my topic guide worked well. I 
noticed how different interviewees responded to questions and how some provided 
more detail than others whilst some required additional prompting. Some 
interviewees needed further questioning with open questions in order to get the 
information I required. 
 
I wondered if my position as a pharmacist would impact on interviewing other 
clinicians. The majority of the interviewees I had not met before or only knew by 
sight but one of the pharmacists I had met on a number of occasions previously and 
the other pharmacist I knew reasonably well as we had trained together. I 
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wondered before the interviews if it might be strange interviewing people I already 
knew but it turned out to be okay. I was aware that I might bring assumptions to 
the interviews however, the prompt guide helped offset any assumptions and 
ultimately, I don’t think this made any difference to the results. Before interviewing 
the pharmacist who I knew particularly well I wondered if it might be a little bit 
awkward but if anything it seemed to be a good thing as there was already a 
rapport built up. 
 
In terms of the consensus groups, I found being a non-participant observer 
challenging at times as despite the facilitator making my role clear when they 
provided the overview people still asked me questions on occasion. As a pharmacist 
I would normally be actively involved in discussion about medicines but on this 
occasion I could only observe not intervene. I found the second consensus meeting 
especially challenging when there were some issues at the beginning with 
interpreting the questions on the LAAT. I found it challenging at times not to 
comment or try and explain instead leaving the facilitator to explain. This was 
related to ownership of the study and I think also due to the implications of 
participants’ misunderstanding the interpretation of the questions on the tool and 
the impact this would have on the study. As I was acutely aware that if this was not 
clarified there would have been problems throughout the assessments with the 
application of the LAAT.  
 
4.8 Analysis 
 
An exploratory approach was taken using thematic analysis. Thematic analysis was 
used to immerse oneself in the data, to organise and focus the data for 
interpretation. According to Marshall and Rossman (1999) thematic analysis can be 
divided into six phases: 
1. Data organisation 
2. Generation of categories or themes 
3. Data coding 
4. Testing emergent understandings od the data 
 
 
 
122 
 
5. Searching for alternative explanations of the data 
6. Data analysis and write-up 
 
Coding is the analytic strategy used in thematic analysis. Coding is a process which 
involves looking for recurrent themes or topics and highlighting similar sections of 
text with a ‘code’ to categorise them. The assigned codes are later used to support 
theoretical interpretation of the data. 
 
The verbatim transcripts of the interviews and field notes recorded during the 
meetings were entered into NVivo 10 (qualitative data analysis software). The first 
step in thematic analysis is familiarisation with the data; this involved repeated 
reading of the transcripts followed by the generation of categories and emergent 
themes. The coding process initially involved line by line open codes which 
produced a large number of initial codes which were later refined into broader 
categories during analysis group meetings. JA, MT, JK, MPe and LB met to discuss 
emerging themes and develop analytical categories. Analysis was verified 
throughout by frequent review of transcripts to identify recurrent patterns and 
themes. LB led the analysis and development of the coding framework in a process 
that had both inductive and deductive aspects. She read transcripts several times to 
develop analytic categories regarding the content and meaning of particular 
transcript sections. LB also referred to the field notes during the analysis to prompt 
her recollection of contextual and process aspects of the interview and use these to 
help interpret the transcript sections. JA an experienced qualitative researcher was 
involved in the analysis as recommended by (Hannes K et al. 2011); experienced 
methodologists may have valuable insights into the analysis and can guide others 
through the critical appraisal process. JA, MT, MPe and JK supported the analysis by 
reading a sample of the transcripts and by ‘testing’ and developing the analysis 
through periodic discussion with LB. All five analysts compared within and between 
a sample of transcripts, and iterated between developing analytical categories and 
new data. Common themes were organised into a coding frame (see appendix 7 for 
coding framework). LB used the framework to analyse all subsequent transcripts. 
The coding frame was refined as the analysis progressed. Selected sections of 
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interview transcripts and observation notes were analysed by a second member of 
the study team. We used NVivo 10 to assist the analysis by indexing relevant 
sections of transcripts to facilitate interrogation of the data. We employed a 
number of methods that are recommended to help ensure rigour in the analysis of 
qualitative data. We examined the exceptional cases, that is, cases that were 
atypical either because of ADR type or clinicians’ experiences and considered how 
differences between these and more typical cases could inform the analysis 
(Strauss, Corbin 1998, Lincoln, Guba 1985). The MDT investigator triangulation 
aimed to ensure the quality and clinical relevance of the analysis. The diversity of 
the analysis team gave a broad perspective as the team was made up of an 
experienced qualitative researcher, pharmacist, doctor and two other non-clinical 
researchers. 
 
4.8.1 Analytical induction 
 
 This approach is an iterative process where data is analysed by reading and re-
reading interview transcripts until themes emerge and concepts are developed. The 
concepts are refined until there is a clear fit with the data and the theory. Fielding 
provides a good description of the use of analytical induction in qualitative 
research:  
 
 Using analytical induction in qualitative research allows the researcher to 
identify some ‘phenomenon’ and generate a provisional hypothesis which is then 
examined further as a ‘case’. A case is studied further to see whether the 
hypothesis relates to it. If not, the hypothesis is reformulated (or the 
phenomenon redefined to exclude the case). While a small number of cases 
support practical certainty, negative cases disprove the explanation, which is 
then reformulated. Examination of cases, redefinition of the phenomenon and 
reformulation of hypotheses is repeated until a universal relationship is shown 
(Fielding, 1988 cited in Silverman, 2011, p.374) (Silverman 2011). 
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Although analytical induction aims to develop concepts and theories from the data, 
in reality, no researcher is completely subjective but comes to the research process 
with preconceptions or ‘theoretical lenses’ based on experience and theoretical 
knowledge (Seale et al. 2006). In the research undertaken in this study there were 
some existing theoretical ideas or ‘lenses’ within which to view the data. These 
were drawn from existing work in the area which examined decision making in 
MDTs (Kidger et al. 2009, Lanceley et al. 2008). Kidger et al (2009) explored the 
factors that influenced decision making in MDTs and they identified three main 
themes central to the decision making process: the unsystematic consideration of 
patient related factors, the variation in team members’ role and level of 
participation in discussions depending on their profession and finally, different 
pathways and outcomes of the discussions which took place. At the beginning of 
the study I already had some existing theoretical lenses particularly the effect of 
different professions on participation in the group, seniority effect and leadership 
skills. During the analysis group meetings we discussed the coded interviews and 
agreed on the following broad themes:  
 
 Clinical Knowledge 
 Conceptual awareness 
 Perceptions of the tool 
 Engagement with the tool 
 Perceptions of groups v’s individuals 
 
4.8.2 Validity and reliability 
 
The trustworthiness of qualitative research has been critiqued for being 
unrepresentative, subjective and lacking in reliability and generalisability. However, 
such criticisms often fail to appreciate the different aims of research and the 
appropriate methods necessary to achieve those aims. However, this does  
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not exclude the need for rigorous research and numerous frameworks for ensuring 
rigour in qualitative work have been proposed (Shenton 2004). Guba (1981) 
proposed four criteria to be considered by qualitative researchers in pursuit of a 
trustworthy study. The concepts outlined in table 4.3 are based on (Lincoln, Guba 
1985) translation of criteria to critically appraise findings from qualitative research. 
We assessed credibility, transferability, dependability and confirmability the criteria 
outlined by (Hannes K et al. 2011, Lincoln, Guba 1985). Qualitative research has 
been criticised in the past as biased, anecdotal and lacking in rigour; however, when 
it is conducted properly it is reliable, credible, rigorous, valid and unbiased 
(Anderson 2010). 
 
 
Table 4.3 Criteria to critically appraise findings from qualitative research (Hannes 
K et al. 2011) 
 
Aspect Qualitative Term Quantitative Term 
Truth value Credibility Internal Validity 
Applicability Transferability External Validity or 
Generalisability 
Consistency Dependability Reliability 
Neutrality Confirmability Objectivity 
 
 
Credibility  
Lincoln and Guba (1985) argue that ensuring credibility is one of the most important 
factors in establishing trustworthiness. “Credibility evaluates whether or not the 
representation of data fits the views of the participants studied, whether the 
findings hold true” (Lincoln, Guba 1985). Evaluation techniques include: member 
checks, peer debriefing, negative case analysis, frequent debriefing, verbatim 
quotes and independent analysis of the data by more than one reviewer (Hannes K 
et al. 2011). This was achieved by the independent analysis of data by more than 
one researcher (LB, JA, MT, MP and JK) multiple researchers from different 
disciplines and they brought different views for example; MT focused on guidelines 
and contributed knowledge regarding existing guidelines whereas JA from a social 
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science background was interested in the distribution of power and turn taking 
during the consensus meetings. The different lenses which the researchers looked 
at the data through were interesting and contributed to the credibility of the data 
however; there was also considerable uniformity as the team had worked together 
before. Meetings were transcribed verbatim and distributed to all researchers for 
comments. Researchers met to discuss transcripts and this included interrogation of 
negative data and cases.  
 
Transferability  
“Transferability evaluates whether research findings are transferable to other 
specific settings.” 
Evaluation techniques include providing details of the study participants, providing 
contextual background information and demographics (Hannes K et al. 2011). 
Lincoln and Guba (1985) suggested that it is the responsibility of the researcher to 
ensure sufficient contextual information is provided to enable the reader to make a 
transfer. We recognised that as this was conducted in a tertiary paediatric centre it 
was important to describe the context within which the study took place, 
participant characteristics and location have been described in the methods section. 
Transferability was assessed by providing the details of study participants, 
background information and demographics.  
 
Dependability 
 “Dependability evaluates if the process of research is logical, traceable and clearly 
documented.” 
Evaluation techniques include: peer review, triangulation, reflective appraisal of the 
project, research design and implementation and audit trails (Hannes K et al. 2011). 
Lincoln and Guba (1985) suggested that dependability is closely related to 
credibility. This was achieved by triangulation and reflexivity a self-critical account 
of the research process, weaknesses and problems overcome. The whole study was 
overseen by an experienced team of researchers who met regularly with the 
research student. Any reflections or changes to the study as a result of these 
meetings were well documented and recorded. 
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Confirmability  
“Confirmability evaluates the extent to which findings are qualitatively confirmable 
through the analysis being grounded in the data and through examination of the 
audit trail.”(Hannes K et al. 2011). This was confirmed by the transparent reporting 
of the coding process as per Appendix 7. LB frequently reflected on how the data 
was interpreted with reference to her own position and regular notes were taken at 
meetings. Versions of transcripts including tracked changes were saved so it was 
possible to follow the process of analysis. Evaluation techniques include: assessing 
the effects of the researcher during the steps of the research process, reflexivity, 
the researcher’s background, beliefs and assumptions (Hannes K et al. 2011). The 
concept of confirmability is the investigators objectivity; steps should be taken to 
ensure that the study’s findings are the results and experiences of the participants 
rather than characteristics of the researcher (Shenton 2004). This was assessed by 
reflecting on LB’s position as the researcher, background, position, seniority, 
education and reflexivity. 
 
4.9 Results 
 
The study was designed to assess whether using the LAAT gave more consistent 
results in the assessment process. Table 4.4 shows the results from the consensus 
groups compared to the ‘gold standard’ (GS) it shows that some cases lead to 
complete agreement. Other cases lead to wide divergence. This includes some 
assessors saying definitely avoidable and others saying unavoidable. There is also 
complete agreement and complete divergence between assessors and gold 
standard. 
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Table 4.4 Avoidability category assignments of consensus groups – a comparison 
to the gold standard 
ADR Type Gold standard 
avoidability 
Consensus group 1 Consensus group 2 Consensus group 3 
Vomiting 
 
 
Definitely avoidable  
(AH chemo N+V) 
 
Not avoidable Not avoidable Not avoidable 
Procedural vomiting Definitely avoidable  
(AH PONV) 
Definitely avoidable  
(AH PONV) 
Definitely avoidable Definitely avoidable 
Somnolence Definitely avoidable Not avoidable Not avoidable Possibly avoidable 
Immunosuppressant 
drug level increased 
Definitely avoidable 
(BNFC) 
Definitely avoidable 
(BNFC/looked for 
tacrolimus guideline) 
Definitely avoidable 
(BNFC) 
Definitely avoidable 
(BNFC) 
Constipation Definitely avoidable Definitely avoidable Definitely avoidable Not avoidable  
(AH NCA/PCA) 
Hallucination Not avoidable Not avoidable Definitely avoidable 
(BNFC) 
Unassessable  
(BNFC) 
Cardiac failure Possibly avoidable Not avoidable Not avoidable  
(SPC) 
Not avoidable  
(SPC) 
Respiratory 
depression 
Possibly avoidable Definitely avoidable Definitely avoidable Possibly avoidable  
(AH NCA/PCA) 
Flushing Not avoidable Possibly avoidable  
(BNFC) 
Possibly avoidable  
(BNFC) 
Not avoidable  
(SPC + BNFC) 
Pruritus Not avoidable  
(AH NCA/PCA)  
Definitely avoidable Definitely avoidable Definitely avoidable 
AH NCA/PCA 
Visual disturbance Not avoidable Not avoidable Not avoidable Not avoidable  
(BNFC/AH PCA) 
Diarrhoea + 
Excoriation 
Not avoidable Definitely avoidable Definitely avoidable Possibly avoidable 
Hypocalcaemia + 
Hypophosphataemia 
Not avoidable 
(BNFC) 
Possibly avoidable Not avoidable  
(SPC) 
Not avoidable  
(SPC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Haematemesis Not avoidable Unassessable Possibly avoidable Not avoidable 
(checked intranet for 
guideline- none found) 
Hypertension Not avoidable Definitely avoidable Possibly avoidable Definitely avoidable 
Infusion associated 
reaction 
Not avoidable 
(BNFC) 
Not avoidable 
(BNFC) 
Not avoidable Not avoidable 
Urinary retention Not avoidable Not avoidable Not avoidable Not avoidable  
(AH NCA/PCA) 
Clostridium difficile 
colitis 
Not avoidable Not avoidable Unassessable Not avoidable 
Stomatitis Not avoidable Not avoidable Not avoidable Not avoidable 
Hypoglycaemia Possibly avoidable Not avoidable Not avoidable Definitely avoidable 
%  Agreement - 45% 40% 55% 
No. of guidelines 
consulted  
6 (3 x BNFC, 3 x AH)  4 (3 x BNFC, 1 x  AH) 5 (3 x BNFC + 2 x 
SPC) 
11 ( 4 x BNFC, 5 x 
AH + SPC x 2) 
% Avoidable 40% 45% 50% 42% 
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The study aimed to explore factors that influenced decision making in the MDT 
consensus meetings and to review group processes, such as turn taking, during 
meetings. Table 4.5 outlines the differences between the three consensus groups 
the information contained in the table was taken from summary data from the 
meeting observations recorded by LB.  
 
Table 4.5 Differences between the three consensus groups: 
Consensus Group  Rapport Group member 
participation 
Use and 
understanding of 
the LAAT 
% of cases 
where 
guidelines were 
consulted 
Consensus group 1 Excellent group 
rapport 
All group members 
participated fully. 
Quickly grasped 
the concept of 
the tool and how 
to use it. Good 
understanding. 
 
20% 
Consensus group 2 Good group 
rapport (took 
slightly longer to 
establish) 
Worked mainly as a 
group but the 
pharmacist seemed 
to take the lead. 
Initially struggled 
to understand 
the central 
boxes. Required 
more clarification 
from the 
facilitator.  
 
25% 
Consensus group 3 Good group 
rapport 
All group members 
participated. 
Worked well 
together. 
 
Overall good 
understanding of 
the tool  
45% 
 
 
The study aimed to review the use of guidelines during MDT consensus meetings. 
From the meeting observations it was clear that there was a difference in the 
attitude and use of guidelines within professions but there was also a difference in 
practice observed between the three consensus groups. Consensus groups 1 and 2 
had a similar approach to the use of guidelines and consulted them for 20 and 25% 
of cases respectively. There was a noticeable difference in the approach taken by 
consensus group 3 they consulted guidelines for 45% of cases. Guidelines were 
consulted in the ‘gold standard’ consensus meetings for 30% of cases.  
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Interviews  
Eight out of nine group members took part. It was not possible to interview the 
ninth member due to scheduling arrangements as a large time period elapsed 
before an interview was possible at which point it would not have been practical to 
have conducted the interview. All the interviews were audio recorded and 
transcribed verbatim. The interviews ranged from 6 to 21 minutes in length with a 
mean time of approximately 11 minutes. Table 4.6 shows the details of the 
interviews and background of the interviewees. 
 
Table 4.6 Details of the post consensus meeting interviews 
Clinician 
type 
Specialty  Grade/number 
of years’ 
experience 
Consensus  
Meeting 
Date 
Date 
interviewed  
Location 
of 
interview 
Duration 
of the 
interview 
Doctors         
GD1 Endocrinology 
& Diabetes 
 
 
ST5 or above 04/02/2014 04/02/2014 Consensus 
meeting 
room 
13 min 
GD2 A&E rotation 
 
 
ST4 or below 10/02/2014 10/02/2014 Consensus 
meeting 
room 
6 min 
GD3 Oncology 
 
ST5 or above 26/02/2014 27/02/2014 LB’s office 10.15 min 
Nurses       
GN1 Oncology/ 
Research nurse  
 
> 10 years 04/02/2014 04/02/2014 Consensus 
meeting 
room 
9 min 
 
GN2 Medical/ 
Research nurse 
 
>10  years 10/02/2014 10/02/2014 Consensus 
meeting 
room 
11 min 
GN3 Oncology/ 
Research nurse  
 
>10 years 26/02/2014 26/02/2014 LB’s office 6.06 min 
Pharmacists       
GP1 Specialist 
paediatric 
clinical 
pharmacist  
 
<10 years 04/02/2014 05/02/2014 LB’s office 21.21min 
 
GP2 Specialist 
paediatric 
clinical  
Pharmacist 
>10 years 10/02/2014 11/02/2014  LB’s office 12.43 min 
GP3 Specialist 
paediatric 
clinical 
pharmacist  
 
>10 years 26/02/2014 n/a n/a n/a 
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The format in which the findings are presented broadly reflect the key themes we 
developed during the course of the analysis. We first describe clinicians’ awareness 
of ADRs and the terminology used. We then describe the clinicians’ experience of 
using the tool. Finally, we describe the clinicians’ thoughts and experiences of being 
part of a MDT group for case assessment. Some key themes which emerged from 
the interviews and observational data are outlined below. 
  
4.10 Key themes 
 
Conceptual awareness 
Clinicians generally reported poor awareness and experience of ADRs and recalled 
relatively mild and common ADRs: “Oh gosh you know diarrhoea with antibiotics, 
constipation with codeine, all the sort of common ones, rashes with antibiotics” 
(GD2). Clinician’s accounts of their experience of ADRs also suggest there is 
confusion around terminology, especially around ADRs, ADEs, medical errors and 
side effects: 
 
Could I describe [pause] ehm many platelet reactions, blood transfusion 
reactions, lots of itching or hives, swollen lips post drugs.  When some of the 
kids have had stem cell transplants some of the reactions there as well.  Even 
with having piriton and hydrocortisone before and yeah still (GN1). 
 
There was also some confusion over the terms causality and avoidability. An 
example of this is highlighted below by the quote from GD3 where they are talking 
about causality rather than avoidability. However, despite this comment in the post 
consensus meeting interview it did not appear to impact on the ADR assessments. 
At the beginning of each consensus meeting the overview provided by the 
facilitator highlighted that the purpose of the meeting was to assess avoidability 
only and that each ADR case report already had a causality assessment completed 
and all the ADRs were deemed either probable or definite.  
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I certainly think it has got a lot of potential.  I think it has got quite a lot of 
potential in trials for example, when you are looking for novel or in turn long-
term pharmacovigilance and I think if there is something like that then there are 
kind of unexpected side effects and things (GD3). 
 
Perceptions  of the tool   
Clinicians were generally positive about the tool and could see how it could be used 
in practice:  
So say if you were getting lots of possibly avoidable then you could say well 
actually we’ve looked at 50 children, pretty much all of these under 5s do get 
constipated, let’s put on our morphine sticker, prescribe a laxative and it solves 
the problem […] Using this tool you could then use it to improve things next time 
in the future so I think that’s good (GD1). 
And also in research: “Yeah a research tool” (GD2). 
 
One clinician also described how the tool could possibly be adapted for use in 
reviewing medical errors:  
 
I’m obviously involved in review for errors and so on.  I suppose you could maybe 
could start thinking about how could that error be prevented, could that error be 
prevented or not and it would require some adaptation but ehm (GP2). 
 
Another clinician felt that using the tool focused the mind to process information in 
certain logical way and that this was helpful: Yeah, it makes you take it apart really, 
you know have a look at it in quite a strategic way. So yeah, I think it is really 
helpful.  (GN2). 
  
An unexpected finding was that one clinician felt the tool promoted self-reflective 
practice: “It’s a good tool to use to assess your own practice. So if there is an 
incident where a patient becomes unwell you can sit and think let’s have a look at 
this” (GP1). 
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Comments on the tool itself or regarding specific boxes on the tool: 
 
Overall clinicians were positive about using the tool and its ease of use. However, 
there were some comments about box 3 and the central box on the LAAT: “Were 
there known preventative strategies and/or appropriate management plan(s) with 
information about ADR avoidance available?” and “Were other information sources, 
or information in the history available for the prevention of the ADR which could 
have been followed?” 
 
“Yeah I think it’s easy to use” (GD1) “Yeah, it was nice and simple, and looking at it 
now, it’s like a clear diagram isn’t it. Initially you’re not put off when you first look at 
it. I think there were just those two questions wasn’t there” (GP2). 
 
Well I think it’s very good, I think as we were saying before, this third box the 
preventative strategies it’s just working out the kind of context of the scenario 
and kind of [02:25:00] I think the way it flows is very good and I would be happy 
kind of using that in the future for other things, it’s well devised (GN1). 
 
Yeah I think it was really helpful. I do think it would be useful, it was just that 
third box that even towards the end, when we were used to using the tool, it got 
me every time really. Yeah just a bit confusing but it just takes longer to think 
about it [...]yeah you just have to stop and think about it whereas, the start of the 
tool is straightforward (GN2). 
 
In reference to the tool’s glossary and reading of information; I suppose I didn’t 
really read that properly [laughs] so that’s why so yeah (GD1). 
 
A suggestion was made by the pharmacist in consensus group 3 about how the tool 
could possibly be improved by the addition of “[…] modification to include 
consideration of ADR and deliberate decision to proceed in a certain course of 
action” (GP3) 
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Perceptions of groups versus individuals   
Clinicians were generally positive about assessing cases within a group and could 
see a number of advantages to working within an MDT.  Clinicians especially valued 
access to expertise: “Yeah I think come to similar conclusions but I think it is easier 
with the group [laughs] yeah especially with a pharmacist.  I think it would take me 
a lot longer on my own to be honest” (GD1). 
 
Observation data from consensus group 1 showed that all members contributed to 
the discussion and there was frequent request for confirmation and agreement for 
each other. Members especially deferred to others where there was a specialist e.g. 
pharmacists for medicine safety or guidelines for example there were several 
examples of both the doctor and nurse looking to the pharmacist for clarification 
regarding doses, guidelines and what was standard practice. 
 
For example, in one case: ADRID 2103 - the patient has a raised tacrolimus level 
after receiving clarithromycin. In consensus group 1 the doctor and nurse asked the 
pharmacist what the normal levels should be for tacrolimus, whether clarithromycin 
was contraindicated and if there were any guidelines. The pharmacist responded 
and there was good group discussion over the case in group 1. Interestingly, in the 
other two consensus groups (groups 2 and 3) it was the pharmacist who was asked 
about what the normal levels of tacrolimus should be and whether any guidance 
exists specifically for transplant patients.  
 
In another case ADRID 477; the patient was receiving prednisolone as part of the 
ICISS trial and they developed hypertension. In consensus group 3 the nurse had 
experience of working on the ICISS study and therefore shared her knowledge with 
the team regarding blood pressure measurements and their frequency. The other 
group members responded well on hearing that GN3 had experience of the ICISS 
study and asked her to share her knowledge of the study protocol and the group 
then deferred to GN3’s experience and familiarity with the study.  
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During the consensus meeting observations there were a couple of cases involving 
particular specialties for example oncology or cardiology where hesitation and 
uncertainty were observed amongst the group. For example, ADRID 2105 - cardiac 
failure related to bisoprolol caused a lot of discussion amongst the groups. A 
number of group members stated they were not very familiar with the area. It was 
noted that there was uncertainty over where to access information about 
bisoprolol. In consensus group 1 and 2 the pharmacists recognised immediately that 
it would not be listed in the BNFC as it is not licensed for children and therefore 
both suggested looking up the SmPC instead. The groups all had lengthy discussions 
about the case and each member contributed to reaching consensus decisions. 
Feedback from the post consensus meeting interviews showed the value of MDTs 
and reliance on colleagues for guidance on areas which were unfamiliar. A quote 
from the post consensus meeting interview with GN2 highlights the value of an 
MDT; in response to being asked about whether they would have reached the same 
conclusions on their own.  
 
Erm, possibly not for a couple of them possibly ehm because other people have, 
so for the cardiac one, I’m not familiar with the cardiac medications and the 
pharmacist obviously was, so no for a couple of them I possibly would have 
struggled (GN2). 
 
Yeah, I think especially with the one, I think it was the mucositis or the oncology 
one.  We were almost at a conclusion until the pharmacist mentioned something 
and it took us right back to the beginning and that led us to think that it was 
unassessable that ADR because you know we needed more information from the 
previous reaction.  Yeah, definitely yeah (GN2). 
 
 
Clinician’s accounts reinforced the observational data and suggest that they 
perceive the expertise in MDTs could help overcome poor use of guidelines: “We as 
doctors very rarely look at all the kind of product information, the EMC and the EMI 
lists and things and probably not as aware of many of the hospital guidelines for 
example” (GD3). “I think finding the guidelines in this hospital is quite hard isn’t it?” 
(GD1).  
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Instead, clinicians reported relying on their own knowledge and experience: “I kind 
of know in my head what I’m supposed to do […] (GD1). Possibly as a result, 
clinicians especially valued the contribution of expertise into the decision making 
process: “And it is how you interpret what this management plan or guideline is, 
especially if it isn’t a fixed guideline and so it was quite helpful having an endocrine 
person there” (GP1). 
 
Yeah, it works quite well as a group […]people brought their experience from-  for 
example the pharmacist was very much kind of looking at the pharmaceutical 
information, the pharmacy information and basically looking at the BNF […] So I 
think when you’ve got the three kinds of reference points it is easier[…]. So it’s 
quite good that you have that triangulation (GD3). 
 
The observation data showed that in consensus group 1 and 3 it was both the 
pharmacist and doctor who consulted the guidelines. In consensus group 2, it was 
mainly the pharmacist who looked up any guidelines.  
 
Some clinicians also reported feeling that working within a multidisciplinary team 
overcame feelings of blame and judgement:  
  
It’s just really interesting that in some situations we have wanted to get away 
from saying it was an avoidable drug reaction […] but actually being able to say 
yes it was avoidable, but that doesn’t mean that anyone was at fault or we’ve 
done anything wrong.  That was just quite an interesting thing (GP1). 
 
Balancing judgements  
In all three consensus meetings there was evidence of balancing judgements 
observed where group members looked to each other for confirmation and 
reassurance. Clinicians reported that making decisions within a group helped reduce 
the chance of missing something and also was very helpful for certain areas or 
specialities that people were less familiar with as outlined above in the cardiology 
and oncology cases.  It was noteworthy in the post consensus meeting with GN3 
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where upon being asked about any potential disadvantages to working in a group 
she responded with “Yeah, I think if somebody was very strong I think it would be a 
little bit difficult, but I think it’s about being able to put your views forward”.  When 
GN3 was asked about being in a group:  
 
Yeah, I did think it worked well because I think if you’ve got the mix of people 
from different areas erm, it gave a good background of knowledge and I think 
having a pharmacist, doctor and nurse I think it was, it had different viewpoints, 
yeah” … “I think if you were doing it on your own you wouldn’t question some of 
the thoughts and everything that some discussion needs to be done, especially in 
some of the areas that you wouldn’t specialise in and you don’t 100% know about 
those.  Yeah, I think definitely a group (GN3). 
 
There was evidence from the meeting observations of group discussion and post 
meeting interviews found participants were positive about working as a group. “I 
think if you were doing it on your own you wouldn’t question some of the thoughts 
[…]some discussion needs to be done, especially in some of the areas that you 
wouldn’t specialise in.” (GN3). “Yeah of course, it also means that someone might 
spot something that you didn’t see” (GP1). “I think it is useful to bounce ideas 
because you can convince yourself of things can’t you? It’s good to do it as a group” 
(GD1). 
 
A small number of clinicians reported some concerns; especially that the MDT could 
prevent a team from reaching consensus:  
 
I think the only thing is that you can have quite different perspectives on stuff 
can’t you, for example, the oral one yesterday you can get a bit bogged down on 
semantics and just individual words and things, but I think there is a bit of 
flexibility in the tool.  I think the ones that two middle boxes are the ones where 
you can get to different routes, kind of allows for that though (GD3). 
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Or that some clinicians may dominate discussions: “I think ehm, somebody who 
wasn’t as confident to speak out, possibly be a disadvantage.  Would they challenge 
somebody who is more out spoken” (GN3). 
 
Disagreement and agreement 
Overall the three consensus groups worked well together to reach a consensus 
opinion.  However we observed a couple of examples of disagreement particularly 
in consensus meeting 3. Strong views on certain cases by some individuals led to 
disagreement. This included ADRID 1294 – constipation: there was some debate 
mainly between the pharmacist and doctor regarding the action taken; as no 
prophylactic laxatives were prescribed. Although there is very limited guidance 
available, the ‘gold standard’ for this case was ‘definitely avoidable’ and it was also 
the outcome reached by the other two consensus groups. In the end the outcome 
reached by consensus group 3 was ‘not avoidable’. “I think that is a fairly difficult 
one because not everyone gets it and you’re not going to start prophylactic laxatives 
on someone who getting opiates on ICU” GD3. 
A quote from the pharmacist highlighted their unease with the assessment: I’m 
struggling with that one because I think everybody knows that opiates can 
constipate and people have been a bit quicker given that he hadn’t opened his 
bowel since admission and he was admitted when […..] GP3. 
There was some discussion over whether there were any available guidelines and 
the Trust’s PCA guideline was consulted. The dialogue between the pharmacist and 
doctor continued and in the end they answered yes to “were there known 
preventative strategies and/or appropriate management plan(s) with information 
about ADR avoidance available?” and then by answering yes to “were the strategies 
and/or management plan (s) followed it took them to ‘not avoidable’. 
GP3  So your clinical knowledge would steer you in that direction 
GD3 So, and I think they have been followed 
GP3 And they’ve been followed? 
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GD3 If I saw this child on HDU over a weekend I would be fairly happy with what’s 
gone on and when it’s been recognised it’s been addressed fairly quickly, it’s 
been treated 
GP3 So in that case that would come out as a not avoidable because the 
strategy and management plan were followed, that doesn’t feel 
comfortable to me  
GD3 No, it’s a possibly avoidable isn’t it 
GP3 Yeah 
GN3 Yeah 
GD3 Because I think just with kind of rigidity of those four outcomes it has to go 
the other way unless you can actually audit through the notes and see 
what decisions were made and at what point 
GP3 Ok, so in changing our minds to say there were preventative strategies, we 
have taken ourselves through to not avoidable 
 
The vomiting related to chemotherapy case was an example of complete divergence 
from the gold standard. All three consensus groups categorised the ADR as not 
avoidable whilst the gold standard assessment was definitely avoidable. 
Interestingly, none of the consensus groups consulted the guidelines. The gold 
standard consensus group consulted the local guidance on prevention of nausea 
and vomiting related to chemotherapy. Although some antiemetics had been given 
prophylactically the chemotherapy the patient received was categorised as high 
emetogenic risk and according to the guidelines could therefore have been given 
additional antiemetics. From the meeting observations it was noted that all three 
groups felt some preventative strategies had been taken and the discussion 
amongst the groups was relatively brief and a decision was reached quickly. Two of 
the groups made reference to the existence of a guideline but chose not to consult 
it. The pruritus case again was an example of complete divergence from the gold 
standard and guidelines were only consulted by consensus group 3. From the 
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meeting observations this case highlighted some difficulty or confusion between 
prevention and management. Consensus group 2 also showed consideration of 
severity in the assessment and they appeared to be confused between the subtle 
difference between prevention and management. They talked about how the ADR 
could have been avoided sooner, the severity of the itching and the interventions 
made by the team which are all valid points but not actually related to avoidability. 
In order to avoid the ADR in the first place chlorpheniramine would have had to 
have been given alongside the fentanyl which is not standard practice. The 
guidelines suggest giving chlorpheniramine if the patient develops pruritus.  
 
4.11 Discussion  
 
Overall clinicians gave positive feedback about using the tool and saw potential for 
its use, but there was some confusion about concepts and terminology that may 
need addressing. The impact of the confidence and competence of using clinicians 
with varying levels of experience may have impacted on the IRR. This may reflect 
wider deficits in the knowledge of clinicians and it highlights the need for additional 
training. These issues could possibly be addressed by the introduction of extra 
teaching and training sessions. We might have expected the groups to have 
performed better than the individuals given the perceived advantage of having a 
MDT input. The impact and advantage of group MDT assessments might have been 
more noticeable in a more experienced group. The lack of experience of some 
reviewers perhaps reduced their ability to contribute to the discussion. 
Clinicians generally liked using the tool in an MDT situation and felt it speeded up 
decision making, promoted more balanced decisions, reduced feelings of blame and 
judgement and could offset the lack of, or lack of use of guidelines because of 
expertise in MDT meetings. Key themes and concepts which emerged from the 
study included conceptual awareness, perception of the tool, perception of groups 
versus individuals and the use of guidelines. People make choices about which 
information to look at and then make decisions with that information. During the 
consensus groups I observed differences in practice, with some clinicians choosing 
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to look up guidelines and reference sources and others not looking at any 
information instead relying on their previous knowledge or the knowledge of 
others. There was variation in patterns of thinking between the groups with some 
groups not looking up any guidelines and instead deferring to colleagues for 
confirmatory purposes rather than contradictory. A survey conducted in the US to 
investigate the attitudes and usage of clinical practice guidelines found that 
guidelines were used by 35% of paediatricians, 44% reported using them in part and 
21% reported they did not use guidelines (Flores et al. 2000). This is similar to our 
own findings where guidelines were consulted in just over 30% of cases.  
 
There was also variation in team members’ role and level of participation in 
discussions depending on their profession; overall the doctors and pharmacists 
appeared to take the lead more in discussions however, there were also examples 
of nurses taking a more central role particularly in consensus group 1 and on certain 
occasions in consensus group 3, for example the hypertension case where the nurse 
in group 3 had worked on the study and was familiar with the study protocol. The 
other group members deferred to the nurse and asked questions about the 
frequency of monitoring and information contained in the ICISS protocol. Examples 
of familiarity were also seen with the cardiology and oncology cases. In the 
cardiology case for example, the pharmacist was familiar with the suspected 
medicine, bisoprolol and was aware that it would not be listed in the BNFC and 
knew to consult the SmPC for information regarding the contraindications and was 
able to share this information with the team in order to facilitate the decision 
making process.  
  
Clinicians were generally positive about using the tool but there was some 
confusion about concepts and terminology that may need addressing as this has 
been shown to have implications for practice, especially in multidisciplinary practice 
(Gandy, Kershaw & Beaumont 2002). The consensus groups consulted more 
guidelines than the individuals (or at least those individuals that specified if 
guidelines were consulted) particularly consensus group 3 as outlined in Table 3.3 
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Chapter 3. Agreement with the ‘gold standard’ was similar for individuals and 
groups. In terms of %EA individuals had marginally better agreement with the ‘gold 
standard’ than the consensus groups. Given the logistic difficulties with groups, 
individual assessments may be preferable but we have shown that both methods 
are possible. Similar to the study by Kidger et al. (2009) there was some variation in 
participation by different professions seen particularly in consensus groups 2 and 3. 
In group 2 the pharmacist (GP2) seemed to take the lead role and in group 3 the 
doctor (GD3) and pharmacist (GP3) appeared to have more dominant roles, 
although the nurse (GN3) contributed well and played a central role in some cases 
(Kidger et al. 2009).The seniority effect where group discussions were dominated by 
senior consultants seen by Kidger et al. (2009) was not seen in this study. Overall, in 
this study each group member participated in the discussions and consensus 
opinion was reached. This study showed that group members deferred to 
specialism within the MDT rather than seniority which may be as a result of the 
diverse group brought together for the purpose of this study one that would not 
necessarily be reflected in real life where a team would be made up of specialists 
and would, in that case defer to seniority. There were no pharmacists involved in 
the MDT in the study by Kidger et al. (2009).The three differential pathways and 
outcomes of discussion reported by Kidger et al. 2009 were similar to those 
observed in this study (Kidger et al. 2009). 
 
A potential study limitation was that the presence of the observer and facilitator 
may have affected the decision making process. However, in reality this did not 
seem to be a problem perhaps because the volume of cases to be assessed in a 
limited time period meant the effect of the observer was lessened. Other possible 
study limitations were the small numbers and number of groups due to practical 
issues and feasibility, the artificial environment and the way in which study 
participants were selected and assigned again due to practical issues and availability 
to attend consensus group meetings.  
 
The study was designed to assess whether using the LAAT gave consistent results. 
Quantitative data and analysis suggests variation in outcome. This variation can 
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occur for a number of reasons and variation in outcome may, or may not, arise from 
variation in process for example how people assess avoidability and the use of 
guidelines. Using qualitative tools different approaches to avoidability assessments 
were observed. The consensus groups were more inclined to attribute a ‘definitely’ 
or ‘possibly’ avoidable assessment to the cases than the individuals. For some cases 
there was complete agreement between the three consensus groups but 
disagreement with the ‘gold standard’. Consensus group 3 had the best agreement 
with the gold standard and they also looked up more guidelines than the other two 
groups. Consensus groups 1 and 2 looked at guidelines less frequently and 
observations suggest that they relied more on tacit knowledge, familiarity and 
recall.   
 
Some of the variation between gold standard and group assessments may have 
arisen because the study team made some assumptions during the development 
and testing of the LAAT. The study team developed and followed a set of ‘rules’ for 
using the tool to assess the avoidability of ADR cases. Different interpretation of 
those ‘rules’ by other groups/individuals may be a reason for different outcomes of 
the assessment. Failure to consult guidelines that may be appropriate is one good 
example of not following the ‘rules’. Given additional instruction or training about 
the rules the agreement between assessors might be closer. Potential ways to 
overcome this might include producing more guidance on the use of the tool. 
However, we were reluctant to do this for two reasons: 1) ideally the tool should be 
useable without too much instruction and 2) we were aware that often people will 
not read the accompanying information as we witnessed in this study. Therefore, 
additional training on the use of the tool is potentially a better way of improving 
agreement and would be more likely to be effective. Strengths of the study include 
positive feedback from participants on the use of the tool and comments which 
reflected the potential utility of the tool in the future.  
 
During discussion about the results it was found that some of the findings resonated 
with the concept of heuristics. Heuristics are ‘efficient cognitive processes, 
conscious or unconscious that ignore part of the information with the goal of 
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making decisions more quickly, frugally, and/or accurately than more complex 
methods’ (Gigerenzer and Gaissmaier, 2011). Research indicates that individuals 
and organisations often rely on simple heuristics in an adaptive way (Gigerenzer, 
Gaissmaier 2011). Simon (1957) showed that we operate within what he called 
‘bounded rationality’. It has been shown that ignoring part of the information can 
often lead to more accurate judgements rather than weighting and adding all 
information. When making a decision, there is so much potentially relevant 
information available, it is impossible to know or process it all (so called ‘bounded 
rationality’) (Simon 1957). He coined the term 'to satisfice', where people seek 
solutions or accept choices or judgments that are 'good enough' for their purposes, 
but could be optimised (Simon 1957). Usually, a limited amount of information is 
selected to reach a sufficiently satisfactory decision, this process known as 
satisficing. Findings from a study which looked at clinical decision making in practice 
were consistent with the theory of bounded rationality which provides plausible 
explanations for a physician’s ability to make intelligent choices quickly and with 
minimum necessary information (Ribeiro Bonilauri Ferreira et al. 2010). 
 
During the analysis the value of heuristics emerged as a useful meta-theme. Looking 
at how people assess avoidability showed that people use familiarity and tacit 
knowledge more often than consulting official guidelines. The use of 
multidisciplinary groups could offset some of this variation. Heuristics may be one 
way that people make choices and one way of assessing variability. Heuristics can 
be structured and improved in contrast to convenient “rules of thumb”. In fact, the 
LAAT may itself be viewed as a heuristic that promotes structured reasoning. 
 
While some avoidability assessments may appear to be inherently variable and 
subjective this does not preclude the use of a tool. Discussions within groups or 
structured assessment by individuals are useful. Clinical actions to avoid ADRs may 
be identified even if avoidability classification differs. The findings of variability 
between assessors and groups raised the question of whether a more standardised 
approach to assessments should be taken. After much consideration it was agreed 
that in practice this would be very difficult to implement. As despite detailed 
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guidance on the use of the tool and how to interpret the questions in this study we 
observed how infrequently this was consulted and in many cases it was not used at 
all. Providing guidelines may not work as we observed that people rarely used 
them. More research is needed on how people make decisions in real life situations.  
For example do they consistently consult other colleagues within a specialism or do 
clinicians defer to seniority as in Kidger’s study (Kidger et al. 2009).  
 
4.12 Conclusion 
 
Overall the findings in this study were similar to those of Kidger et al. (2009). In this 
study, on average guidelines were consulted for just over thirty percent of the 
cases. Overall it appeared that reviewers relied on tacit knowledge and experience 
(either their own or others) than on guidelines and this may have implication for the 
generalisability of the study findings and also who should/could use the tool (for 
example is there a threshold of experience that is needed before using the tool 
effectively?). The research undertaken in Chapters 3 and 4 has shown that a mixed 
methods approach was justified and consistent with the research questions. The 
benefit of a mixed methods approach has been the rich data generated through the 
interviews and consensus groups which could not have been gathered otherwise. 
The qualitative data complements the quantitative data and perhaps begins to 
explain the results found during the quantitative research.  
 
The meeting observations and post-consensus meeting interviews have helped to 
explain possible reasons for variation in outcome of results and the observed 
differences between the three consensus groups and the gold standard consensus 
group. We have observed in practice that groups were reluctant to look up 
guidelines and information this may have implications for how the tool is used in 
the future. Further work could be carried out to optimise group assessments and 
use of the tool.  However, the tool has also been shown to be used effectively by an 
individual as described in Chapter 5. The tool designers developed and followed a 
set of rules and if those rules are interpreted differently by groups or individuals 
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this may explain some of the observed differences. The provision of additional 
instruction or training about the use of the tool might help improve agreement.  
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Chapter 5: Avoidability assessment of the ADRIC admissions 
study cases using the LAAT and a comparison to existing 
Hallas scores  
 
5.1 Introduction 
 
As outlined in Chapter 2, there have been many attempts to devise tools or scales 
to help determine avoidability. Commonly used scales include, Hallas (1990) and 
Schumock and Thornton (1992) which are based on appropriateness of prescribing 
or treatment choice. The Hallas scale (1990) was used for the ADRIC admissions 
study but it quickly became clear that it was not suitable for the ADRIC inpatient 
study due to difficulties encountered particularly, around the terminology used, as 
discussed in detail in Chapter 2. As a result of this, it was decided by the study group 
that we would design a new AAT which would be more applicable for use in 
paediatrics but could also be used in other settings. Ideally, the newly developed 
tool should be reproducible, easy to use and generalisable to a variety of different 
patient groups. Hakkarainen et al (2012a) recommended that any new avoidability 
instruments should be compared to existing ones. Therefore, we compared the 
newly developed LAAT to the Hallas scale (1990) which was used to assess 
avoidability in the ADRIC admissions study (Gallagher et al. 2012) by comparing the 
results of the avoidability assessments for both tools. 
 
The ADRIC admissions study was a prospective observational study carried out over 
a one year period (1st July 2008 to 30th June 2009) which looked at ADRs causing 
admission to hospital. During the study period, there were 8345 admissions. The 
estimated incidence of admissions due to ADRs was 2.9% (249) (Gallagher et al. 
2012). Of the 249 ADRs in the study 120 of them were oncology related (48%). The 
Hallas scale (1990) was used to determine avoidability via a consensus method. 
Gallagher et al.  (2012) found that 78% of ADRs were unavoidable, and 22% were 
either possibly or definitely avoidable. Gallagher et al. (2012) suggested some 
potential prevention strategies for ADRs based on their assessment of the ADRs 
they classed as ‘definitely avoidable’: that more careful attention to practical 
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aspects of care, such as improved monitoring, following prescribing guidelines and 
improved patient education could lead to a reduction in the frequency of ADRs 
causing admission. 
 
5.2 Aim 
To assess the avoidability of the ADRIC admissions study cases using the newly 
developed Liverpool avoidability assessment tool and to compare the results to the 
existing Hallas assessments carried out as part of the ADRIC programme. 
 
Objectives 
 To examine the agreement between the LAAT and Hallas assessments 
 To identify the types of ADRs that may be avoidable 
 
5.3 Methods 
All 249 ADR case reports identified during the ADRIC admissions study were 
individually reviewed by one person (LB) using the LAAT to assign an avoidability 
outcome for each case. The pathway taken on the LAAT for each case was recorded 
and any guidelines consulted were noted. In addition if a case was classified as 
‘possibly’ or ‘definitely avoidable’, the rationale for the perception of avoidability 
was recorded. The case reports contained anonymised demographic data for the 
affected patient, details of suspected and concurrent medication, past medical 
history, and a description of the adverse reaction, treatment and outcome. After all 
the assessments with LAAT had been completed the LAAT assessments were 
compared to the Hallas scores previously assessed as part of the admissions study 
via a consensus method (Gallagher et al. 2012). Categorical scores for both the LAAT 
and the Hallas scale use the same four point ordinal scale: ‘Definitely avoidable’, 
‘possibly avoidable’ ‘not aovidable’ or ‘unavoidable’  and ‘unassessable’ or 
‘unevaluable’.  
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Validation  
For quality assurance purposes a purposive sample - 10% of cases (25) were 
assessed by a second reviewer- senior investigator (MT).  
 
Analysis 
A descriptive analysis for all ADRs in the sample was conducted. The ADRs were 
counted according to their classification: definitely avoidable, possibly avoidable, 
not avoidable, or unassessable. The avoidability categories assigned using the LAAT 
were compared to the Hallas assessments (Gallagher et al. 2012).  
 
The overall agreement for LAAT assessments and Hallas assessments were 
summarised using descriptive statistics, means with 95% confidence intervals 
alongside the exact agreement statistics. Exact agreement percentages were 
computed to measure the absolute concordances between assessor scores that is 
the percentage of cases that were given the same category in the two assessments. 
The percentage of extreme disagreement (%ED) where the avoidability scores 
between the two raters of the same case are wider than one interval apart was 
classed as extreme disagreement; for example a case classified as definitely 
avoidable by one rater and not avoidable by the other. Kappa values were 
interpreted according to the guidance from Altman (1991) as per Chapter 2.  
 
Ethics approval 
This study was part of a larger study which used routinely collected clinical data in 
an anonymised format. The Chair of Liverpool Paediatric Research Ethics Committee 
(REC) issued a formal opinion that the larger study did not require individual patient 
consent or review by an Ethics Committee. The planned analysis required routinely 
collected patient data and was therefore classified as an audit. 
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5.4 Results 
 
Assessment of the 249 ADR case reports using the LAAT found that 19.3% were 
either possibly or definitely avoidable (Table 5.1). This was similar to the Hallas 
results where 22% of the reactions were either possibly or definitely avoidable 
(Gallagher et al. 2012).  Of the 120 (48%) oncology related ADRs 7 were classified as 
avoidable: 4 as possibly avoidable and 3 as definitely avoidable. Of the three 
‘definitely avoidable’ cases, two were vomiting related and one was constipation 
related. Three of the possibly avoidable cases were related to constipation where 
two were attributable to vincristine and ondansetron and one had dihydrocodeine, 
all without laxative prophylaxis. The fourth possibly avoidable ADR was a gastritis 
case related to dexamethasone. Of the 129 non-oncology cases 41 were classified 
as avoidable: 36 as possibly avoidable and 5 as definitely avoidable. 
 
Overall percentage exact agreement (%EA) was 90%; when subcategorised into 
oncology and non-oncology cases the %EA was found to be 94.2 and 86% 
respectively. %ED was 0.8%. The two cases with extreme disagreements were 
oncology cases (Tables 5.1 and 5.2). The kappa score was 0.71 (95% CI 0.60 - 0.82) 
for all cases, 0.54 (95% CI 0.40 - 0.68) for the oncology cases and 0.73 (95% CI 0.58 - 
0.88) for the non-oncology cases. Overall there were 25/249 cases with 
disagreement, shown in Figure 5.1.  In total there were 48 cases that were 
categorised as either possibly or definitely avoidable. The cases and the reasons for 
their categorisation are summarised in Table 5.3. 
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Table 5.1 Avoidability of ADRs oncology versus non-oncology 
 
Table 5.1 shows the comparison of avoidability categories for Hallas compared to 
the LAAT overall and in terms of oncology and non-oncology breakdown. 
 
 
 
 
 
ADR 
Type 
 
Hallas Avoidability 
Count of ADRs (%) 
 
 
 
LAAT Avoidability 
Count of ADRs (%) 
Unavoidable 
 
Possibly 
avoidable 
Definitely 
avoidable 
 
Unavoidable 
 
  
Possibly 
avoidable 
Definitely 
avoidable 
 
 
Oncology 
(n=120) 
 
 
112 (93.3)
  
  
 
 
6 (5) 
 
2 (1.7) 
 
113 (94.2) 
 
4 (3.3) 
 
3(2.5) 
 
Non - 
oncology 
(n =129 
 
82 (63.6) 39 (30.2) 8  (6.2) 88 (68.2) 36 (27.9) 5(3.9) 
 
Overall 
 (n= 249) 
 
 
194 (77.9) 
 
45 (18.1) 
 
10 (4) 
 
201 (80.7) 
 
40 (16.1) 
 
8(3.2) 
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Figure 5.1 ADRs with disagreement oncology versus non-oncology 
 
 
Figure 5.1 shows the ADR cases where disagreement occurred between Hallas and 
the LAAT and the breakdown in terms of oncology and non-oncology cases. 
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Table 5.2 Breakdown and overall agreement between Hallas and LAAT 
 
 
Table 5.2 shows the overall agreement between Hallas and the LAAT and the 
breakdown of oncology and non-oncology cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADR Type 
 
 
Hallas assessment versus 
LAAT assessment 
 
Agree Disagree 
 
Oncology (n=120) 
 
 
113 (94.2%) 
 
7 (5.8%) 
 
Non-oncology (n= 129) 
 
 
111 (86%) 
 
18 (14%) 
 
Overall (n= 249) 
 
224 (90%) 
 
25 (10%) 
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Table 5.3 Possibly and definitely avoidable ADR cases and rationale for assessment 
Avoidable Frequency ADR Type Drug Classes Reason for potential 
avoidability 
Definitely 1 Constipation Opioid analgesics, 
Cytotoxics 
No prophylaxis given 
Definitely 1 Deranged Renal 
Function 
 
Drugs affecting the 
renin-angiotensin 
system 
Frequency of monitoring 
Definitely 1 Diarrhoea 
 
Antibacterial Appropriate indication for 
antibiotics signs/symptoms 
of viral illness? 
Definitely 1 Hypoglycaemia 
 
Drugs used in 
diabetes 
Avoidable with improved 
patient education – for 
example insulin use when 
unwell. Patient had a past 
history of the same when 
unwell previously. 
Definitely 2 Immunosuppression 
 
Corticosteroids, 
Drugs affecting the 
immune response 
Frequency of monitoring of 
drug levels 
Definitely 2 Vomiting Cytotoxics Post chemo vomiting -
appropriate antiemetic 
prophylaxis used? 
Possibly 1 Adrenal suppression Corticosteroids Frequency of monitoring 
Possibly  1 Intestinal obstruction 
 
Anti-motility drugs Avoidable with improved 
patient/parent education 
Possibly 1 CNS depression Opioid analgesics Monitoring for drowsiness 
Possibly 8 Constipation  Drugs for urinary 
frequency, enuresis 
and incontinence, 
Opioid analgesics, 
NSAIDs, Cytotoxics, 
Calcium channel 
blockers, Calcium 
supplements, Drugs 
used in nausea 
No prophylaxis given 
Possibly 6 Diarrhoea 
 
Antibacterial Query appropriate indication, 
signs/symptoms of viral 
illness 
Possibly 1 Gastritis 
 
Corticosteroids  Past history of gastritis- could 
have given appropriate 
prophylaxis? 
Possibly 2 Haematemesis 
 
NSAIDs Developed haematemesis 
with vomiting. Avoidable 
with improved education 
Possibly 1 Hyperglycaemia 
 
Corticosteroids Prolonged course of 
steroids/monitoring 
frequency 
Possibly 6 Hypoglycaemia 
 
Drugs used in 
diabetes 
Avoidable with improved 
patient education – for 
example insulin use when 
unwell. Frequency of 
monitoring 
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Table 5.3 shows the possibly and definitely ADR cases, the drug classes involved in 
the ADR and a rationale for avoidability. Table 5.4 shows the avoidability themes 
associated with ADRs categorised as either possibly or definitely avoidable. Table 
5.5 shows the results from the validation check where MT checked 10% of the 
cases. 
 
 
Possibly 1 Ileus 
 
Opioid analgesics Avoidable with more rational 
prescribing- lots of opioids 
were given 
Possibly 2 Immunosuppression 
 
Corticosteroids, 
Drugs affecting the 
immune response 
Frequency of monitoring of 
drug levels. More rational 
prescribing 
Possibly 1 Rash, lip swelling Anti-bacterial History of the same ADR to 
the same medicine 
Possibly 6 Respiratory 
depression 
Drugs used in status 
epilepticus, 
Hypnotics 
Alternative medicine 
available. Multiple doses 
given. Dose slightly high and 
multiple doses given 
Possibly 1 Seizure 
 
Antihistamines History of seizure in the past 
with similar antihistamine  
Possibly 1 Vomiting Anti-bacterial Appropriate indication for 
antibiotics signs/symptoms 
of viral illness? 
Possibly 1 Hyperglycaemia Parenteral 
preparations 
Frequency of monitoring 
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Avoidability 
theme 
Number of 
possibly 
avoidable cases 
Number of 
definitely 
avoidable 
cases 
Proportion of ADRs 
associated with each 
theme for avoidable 
ADRs 
Proportion of 
ADRs associated 
with each theme 
for all ADRs  
Therapeutic areas involved in this theme 
(number for each area) 
Inappropriate or 
suboptimal 
prescribing 
 
26 4 60% 12% Opioid analgesics (4) 
Drugs used in nausea (3) 
Cytotoxics (3) 
Antibacterial (8) 
Corticosteroids (2) 
Antihistamines (1) 
Drugs used in status epilepticus (6) 
Hypnotics (1) 
Drugs for urinary frequency, enuresis and 
incontinence (1) 
Antiepileptics (1) 
Muscle relaxants (1) 
Topical  corticosteroids (1) 
Calcium channel blockers (1) 
Calcium Supplements (1) 
Inadequate 
monitoring 
 
10* 3 25% 5% Drugs affecting the renin-angiotensin system (1) 
Corticosteroids (4) 
Drugs affecting the immune response (1) 
Opioid analgesics (1) 
Drugs used in diabetes (5) 
Parenteral preparation (1) 
Inadequate 
education 
 
6* 1 15% 3% Drugs used in diabetes (3) 
Anti-motility drugs (1) 
NSAIDs (2) 
*Two possibly avoidable ADRs were categorised in two themes (inadequate monitoring and inadequate education) 
 Number  Proportion of eligible admissions (8345) taken from Gallagher et al. 2012 
All avoidable ADRs 48 0.6%  
Table 5.4 Avoidability themes associated with ADRs 
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Table 5.5 Results from validation -10% check  
ADRID ADR Type 
LAAT Outcome 
MT LAAT Outcome LB Hallas Outcome 
2 Seizure Not avoidable Not avoidable Possibly avoidable 
6 Neutropenia  Not avoidable Not avoidable Possibly avoidable 
19 Rash, lip swelling Possibly avoidable Possibly avoidable Definitely avoidable 
60 Hypoglycaemia Not avoidable Not avoidable Possibly avoidable 
227 Hypercalcaemia Not avoidable Not avoidable Possibly avoidable 
235 Adrenal suppression Possibly avoidable Possibly avoidable Definitely avoidable 
9 Immunosuppression Not avoidable Not avoidable Not avoidable 
13 Diarrhoea Not avoidable Not avoidable Not avoidable 
17 Constipation Possibly avoidable Possibly avoidable Possibly avoidable 
32 Deranged LFTs Not avoidable Not avoidable Not avoidable 
33 Epigastric pain Not avoidable Not avoidable Not avoidable 
64 Nausea Not avoidable Not avoidable Not avoidable 
81 Mucositis Not avoidable Not avoidable Not avoidable 
83 Hyperkalemia Not avoidable Not avoidable Not avoidable 
119 Headache Not avoidable Not avoidable Not avoidable 
122 Vomiting  Not avoidable Not avoidable Not avoidable 
146 
Post-tonsillectomy 
bleed Not avoidable Not avoidable Not avoidable 
160 Increased appetite Not avoidable Not avoidable Not avoidable 
164 Ileus Not avoidable Possibly avoidable Possibly avoidable 
167 
Deranged Renal 
Function Not avoidable Definitely avoidable Definitely avoidable 
187 Haematemesis Not avoidable Possibly avoidable Possibly avoidable 
228 Gastritis Definitely avoidable Possibly avoidable Possibly avoidable 
79 Hyperglycaemia Not avoidable Possibly avoidable Possibly avoidable 
1 
Respiratory 
depression Not avoidable Possibly avoidable Possibly avoidable 
4 Intestinal obstruction Not avoidable Possibly avoidable Definitely avoidable 
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5.4.1 Results from the validation check 
The results from the validation check are summarised in Table 5.5. Overall %EA 
agreement was 72%. Of the seven case reports where disagreement occurred, 6/7 
had the same avoidability classification assigned by LB using the LAAT as those 
determined using the Hallas scale. 
 
**Please note some of the identifiable data has been removed from the ADR case 
reports in order to protect patient confidentiality. ** 
 
The cases with disagreement are described below. 
 
ADRID 164 - Ileus 
A surgical patient with Spina Bifida and neuropathic bladder who was readmitted 
the day after discharge (six days after bladder surgery) with vomiting and abdominal 
pain was diagnosed with ileus. Suspected medicines were codeine and fentanyl. 
Post operatively whilst in hospital the patient had a fentanyl patient controlled 
analgesia (PCA) for 3 days and received regular codeine. They did not open their 
bowels until day 4 post-op. On day 5 post-op the patient required a glycerine 
suppository which was reported to be ineffective they were later discharged home 
and mum said they had lactulose at home. The patient was readmitted the next day 
due to vomiting (unable to keep fluids down) and they complained of intermittent 
abdominal pain which was reported to be relieved by vomiting. Prior to admission 
they passed a small hard bowel motion that morning at home. On exam their 
abdomen was reported to be soft, distended and no bowel sounds present. An 
abdominal x-ray showed dilated upper loops. A nasogastric tube (NG) was passed. 
They were treated with lactulose, a phosphate enema and IV fluids. The patient 
reportedly had a faecal vomit overnight and the following night opened their 
bowels. The next day they tolerated fluids and started light diet. The patient was 
discharged home three days later. 
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The Hallas assessment for this case was ‘possibly avoidable’ and the reason 
provided was “ileus after 6 days post-op opioid use, avoidable with more rational 
prescribing (possibly use alternative analgesia). 
 
In terms of the avoidability assessments using the LAAT one reviewer categorised 
the case as ‘possibly avoidable’ and the other as ‘not avoidable’. Divergence 
occurred answering the question ‘Were there known preventative strategies and/or 
appropriate management plan(s), with information about the ADR and its 
avoidance, available?’ One reviewer answered ‘yes’ here which took them on to 
answer ‘Were other information sources, or information in the history available for 
prevention of the ADR which could have been followed?’ they answered ‘yes’ here 
and went on to categorise the ADR as ‘possibly avoidable’ (the rationale provided 
was that the patient was given a lot of opioids). The other reviewer answered ‘no’ 
to the question ‘Were there known preventative strategies and/or appropriate 
management plan(s), with information about the ADR and its avoidance, available?’ 
They answered ‘no’ to the question ‘Were other information sources, or 
information in the history available for prevention of the ADR which could have 
been followed?’ which led to them categorising the case as ‘not avoidable’. The 
rationale provided was that the opioids were presumably deemed necessary to 
control the pain and other options for pain relief had been considered by the clinical 
team. 
 
ADRID 167- Deranged renal function 
A baby with heart disease had deranged renal function (raised urea and creatinine 
on admission to Alder Hey) following treatment with captopril at another hospital. 
Prior to commencing captopril at the other hospital the patient’s urea (UR) and 
creatinine (CR) were raised (UR 14.8 mmol/l and CR 73 micromol/L) (normal values 
for age range: UR 2.0-5.0 mmol/l and CR < 40 micromol/L).  Three days after 
commencing captopril the patient’s UR had increased to 25.5 mmol/l and their CR 
had increased to 101 micromol/L. The captopril was stopped on admission to Alder 
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Hey as it was suspected as causing the renal dysfunction. The urea and electrolytes 
(U+Es) were reported to have improved upon stopping the captopril. Two days after 
stopping the captopril the patient’s UR had decreased to 15.9 mmol/l and their CR 
had dropped to 55 micromol/L. The medical team considered restarting the 
captopril later once the U+Es had improved but this wasn’t done. Monitoring of 
U+Es was completed but the frequency was variable between 3 and 6 days.  
 
The Hallas assessment for this case was ‘definitely avoidable’ and the reason 
provided was “avoidable with improved monitoring”. In terms of the LAAT 
avoidability assessments there was extreme disagreement for this case, one 
reviewer categorised it as ‘definitely avoidable’ and the other reviewer as ‘not 
avoidable’. Both reviewers answered ‘yes’ to the question ‘Were there known 
preventative strategies and/or appropriate management plan(s), with information 
about the ADR and its avoidance, available?’ which led them to answer the next 
question ‘were the strategies and/or management plan(s) followed? One reviewer 
answered ‘no’ here and categorised the ADR as ‘definitely avoidable’ the rationale 
provided was the frequency of the monitoring particularly in a child who had 
deranged renal function prior to initiating the captopril. The other reviewer 
answered ‘yes’ therefore categorising the ADR as ‘not avoidable’. The rationale 
provided was that the initial baseline renal dysfunction could not have been 
avoided but perhaps the extent of the exacerbation of renal dysfunction could have 
been minimised. If starting captopril was clinically appropriate then the only way to 
detect worsening renal function would be to monitor renal function but by the time 
worsening renal function was detected then it would have already have happened. 
Thus worsening renal function could not have been avoided by more frequent 
monitoring. Discussion of this case between the two reviewers highlighted the 
subtleties in interpretation of the questions and information contained in the case 
reports. The reviewer who assessed the ADR as unavoidable was working to assess 
the occurrence of the ADR while other reviewers may have had a different 
perspective.  
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ADRID 187- Haematemesis 
A child under 6 years with a 2 days history of vomiting was reported to have been 
vomiting every hour. They were given a dose of paracetamol and ibuprofen. Was 
reported to have had haematemesis the following morning, at first coffee ground 
vomit followed by 5 bright red fresh blood vomits.  Admitted for observation later 
discharged as haematemesis had stopped and the patient was tolerating diet and 
fluids. 
 
The Hallas assessment for this case was ‘possibly avoidable’ and the rationale 
provided was “avoidable with improved patient education/more rational 
prescribing (less NSAID use)”. Using the LAAT one reviewer classified the case as 
‘possibly avoidable’ the rationale provided was ‘perhaps ibuprofen was not 
appropriate as the patient was vomiting regularly and not able to tolerate food one 
of the counselling points with ibuprofen (as per BNFC guidance) is to be taken with 
or just after food. This ADR might be ‘possibly avoidable’ with improved education.’ 
The other reviewer categorised the ADR as ‘not avoidable’ by answering ‘no’ to 
‘Were there known preventative strategies and/or appropriate management 
plan(s), with information about the ADR and its avoidance, available?’ which led 
them to the next question ‘Were other information sources, or information in the 
history available for prevention of the ADR which could have been followed?’ 
answering ‘no’ here took the reviewer to ‘not avoidable’. The reviewer felt that the 
family had acted within standard practice for families and that improved education 
that would reach every family about every warning relating to commonly used 
children’s medicines was a theoretical possibility with minimal relevance in the real 
world. Answering ‘yes’ to ‘Were there known preventative strategies and/or 
appropriate management plan(s), with information about the ADR and its 
avoidance, available?’ took the other reviewer to ‘Was appropriate action taken to 
avoid the ADR’. They answered ‘no’ here and therefore categorised the ADR as 
‘possibly avoidable’. The divergence here appeared to relate to the extent to which 
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all theoretical possibilities were considered relevant to the assessment and the 
extent to which the assessment should be guided by “real world” thinking. 
 
ADRID 228 - Gastritis 
This gastritis case occurred in an oncology patient who was prescribed 
dexamethasone as part of their treatment regime for acute lymphoblastic 
leukaemia (ALL). It was recorded in the case history that they had experienced 
gastritis during a previous admission which was initially treated with Gaviscon 
Advance® prn, before ranitidine was added in twice daily the patient appeared to 
subsequently be switched to omeprazole once daily but it was not clear why, there 
was no mention of how effective the treatment was or when it resolved. On this 
occasion the ADR was detected after the patient complained of left sided chest pain 
and was admitted for observation. A diagnosis of gastritis secondary to steroids was 
made. The ranitidine was restarted which was reported to be effective and the 
symptoms resolved. No further reports of gastritis were reported although the case 
report stated that the steroid course was completed shortly after the admission. In 
terms of the avoidability assessments using the LAAT one reviewer categorised the 
case as ‘possibly avoidable’ and the other as ‘definitely avoidable’ this was due to 
the differences in answering the question ‘Were there known preventative 
strategies and/or appropriate management plan(s), with information about the ADR 
and its avoidance, available?’ Answering ‘no’ to this question (as prophylactic 
ranitidine or other gastro-protective treatment is not listed in the ALL treatment 
protocol) takes the reviewer on to ‘Were other information sources, or information 
in the history available for prevention of the ADR which could have been followed?’ 
answering ‘yes’ to this question (based on the fact that we know the patient had a 
history of gastritis on a previous admission and required treatment) takes the 
reviewer on to answer ‘was appropriate action taken to avoid the ADR?’ and 
answering ‘no’ to this categorises the ADR as ‘possibly avoidable’. The other 
reviewer answered ‘yes’ to the question ‘Were there known preventative strategies 
and/or appropriate management plan(s), with information about the ADR and its 
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avoidance, available?’ which led them on to answer ‘were the strategies and/or 
management plan(s) followed?’ and in answering ‘no’ here categorised the ADR as 
‘definitely avoidable’.  
 
In theory, perhaps ranitidine could have become part of the personalised 
management plan for this child however this would have meant a change in the 
tool’s glossary to incorporate ‘personalised management plan’ in the section where 
other management plans are listed. At the time of assessment we defined 
appropriate management plans as per the statement below (See glossary in 
appendix): 
 
Appropriate management plan(s): a plan that would be recognised as appropriate 
by a reasonable body of opinion. This could refer to any local, national or 
international guideline that could be available to the prescriber e.g. hospital 
guidelines, National Institute for Health and Care Excellence (NICE), Scottish 
Intercollegiate Guidelines Network (SIGN). The glossary was subsequently amended 
to reflect this change (see Appendix 8 for the final version of the glossary): 
 
Appropriate management plan(s): a plan that would be recognised as appropriate 
by a reasonable body of opinion. This could refer to any local, national or 
international guideline that could be available to the prescriber e.g. hospital 
guidelines, National Institute for Health and Care Excellence (NICE), Scottish 
Intercollegiate Guidelines Network (SIGN) or a ‘personalised management plan’. 
  
ADRID 79 - Hyperglycaemia  
The hyperglycaemia case occurred in a child under 12 with ulcerative colitis gastric 
symptoms who had been on oral prednisolone 30-40mg for 3-4 months. It was 
reported that they had tried several times to reduce the dose but after symptoms 
worsened the dose was increased again. The patient reported an increased 
frequency of passing urine at home (up to 30 times/day). They presented to 
accident and emergency (A&E) with glycosuria and a blood sugar of 14.7. Seen by 
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endocrine team who thought it was ADR to prednisolone and prescribed insulin to 
control symptoms. 
 
The Hallas assessment for this case was ‘possibly avoidable’ and the rationale 
provided was ‘avoidable with more rational prescribing (prolonged course of 
steroids used)’. Using the LAAT one of the reviewers categorised the ADR as 
‘possibly avoidable’ and the other as ‘not avoidable’. The divergence occurred at 
the question ‘Was appropriate action taken to avoid the ADR?’; one reviewer 
answered ‘no’ here categorising the ADR as ‘possibly avoidable’ the rationale 
provided was guidance from the BNFC suggests using the lowest possible dose 
(treatment might be required for 4-8 weeks), frequent monitoring and dose 
reduction perhaps the dose could have been tapered sooner? The other reviewer 
answered ‘yes’ categorising the ADR as ‘not avoidable’: making the assumption that 
the treating team had made all reasonable effort to reduce the dose – once 
reduction had been tried “several times” it would be unreasonable to subject the 
child to unnecessary flareups since not every child would develop diabetes on 
steroids while this child would develop flareups. The divergence in this case 
appeared to the balance between different assessments of causal chains that 
clinicians make in practice. 
 
ADRID 1- Respiratory depression 
The respiratory depression occurred in a child with epilepsy who was started on 
desmopressin 5 days prior to the seizure. Had status epilepticus and was given 
diazepam rectally in school. Decreased respiratory effort and decreased Glasgow 
Coma Scale (GCS) patient was unresponsive. They required intubation and 
ventilation and were admitted to PICU. They recovered on PICU and no further 
problems were reported.  
The Hallas assessment for this case was ‘possibly avoidable’ and the rationale 
provided was ‘alternative medicine available, avoidable with more rational 
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prescribing’. Using the LAAT one reviewer categorised the ADR as ‘possibly 
avoidable’ and the other as ‘not avoidable’. The divergence occurred at the 
question ‘Were other information sources, or information in the history available 
for prevention of the ADR which could have been followed?’ One reviewer 
answered ‘yes’ categorising the ADR as ‘possibly avoidable’ and the other reviewer 
answered ‘no’ categorising the ADR as ‘not avoidable’.  The rationale provided for 
categorising the ADR as ‘possibly avoidable’ was alternative medicines were 
available. The other reviewer assumed if the medicines had been available to the 
team treating the child they would have been used. In this view, if the treating team 
had no choice about the medicine then the ADR was not avoidable. The way to 
avoid the ADR would be for the health care system (school, ambulance, neurologist 
etc.) to make a different policy decision. This view led to a discussion of proximate 
and distal (ultimate) causes. According to the WHO ‘the chain of events leading to 
an adverse health outcome includes both proximal and distal causes’ (World Health 
Organisation 2002). The proximate cause of ADRID 1 was the use of diazepam. The 
ultimate cause was the selection of medicines outside the hospital setting. One 
reviewer examined the proximate cause of the ADR. The other reviewer examined 
the distal cause of the ADR. Assessors could set different limits on the search for 
distal causes and this might lead to different assessments of avoidability. 
 
ADRID 4- Intestinal obstruction 
The patient had a history of diarrhoea and abdominal pain for 4 days. They were 
prescribed loperamide. The day before admission they were reported to have not 
opened their bowels for 2 days. They reported worsening abdominal pain so the 
loperamide was stopped (after 4 days of treatment). On admission they had a 
contrast study which showed obstruction. They went to theatre and had 
adhesiolysis, resection of small gut and reanastomosis. The pathology report 
showed gangrenous small gut section with impacted faeces.  
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The Hallas assessment for this case was ‘definitely avoidable’ and the rationale 
provided was ‘could be prevented by improved patient/parent education’.  In terms 
of the LAAT assessments one reviewer categorised the ADR as ‘possibly avoidable’ 
and the other as ‘not avoidable’. The divergence occurred at the question ‘Was 
appropriate action taken to avoid the ADR?’ one reviewer answered ‘no’ 
categorising the ADR as ‘possibly avoidable’ and the other reviewer categorised the 
ADR as ‘not avoidable’. The rationale provided for assessing the case as ‘possibly 
avoidable’ was that it was potentially avoidable with improved patient/parent 
education. The parents should have been counselled on what to look out for and 
when to stop the medicine. The patient information leaflet states that loperamide 
can be taken for up to 5 days but if no improvement after 2 days of taking the first 
dose of loperamide to go back and visit the doctor. The rationale for the response 
“not avoidable” was that intestinal obstruction was due to the adhesions which 
were not due to loperamide. 
Some of the divergence is related to the burden of proof required for avoidability. 
One position is that avoidability relates to any conceivable different course of 
action. Another position is that avoidability relates to plausible courses of action. If 
these positions are widely held then some degree of divergence may be 
unavoidable, particularly within the group of people working to “plausible” courses 
of action. The sources of divergence may reflect personality type, approach to 
clinical care or practical experience. The divergence is analogous to the burden of 
proof in civil cases “balance of probability” vs “beyond a reasonable doubt”. For 
example the evaluation of clinical features may be done in more than one way. One 
extreme would be to consider clinical features to be relevant if they contributed to 
the ADR beyond a reasonable doubt. Another approach would be to consider 
clinical features to be relevant if they contribute on a balance of probabilities.   
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Personal reflection on different approaches to using the LAAT 
During the development and validation of the LAAT I observed many different 
people from different backgrounds and professions with varying levels of 
experience use the LAAT. I observed different approaches to assessing the 
avoidability of ADR case reports with some clinicians taking a very practical 
approach and others a more theoretical approach where they considered many 
aspects of avoidability and made comments that the ADR may not be avoidable on 
this occasion but would be avoidable on any subsequent occasions. Some took a 
systematic approach and were careful to answer the questions in the same way 
when assessing different cases of the same ADR types. Others were less consistent 
and at times showed evidence of interpreting the questions differently for different 
cases of the same ADR type, perhaps sometimes this was due to subtle differences 
in the case reports but not always. Some reviewers appeared to have a predefined 
opinion on whether or not the case was avoidable before conducting an avoidability 
assessment with the LAAT and then went on to answer questions in a certain way in 
essence using the tool as a validation check to confirm their line of thinking. 
  
5.5 Discussion 
 
The LAAT showed good agreement overall with Hallas (1990), good agreement for 
the non-oncology cases and moderate agreement for the oncology cases. The sub-
categorisation of the analysis into oncology and non-oncology cases showed a 
marked change in the number of avoidable cases. Overall assessment with the LAAT 
showed that approximately 19% of cases were either possibly or definitely 
avoidable. This figure increased to almost 32% for the non-oncology cases and 
decreased to 5.8% for the oncology cases. This was comparable to the Hallas 
assessments where overall avoidability was approximately 22%; this increased to 
approximately 37% for the non-oncology cases and decreased to approximately 7% 
for the oncology cases (Gallagher et al. 2012). 
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The reason for this marked difference may be explained by the nature of the 
oncology ADRs. Of the 120 oncology cases, the most common reactions were 
neutropenia (89), thrombocytopenia (55) and anaemia (38) (Gallagher et al. 2012). 
These ADRs are expected, largely ‘not avoidable’ given the benefit risk ratio and 
accounted for over 40% of all oncology ADRs4. Although some possible prevention 
strategies for neutropenia are used in adults such as granulocyte colony stimulating 
factors (GCSF) there is no definite evidence regarding the use of GCSF in children 
(Sasse EC et al. 2005). This may explain the drop in the number of avoidable ADRs 
from 19% overall to 5.8% for the oncology ADRs. The types of oncology ADRs which 
were classified as possibly or definitely avoidable were constipation without laxative 
prophylaxis, vomiting after chemotherapy where additional antiemetic prophylaxis 
could have been given and gastritis following the use of corticosteroids in a patient 
with a past history of gastritis following corticosteroid use. The gastritis case might 
have been avoidable if the patient was given appropriate prophylaxis such as 
ranitidine. 
The systematic review by Smyth et al. (2012) highlighted two key points regarding 
avoidability. Firstly, they found a noticeable lack of avoidability data; with only 19% 
of studies assessing avoidability. Data were available for fourteen studies and the 
avoidability rates differed greatly amongst studies; with 7-98% of ADRs categorised 
as possibly/definitely avoidable. One of the possible reasons for the wide variation 
may be explained by the difference in study types, which included those causing 
admission, in hospital, community and combined settings (causing admission and in 
hospital). Another possible reason is the method used for assessing avoidability; ten 
studies used a recognised avoidability assessment tool. Half of the studies used 
Schumock and Thornton (1992) and Hallas (1990) was also used.  
The assessment of the ADRIC admissions study cases did highlight a discrepancy on 
two separate occasions. Firstly, the ADR of rash and lip swelling due to amoxicillin in 
                                                          
4
 431 reactions in 249 ADR case reports 
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a patient with a history of the same ADR previously to amoxicillin; assessment of 
this case using the LAAT categorised the ADR as ‘possibly avoidable’. Although the 
reviewer wanted to categorise it as ‘definitely avoidable’ the tool didn’t allow this 
as a route. The route taken was via the central boxes ‘Was there a known history of 
allergy or previous similar reaction to the drug’ - answered ‘yes’ which led to ‘Were 
other information sources, or information in the history available for prevention of 
the ADR which could have been followed’ - answered yes (patient had a history of 
same ADR), ‘Was appropriate action taken to avoid the ADR?’ - answered ‘no’ and 
therefore the ADR was classified as ‘possibly avoidable’. The Hallas assessment for 
this case was ‘definitely avoidable’ with the rationale provided as ‘same ADR 
previously to same medication’ (Gallagher et al. 2012). The second case was a 
gastritis case where the ADR was due to dexamethasone; the patient had a history 
of gastritis since commencing steroids and had been prescribed ranitidine in the 
past for this. However, there was no information available in the case report on the 
efficacy of the ranitidine during the previous episode of gastritis.  Assessment of this 
case using the LAAT categorised the case as ‘possibly avoidable’ based on the 
patient having a history and appropriate action not taken to avoid the ADR. The 
Hallas assessment of this case was ‘possibly avoidable’ with the rationale provided 
as ‘previous gastritis - possibly avoidable with improved prophylaxis’. This case was 
also assessed by MT as part of the 10% validation and categorised as ‘definitely 
avoidable’. It highlighted the need for an amendment to the tool’s glossary to 
include ‘personalised management plan’ under appropriate management plans (see 
Appendix 8 for details) to allow for this in future assessments.  
As discussed earlier the divergences relate to the burden of proof required for 
avoidability. The assessment of avoidability is complex and subjective which may 
lead to a degree of divergence which is unavoidable. The LAAT aims to minimise the 
subjectivity by taking the reviewer through a series of questions however, it is 
impossible to eliminate subjectivity completely as reviewers may differ in their 
beliefs, experience and approach. This was evident in the qualitative work discussed 
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in Chapter 4, there were elements of bounded rationality and heuristics displayed in 
the ADR assessments by the consensus groups. See Chapter 4 for a discussion of 
heuristics. 
Thus, as noted at the end of Chapter 3, implementing an AAT will require more than 
developing a tool, validating it and rolling out. It will be important to identify 
systematic differences between people and groups. These differences may be 
mitigated through training or interpretation. Training could point out the 
differences and ask assessors to take a specific approach in the interests of 
consistency. Interpretation could take account of the variation that is intrinsic to the 
process of avoidability assessment (see Chapter 6). 
One of the objectives of this thesis was to identify potentially avoidable ADRs and 
investigate ways to reduce their incidence. In terms of avoidability constipation was 
the ADR most frequently categorised as avoidable with nine cases in total classified 
as either ‘definitely’ or ‘possibly avoidable’. The reason for these cases being 
potentially avoidable was that no laxatives were given prophylactically. Eight out of 
the nine constipation cases assessed with the LAAT were classified as ‘possibly 
avoidable’ rather than ‘definitely avoidable’ as there is not always a guideline 
available. Other examples of potentially avoidable ADRs include 
immunosuppression, respiratory depression, vomiting and hypoglycaemia. Three 
key themes for avoidability have been established through a review of the existing 
literature (Jonville-Béra et al. 2009, Smyth et al. 2012, Gallagher et al. 2012, Temple 
et al. 2004) the themes are:   
 
1. Inappropriate or suboptimal prescribing - this includes failure to follow written 
recommendations or failure to apply information derived from other sources. 
Specific examples include:  
 Inappropriate indication: diarrhoea due to antibiotics prescribed for a viral 
infection 
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 Inappropriate duration of treatment: adrenal suppression due to 2 years’ 
continuous treatment with intranasal corticosteroid  
 Medication administered to patient with history of ADR: seizure due to 
antihistamine use in a patient who had previously experienced the same 
reaction to the same medication 
 Preventative measures not implemented: laxatives not prescribed and 
patient developed constipation due to opioid use 
 
2. Inadequate monitoring again this includes failure to follow written 
recommendations or failure to apply information derived from other sources, 
for example: 
 Hypercalcaemia in a patient receiving oral calcium supplementation 
 
3. Inadequate patient or parent education, for example: 
 Hypoglycaemia due to failure to adjust insulin dose when child unwell at 
home 
 Prolonged diarrhoea due to continuation of laxatives when diarrhoea first 
developed 
 
There was evidence of these themes in the assessment of the ADR cases in this 
study, as summarised in Table 5.4. The next step is to develop strategies to prevent 
these types of ADRs.  This will be discussed in Chapter 6. This work also provides a 
preliminary estimate of the frequency of the incidence of the three avoidability 
themes. Table 5.4 avoidability themes associated with ADRs suggests that the 
inappropriate or suboptimal prescribing theme is the most frequent and this could 
be one way to prioritise educational interventions. With respect to therapeutic 
areas antibactericals were the most frequently implicated drug class involved in 
avoidable ADRs and this could be another way to target efforts. The overall 
incidence of avoidable ADRs was 6 per thousand admissions (Table 5.4). This figure 
is based on ADRs causing admission, although it was not possible in this study to 
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look at the incidence of avoidable ADRs in inpatients, preliminary findings based on 
work in Chapter 2 suggest that the figure would look quite different for inpatient 
ADRs due to the difference in nature and types of ADRs.  This estimate is likely to be 
an underestimate because some ADRs are not detected on admission. 
The development of the LAAT was an iterative process conducted by a MDT using 
ADR case reports from the ADRIC study. We have conducted extensive testing of 
the LAAT including both individual and group testing. In addition to this rigorous 
testing, we have followed the recommendations set out in a recent systematic 
review of methods for assessing avoidability (Hakkarainen et al. 2012a).  
 
A limitation of this study was that LB only assessed the cases using only the LAAT 
and not Hallas in addition to allow a direct comparison. Secondly, LB assessed the 
cases individually whilst the Hallas assessments were conducted in a group. 
Although the decision to conduct the assessments individually was taken after the 
consensus meeting and individual testing phase which showed that there was no 
real difference between individuals or groups using the LAAT (Chapter 3). Due to 
feasibility of assessments it was decided that the ADR cases would be assessed 
individually. The good agreement in this study between Hallas and the LAAT has 
shown that individual avoidability assessments are possible using the LAAT.  It has 
also shown that the Hallas scale (1990) is a suitable alternative tool to use 
depending on the study population, as we know from the ADRIC inpatient study 
there were difficulties using Hallas due to the language used, the breadth of 
knowledge required and the conditions represented in the cohort (Thiesen et al. 
2013).  
 
The LAAT removes some of the subjectivity that perhaps makes it easier for less 
experienced assessors to use the tool. The questions on the tool are designed to 
guide the reviewer through a particular pathway to one of the four avoidability 
categories. Hallas may be quick and easy to use by experienced assessors but can be 
difficult to use by those with less experience of assessing avoidability, in which 
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instance it may work best as a consensus group.  The LAAT assesses whether at the 
time the drugs were prescribed and administered if the ADR was avoidable or not. 
This is where the LAAT differs to Hallas, in that Hallas really is about reflecting on 
whether you have read some obscure or new paper somewhere that you ought to 
be applying in practice. This is one of our reasons for not using Hallas in the 
inpatient study as it seemed to us not to be appropriate in terms of talking about 
avoidability at the time. This study has shown very similar results for the two tools, 
however, one tool was used in a consensus group setting (Hallas scale) and the 
other (LAAT) by an individual assessor. Therefore, depending on the study team, 
study population, time constraints and personal preference then either tool may be 
suitable for assessing avoidability of ADRs.  
The LAAT did not give consistent results for a number of reasons. Some of the 
reasons for this were explained earlier in this chapter in the section on personal 
reflection on the different approaches to using the LAAT. Firstly, assessors applied 
the LAAT in different ways. This occurred for a number of reasons. Some, but not all 
assessors were inconsistent. Assessors have different approaches to establishing 
the nature of expected management for a clinical case. Some assessors expected to 
review guidelines for every case; others were prepared to base their judgments on 
recall of guidelines that could be incomplete or inaccurate. Other assessors did not 
consult guidelines at all. These findings suggest that consistent assessment of 
avoidability requires more than the introduction of a structured assessments tool. 
Secondly, many guidelines did not include information about ADRs and ways to 
prevent ADRs. This allowed assessors to take a number of approaches to 
assessment (as well as being a primary way to reduce avoidable ADRs). 
Thirdly, assessors bring different cognitive styles to the assessments. This was 
illustrated by the comparisons between LB and MT. Discordant assessments could 
arise because of different standards of proof. Did an ADR have to be not avoidable 
beyond a reasonable doubt, or could an ADR be not avoidable on a balance of 
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probabilities? How far down the chain of causality should one search before 
concluding that none of the causal links contributed to avoidability? How much 
variation in practice between clinicians and families is appropriate when handling 
complex balances between benefit and the risk of avoidable ADRs? These three 
reasons for inconsistency suggest that there will always be an irreducible lack of 
consistency during the assessment of whether ADRs are avoidable. The implications 
of this are discussed further in Chapter 6. 
 
5.6 Conclusion 
In summary, we have designed a new avoidability assessment tool, developed by a 
multidisciplinary team that had good agreement with the existing Hallas (1990) 
assessments that were carried out as a group consensus. This chapter has shown 
that individuals can use the new tool effectively. This is an advantage as the time 
constraints and organisational issues involved in holding MDT consensus meetings 
can be challenging at times. This study found the incidence of avoidable ADRs to be 
19.3% which was similar to that found by Gallagher et al. (2012) using the Hallas 
scale (1990).  However, we know from the recent systematic review (Smyth et al. 
2012) that avoidability rates varied widely between studies; with 7-98% of ADRs 
being classified as possibly/definitely avoidable. This work has also provided a 
preliminary estimate that 6 per 1000 admissions to a children’s hospital are due to 
avoidable ADRs. Further work needs to be conducted in this area to determine the 
avoidability rate of ADRs in children and identify the potentially avoidable ADRs in 
order to develop possible prevention strategies. Unfortunately, it was outside the 
scope of this thesis but plans for future work include the avoidability assessment of 
all the ADRIC inpatient study cases. This would enable us to focus on the potentially 
avoidable ADRs and ideally develop prevention strategies to reduce the incidence of 
ADRs in children. A more in-depth, expert-led review of avoidable ADRs and their 
prevention is required before detailed and clinically relevant interventions can be 
implemented. 
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Chapter 6: Discussion   
 
6.1 Thesis findings - Summary 
 
This thesis focuses on the assessment of the avoidability of adverse drug reactions 
in children. The impetus leading to the work was the lack of information about the 
avoidability of ADRs in children. The ADRIC systematic review highlighted that very 
few studies investigated avoidability (19%) and, when they did, there was wide 
variation in the avoidability rates between the studies (7-98%) (Smyth et al. 2012). 
Secondly, difficulties were encountered during the assessment of avoidability in the 
ADRIC inpatient study using existing tools (Thiesen et al. 2013).  
 
The overall aim of this thesis was to develop a new avoidability assessment tool 
suitable for use in paediatrics (Chapter 2) as none of the existing tools were 
specifically designed for use in children. This thesis also looked at the methodology 
for assessing ADR avoidability and compared individuals to group assessments 
(Chapters 3 and 4). In Chapter 3 the hypothesis that group avoidability assessments 
were superior to individual avoidability assessments was tested. Chapter 4 
examined the qualitative aspects of decision making in MDTs. Finally, in Chapter 5 
the newly developed LAAT was used to assess the avoidability of the cases from the 
ADRIC admissions study and compared to the results of the existing assessments 
using the Hallas method from the ADRIC programme (Gallagher et al. 2012, Hallas 
et al. 1990). This thesis aimed to establish which types of ADRs are avoidable and to 
describe the context of avoidability of ADRs in the care of children. It also aimed to 
identify potential strategies for clinical practice that might reduce the incidence of 
ADRs.  
 
There is large variation in the reported avoidability rates of ADRs in paediatrics; 
work from this thesis suggests that approximately 20% of ADRs involved in causing 
admission to hospital are avoidable (Chapter 5). This is similar to the assessments 
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made by Gallagher et al. (2012). In adults this figure is higher; a meta-analysis 
conducted by Hakkarainen et al. (2012b) found that roughly half of all ADRs 
amongst adult inpatients (45%) and outpatients (52%) may be avoidable. Assessing 
the avoidability of ADRs is a complex process which requires consideration of a 
number of factors. There are different levels of avoidability including patient, ward, 
departmental, institutional, professional and national. 
 
Despite these complexities a number of previous studies have been conducted. This 
experience prompted the assumption that it would be relatively straightforward to 
develop a new scale using the methodological suggestions put forward by 
Hakkarainen (2012a).  However, we found several difficulties with avoidability that 
have not previously been described in the literature. A common theme that 
emerged in the work undertaken in Chapters 3 and 4 of this thesis was the lack of 
available treatment guidelines. Where guidelines were available few contained 
information about ADRs or preventative strategies. The majority of clinicians relied 
on their experience and tacit knowledge rather than on guidelines.  
 
In adults, ADRs contribute significantly to patient morbidity, mortality and 
hospitalisation costs (Davies et al., 2009, Khan 2013). The impact of ADRs in 
paediatrics is not as well quantified (Khan 2013); however, it is expected to include 
similar types of costs. These costs include additional clinician time, additional 
diagnostic tests, treatment and prolonged hospitalisation (Visconti and Smith 2006). 
Therefore, work to quantify the impact of ADRs in children and the development of 
interventions to reduce that impact are important.  
 
In the ADRIC admissions study, 129 ADRs were detected in non-oncology patients. 
36.4% of these were possibly or definitely avoidable (Gallagher et al., 2012). If some 
of the ADRs detected were avoidable, this implies that the right intervention at the 
right time would have prevented the ADR. A thorough exploration of avoidable ADR 
cases is needed to inform the development of practical interventions that can be 
 
 
 
177 
 
translated into clinical practice. This work was beyond the scope of this thesis but is 
a logical development of the work completed to date.  In Chapter 5, three main 
avoidability themes were described with inappropriate or suboptimal prescribing 
being the most common theme. Inappropriate or suboptimal prescribing accounted 
for 60% of the ADRs categorised as either possibly or definitely avoidable. Raising 
awareness of ADRs with prescribers and incorporating training in teaching sessions 
at undergraduate and postgraduate levels may help to reduce the number of ADRs. 
This is discussed in more detail in Section 6.3.1 Identification of potentially 
avoidable ADRs and strategies to reduce their incidence. 
 
6.2 Interpretation of findings and limitations 
 
6.2.1 Development of a new avoidability assessment tool 
 
The aim of this study was to develop a new avoidability assessment tool that was 
suitable for use in specialist in-patient paediatrics, was generalisable to other 
settings where the abstract concepts included in the Hallas score are impracticable 
and met all the criteria of a good tool as described by Hakkarainen et al. (2012a). No 
tools were available specifically for characterisation of ADRs in children and 
therefore there was a requirement to develop such tools (Smyth et al. 2012). The 
development of the LAAT was an attempt to improve the assessment of avoidability 
of ADRs in children in paediatric inpatients across all subspecialties of paediatrics. 
Multiple testing phases were conducted. A limitation of this study was the number 
of cases assessed in the different phases with twenty cases being used for some of 
the assessments. This was due to feasibility and time constraints. This resulted in 
the development of a new avoidability assessment tool by a MDT, which we believe 
to be at least equivalent to, if not more appropriate for use in paediatrics than, the 
Hallas scale. The LAAT is practicable and has undergone extensive testing and 
validation. The new tool was used effectively by individuals and by groups. Use by 
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individuals is an advantage as the time constraints and organisational issues 
involved in holding MDT consensus meetings can be challenging at times. 
 
6.2.2 Consensus meetings, individual testing and qualitative work 
 
Chapters 3 and 4 of this thesis investigated if group assessments were superior to 
individual avoidability assessments and explored factors that influenced decision-
making in MDT consensus meetings. A mixed methods approach was taken. 
Quantitative analysis examined the extent to which individuals and groups agreed 
with the ‘gold standard’ as outlined in Chapter 3 and qualitative methods were 
chosen to gain an insight into clinician’s thoughts, experiences and practices in 
relation to the assessment of ADR avoidability, Chapter 4.  
 
Following initial testing of the LAAT with individuals it was decided to investigate if 
group avoidability assessments were superior to individual avoidability 
assessments. It was hypothesised that MDT groups would be superior to individual 
assessments given the nature of the assessments. However, agreement with the 
‘gold standard’ was similar for individuals and groups. In terms of %EA individuals 
had marginally better agreement with the ‘gold standard’ than the consensus 
groups. The cases were informative with marked divergences for some ADR types. 
Possible reasons for divergence might be evidence based, practice based or 
irreducible divergence. The small sample size was a limitation of the study and 
therefore caution should be taken with over interpretation of the data; but the 
divergences show what is possible within overall performance. The LAAT supports 
consistency within a single assessor or group and has face validity for paediatrics. 
 
Clinicians were generally positive about using the tool but there was some 
confusion about concepts and terminology that may need addressing. They seemed 
to rely more on tacit knowledge and experience (either their own or others) than on 
guidelines although, the consensus groups consulted more guidelines than the 
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individuals (or at least those individuals that specified if guidelines were consulted). 
The consensus groups were more inclined to attribute a ‘definitely’ or ‘possibly’ 
avoidable assessment to the cases than the individuals. For some cases there was 
complete agreement between the three consensus groups but disagreement with 
the ‘gold standard’. The groups developed specific heuristics based on the personal 
preferences and group behaviour. 
 
6.2.3 Comparison to existing tools  
 
One of the recommendations by Hakkarainen et al. (2012a) was to compare newly 
developed assessment tools to existing ones so that if one or more tools(s) gained 
rigorous evidence and became a gold standard it would facilitate the comparison of 
different studies. We compared the LAAT to Hallas (1990) for the assessment of the 
ADRIC admissions study ADR cases (Gallagher et al. 2012).  
 
A limitation of this study was that the individual assessment of the cases was done 
using only the LAAT, and not Hallas as well to allow a direct comparison. Secondly, 
the LAAT assessments were conducted by an individual and compared to Hallas 
assessments which were conducted in a group setting. Although the decision to 
conduct the assessments individually was taken after analysis of the work 
conducted in Chapter 3; which showed that there was no real difference between 
individuals or consensus groups in terms of agreement with the ‘gold standard’. 
Therefore, from a practical standpoint it was decided that the cases would be 
assessed individually. This work showed that the LAAT could be used effectively by 
individuals, which is advantageous due to time constraints and the challenge of 
conducting MDT consensus meetings. The data also suggests that the Hallas scale 
(1990) is a suitable alternative tool to use depending on the study population; as 
witnessed from the ADRIC inpatient study, there were difficulties using Hallas due 
to the language used and the nature of prescribing (Thiesen et al. 2013).  
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The assessment of avoidability is complex and subjective which may lead to a 
degree of divergence which is unavoidable. The LAAT aims to minimise subjectivity 
by taking the reviewer through a series of questions but, it is impossible to 
eliminate subjectivity completely as reviewers may differ in their beliefs, experience 
and approach. 
 
6.3 Future considerations - implications for research 
 
ADRs form a large economic and social burden; the application of prevention 
strategies is thus of high importance. Clearly, more research is needed into 
interventions to help reduce the burden of ADRs in children. A thorough exploration 
of avoidable ADR cases could inform the development of practical interventions 
that can be translated into clinical practice. Key to this is the reduction of 
inappropriate or suboptimal prescribing and promotion of appropriate monitoring 
by: incorporating evidence-based updates to guidelines that specifically relate to 
the prevention and management of ADRs. Also there is a need to improve access to 
guidelines as seen in the consensus group meetings in Chapter 3; many clinicians 
had difficulty finding guidelines.  
  
The three reasons for inconsistency suggest that there will always be an irreducible 
lack of consistency during the assessment of whether ADRs are avoidable and these 
factors need to be considered in the design of future studies. The development of 
other assessment tools, and further testing of the LAAT could be done in different 
ways. 
 
This includes: 
 Inclusion of an arm for unstructured assessment of cases in addition the 
existing approach 
 A cross-over design between different approaches to assessment might also 
have been useful  
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 Interview people who were not in groups in order to get feedback on 
individual assessments  
 Use of the LAAT by others outside the ADRIC group 
 
In terms of improving the tool; external validation is the next logical step. External 
validation would ideally include the relevant experts from the different areas; so for 
example anaesthetists could be invited to review the ADR cases related to general 
anaesthetics; including the PONV cases. Consultant oncologists and Specialist 
oncology nurses and pharmacists could be invited to review ADRs related to 
chemotherapy. External validation could also be conducted using a panel of 
reviewers with experience and knowledge of ADRs for example members of the 
Paediatric Medicines Expert Advisory Group or Medical Assessors from the MHRA   
MHRA  which would allow us to test the “utility” of the tool and identify if some of 
the observed difficulties were related to the tool or the types of reviewer. 
 
Another possible study could involve asking reviewers to assess a set of cases for 
avoidability individually prior to attendance at a consensus meeting and to submit 
their assessments in advance of the meeting. The next step would involve 
attendance at a consensus meeting which would be chaired by an external 
moderator; to investigate if the results differed and whether there were examples 
of reviewers changing their minds. IRR testing could be conducted for both phases 
and results compared. 
 
Assessing cases in “real time” and using case notes instead of case reports may give 
a more complete understanding of the situation and a greater awareness of 
contextual factors. For example, BP measurements should be available in “real 
time” assessments and therefore, may reduce the number of “unassessable” cases. 
Conducting prospective assessments using case notes may improve IRR. The 
rationale for using the ADRIC case reports in this work was that the LAAT was a tool 
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being validated to be used in paediatric inpatient avoidability assessments. Future 
work could include the assessment of ADRs prospectively using case notes. 
 
6.3.1 Identification of potentially avoidable ADRs and strategies to reduce 
their incidence 
 
Identification 
One of the objectives of this thesis was to identify potentially avoidable ADRs and 
investigate ways to reduce their incidence. In terms of avoidability, constipation 
was the ADR most frequently categorised as avoidable. The reason for these cases 
being potentially avoidable was that no laxatives were given prophylactically.  
However, there is a lack of evidence in this area. The cases assessed with the LAAT 
were mainly classified as ‘possibly avoidable’ rather than ‘definitely avoidable’ as 
there is not always a guideline available. Other examples of potentially avoidable 
ADRs include immunosuppression, respiratory depression, vomiting and 
hypoglycaemia. Three key themes for avoidability have been established through a 
review of the existing literature (Jonville-Béra et al. 2009, Smyth et al. 2012, 
Gallagher et al. 2012, Temple et al. 2004) the themes are: inappropriate or 
suboptimal prescribing, medication administered to patient with history of ADR and 
Inadequate patient or parent education. 
 
Table 5.4 in Chapter 5 indicates which therapeutic areas may be the most fruitful 
for future research including antibactericals, drugs used in diabetes, drugs used in 
status epilepticus and opioid analgesia. The predominant theme for avoidability was 
inappropriate or suboptimal prescribing in the case of the ADRs involving 
antibactericals there was a question over the indication for antibiotics given the 
evidence of viral illness. The majority of opioid related ADRs were constipation, in 
theory some of these ADRs might be avoidable with clearer guidance on the 
prevention of opioid related constipation and guidance on the co-prescribing of 
laxatives.  
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Potential strategies to avoid or reduce the incidence of ADRs 
Gallagher et al. (2012) suggested some possible prevention strategies including 
improved monitoring, adherence to guidelines and patient education. From the 
assessment of the ADRs in this study the suggested strategies appear to fit with the 
data, further work needs to be done in this area to develop these strategies. Rashed 
et al. (2011) have suggested that knowledge of factors that predispose a patient to 
an ADR is important in the development of prevention strategies. They highlight the 
importance of improving the education of prescribers on identifying risk factors for 
ADRs and the concept of risk benefit assessments before prescribing medicines. This 
is similar to what is suggested by Pirmohamed and Ferner (2003) that educating 
prescribers and increasing patient’s awareness is useful in the prevention of ADRs 
(Pirmohamed, Ferner 2003).  
 
In adults, suggested prevention strategies include: the regular review of 
prescriptions, determining the clinical need for a particular medicine in a patient 
and using the lowest possible dose necessary to achieve benefit, the involvement of 
pharmacists in assessing prescribing behaviour and the use of electronic prescribing 
(Pirmohamed et al. 2008). Also, the work described in Chapters 3 and 4 have 
highlighted the need for improvement in the area of guidelines both in terms of 
accessibility and updates to include information that relates specifically to the 
prevention and management of ADRs.  
 
Improving the practice of history taking and record keeping, educating patients 
and/or parents on their medicine’s and raising awareness of ADRs amongst 
healthcare professionals are just a few examples of potential intervention 
strategies. The advances in technology and the use of Electronic prescribing (EP) 
and Clinical decision support systems (CDSS) could be targeted to help prevent 
ADRs occurring.  Overall, CDSS have shown to reduce the numbers of ADEs 
(Routledge, O'Mahony & Woodhouse 2003, Wiffen et al. 2002). However, they also 
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introduce their own issues such as alert fatigue, sources of potential errors and 
rigidity of systems (Ash et al. 2007). EP has the potential to incorporate guidelines 
or clinical pathways making them more accessible to the prescribing clinician. These 
systems have the ability to prompt prescribers to consider co-prescribing 
prophylactic medicines in certain situations for example antiemetics in PONV or in 
oncology patients. By alerting clinicians to the potential risk of an ADR occurring and 
reminding them to consider appropriate laboratory monitoring (for example U&Es 
for ACE inhibitors) may help prevent ADRs from occurring in the first place or aid in 
the earlier detection of ADRs. However, whilst EP and CDSS have been shown to be 
beneficial they are not entirely perfect systems.  
 
The advances in personalised medicines and pharmacogenomics may represent the 
ultimate method of avoidability. Pharmacogenomics aims to ultimately produce 
tailored medicines regimens based on a patient's genetic characteristics. 
Pharmacogenomic research in paediatric populations is ongoing but there are 
currently few clinical applications in paediatrics. However, there is considerable 
potential to improve the safety profile of medicines used in children (Hawcutt et al. 
2013). The potential impact of personalisation of medicines, improving efficacy and 
reducing the side effects is an exciting area. An example of using 
pharmacogenomics to prevent ADRs in children is the treatment of acute 
lymphoblastic leukaemia (ALL). A pharmacogenetic test to determine the 
metabolism status of thiopurine methyltransferase has been incorporated into the 
treatment protocol (UKALL-2003). This allows patients who are found to be poor 
metabolisers to have their dose of 6-mercaptopurine amended to avoid any 
unwanted accumulation; thereby reducing the incidence of bone marrow toxicity. 
The changes to the guidance on the use of codeine have highlighted the importance 
of pharmacogenomics (Rieder, Carleton 2014). 
 
 
 
 
 
185 
 
Ototoxicity is a well-known ADR to cisplatin, but not all children who receive 
cisplatin will develop hearing loss. There is wide inter-patient variability even within 
standardised treatment regimens (Xu et al. 2015). There have been many studies to 
investigate cisplatin related ototoxicity and many potential candidate genes have 
been investigated but results have been inconsistent. The potential significance of 
identification of these genes could lead to interventions to reduce cisplatin related 
hearing loss and potentially aid in the development of less ototoxic therapies (Xu et 
al. 2015). Two genes which have been previously identified with known variants are 
thiopurine S-methyltransferase (TPMT) and catechol-O-methyltransferase (COMT). 
However there is conflicting evidence on their involvement. A paper published by 
Ross et al. (2009) reported a link between TPMT, COMT and ATP-binding cassette 
transporter C3 (ABCC3) variants and risk of ototoxicity. However, a contradictory 
article was published in 2013 where the authors concluded there was no link with 
genetic variation in COMT or TPMT and hearing loss related to cisplatin (Yang et al. 
2013). Similarly no link was found by other researchers (Xu et al. 2015, Lanvers-
Kaminsky et al. 2014).  
 
Xu et al. (2015) conducted a genome-wide association study (GWAS) and identified 
common variants in ACYP2 which were associated with cisplatin related ototoxicity. 
The study involved 238 children with newly diagnosed brain tumours, they 
identified common variants in ACYP2 that were overrepresented in cisplatin-treated 
children who developed significant hearing loss. They conducted further testing on 
another 68 young children treated for brain tumours to validate their findings. They 
concluded further testing was needed in a larger cohort of patients but the clinical 
usefulness could be examined in future trials especially with a view to developing 
clinical interventions for at risk patients (Xu et al. 2015). Risk profiling children who 
are at increased risk of ADRs may help identify the most susceptible children and 
therefore identify where to focus efforts.  
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As mentioned earlier in Chapter 6, the addition of education sessions on the 
prevention and management of ADRs to undergraduate and postgraduate clinical 
training, or through the design of bespoke training packages may help to raise the 
awareness of ADRs among clinicians. A study conducted in Scotland in 2006 
investigated the clinical pharmacology and therapeutics undergraduate training 
provided to first year foundation (FY1) programme doctors and whether or not this 
prepared doctors to prescribe safely. When asked specifically about ADRs 74% of 
participants reported having witnessed an ADR, of which approximately one third 
thought that the ADRs they had witnessed were both predictable and avoidable. 
Almost half of the participants felt that they had not received adequate training as 
an undergraduate about avoiding ADRs. The findings from this study highlighted the 
need to provide further training in ADRs, drug-drug interactions, contraindications 
and safe and rational use of medicines (Tobaiqy, M., McLay, J., & Ross, S 2007).  
 
The Centre for Pharmacy Postgraduate Education (CPPE) launched an e-learning 
package (a three part series) on ADRs designed to help increase understanding and 
awareness of ADRs, their identification and prevention (CPPE 2014). In 2012 the 
BMJ and MHRA together launched an interactive e-learning module on 
pharmacovigilance free for all healthcare professionals in the UK. The aim of this 
training package was to provide guidance and support for healthcare professionals 
and to provide training on how and when to report ADRs (BMJ Learning 2012). In 
Liverpool a pilot study, randomised controlled trial (RCT) was conducted to test 
whether an e-learning tool which was developed to provide training in the use of 
the Liverpool causality assessment tool (LCAT) improved the ability of medical 
trainees to assign ADR causality using a series of reference ADR cases (Conroy et al. 
2015). 
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Arnott et al. (2012) conducted a qualitative study with parents of children who had 
experienced a suspected ADR to gain some insight into their thoughts and 
experiences. Overall they found communication was poor and parents were 
generally disappointed with how clinicians communicated about suspected ADRs. 
Many parents reported receiving little or no information prior to starting a medicine 
about any potential ADRs which might occur. Consequently parents were often 
surprised when their child experienced a suspected ADR. Parents were concerned 
about their child experiencing ADRs in the future and what steps could be taken to 
prevent a reoccurrence. Parents appeared to undergo a similar process to clinicians 
establishing causality; they showed signs of linking their child’s symptoms to the 
medicines prescribed. Interestingly, they found parents of children with cancer 
were generally highly satisfied with the level of communication provided by 
clinicians (Arnott et al. 2012). Improving patient and parent education by providing 
verbal counselling supported by written information about ADRs; this would inform 
patients about the potential for ADRs, advise them about what to look out for and 
what action to take if an ADR develops. 
 
Arnott et al. (2012) indicated that parents would like to be better informed 
regarding their child’s medicines and any potential side effects; perhaps by 
improving communication and involving parents in their child’s treatment and 
alerting them to possible problems could potentially lead to a reduction in ADRs. 
Parents may be able to recognise ADRs and alert clinicians to their occurrence and 
in the case of previous suspected ADRs they can ensure this has been 
communicated to the clinical team and therefore help prevent the reoccurrence of 
and ADR where their child has a past history. Improved communication and 
documentation in patient records is a simple but effective method of ADR 
reduction. Examples of this were seen in Chapter 5, where a child had a past history 
of the same ADR which could have been potentially avoided on the second occasion 
with improved communication or documentation in the patient’s notes. 
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Simple measures such as regular review of prescriptions, use of electronic 
prescribing, involvement of pharmacists in prescribing may all reduce ADRs (Davies 
et al. 2009). Prescribers should be vigilant for the occurrence of ADRs. The lowest 
possible dose and shortest duration of treatment should be considered. Patients 
should be monitored for ADRs to enable early detection. By involving parents more 
in their child’s treatment and communicating the possibility of ADRs as suggested 
by Arnott et al (2012) may help with early detection of ADRs. 
 
 
6.4 Conclusion 
This thesis has shown that ADRs are a significant problem in children and that 
almost one fifth of them might be avoidable. Thus, 1 in 167 (0.6%) children 
admitted to hospital may have an avoidable ADR based on the figures from the 
ADRIC admissions study (Gallagher et al. 2012). It has highlighted the lack of reliable 
data available on ADRs and their prevention in children. In investigating the 
avoidability of ADRs, this thesis has contributed to the knowledge and highlighted 
the importance of further work being conducted in this area. This thesis has 
identified specific gaps in the literature and indicated key areas for future work.  
 
 
The lack of common definitions (as discussed in Chapters 1 and 2) has caused 
problems in the past for comparison of studies and determining accurate 
avoidability rates (Hakkarainen et al. 2012a, Smyth et al. 2012). The introduction of 
common definitions would be a platform to do more. It would facilitate direct 
comparison of studies and enable a more accurate estimate of ADR avoidability 
rates in children. Educating and training of healthcare professionals at 
undergraduate and postgraduate levels and generally raising the awareness of ADRs 
promoting a culture within NHS and institutions could also potentially reduce the 
number of ADRs.  
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Although the LAAT was designed predominantly as a research tool it could possibly 
be used in other settings. It could potentially be used for organisational change by 
inviting members of the drug and therapeutic committee and senior clinicians with 
experience in the regulatory field to assess the avoidability of a selection of ADR 
case reports using the LAAT to help identify prevention strategies and inform 
change.  
 
In summary, we have designed a novel avoidability assessment tool, developed by a 
MDT approach which has shown that it is comparable to an existing avoidability 
tool, can be used by individuals and most importantly is suitable for use in 
paediatrics or other areas where the clinical conditions extend beyond the expertise 
of individuals.  A more in depth, expert-led review of ADRs and their prevention is 
required. The next step is to design interventions based on the findings in Chapter 5 
(Table 5.4) as outlined in the discussion.  
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Appendix 1 Sample ADR case 
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Appendix 2 Avoidability tool glossary – Liverpool ADR avoidability 
assessment tool glossary 
 
 Known preventative strategies: prophylactic or concomitant medicines or any necessary monitoring. 
 Appropriate management plan(s): a plan that would be recognised as appropriate by a reasonable body of opinion. This 
could refer to any local, national or international guideline that could be available to the prescriber e.g. hospital 
guidelines, National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), 
British thoracic society (BTS), the British society for paediatric and adolescent rheumatology (BSPAR) or World health 
organisation (WHO).  
For example in the case of post-operative nausea and vomiting; examples of appropriate management plans could include: 
Alder Hey Children's NHS Trust guideline on post-operative nausea and vomiting or the association of paediatric anaesthetists 
of Great Britain and Ireland (APA) guideline on the prevention of post-operative vomiting in children. 
 Information about the ADR and its avoidance: does the management plan mention any preventative measures to be 
taken to avoid the ADR including medicines to be given prophylactically or concomitantly or any necessary monitoring 
etc. (electrolytes, FBC or BP)? A management plan may or may not contain information regarding prevention of ADRs 
but more often than not they contain no information regarding the prevention of ADRs. 
 Other information sources: examples include the BNFC (British National Formulary for children), SmPC (Summary of 
Product Characteristics), advice from colleagues, history from the parents/patients or information from a journal article 
etc. (if the prescriber could reasonably be expected to use these sources) 
 Unassessable: the case could not be assessed due to lack of information about the case and/or treatment; or due to 
conflicting information. 
 Not avoidable: the ADR was unavoidable based on the information available at the time of the reaction.  There are four 
scenarios which lead to an ADR being categorised as “not avoidable”  
1. If the reaction was unpredictable and there was no known history of previous similar reaction or allergy to the 
drug. 
2. If there was an appropriate management plan with information about the ADR and its avoidance and it was 
followed. 
3. If there was no appropriate management plan, with information about the ADR and its avoidance available, there 
were no other information sources available to consult and there was no information in the history available for 
prevention of the ADR. 
4. If there was no appropriate management plan, with information about the ADR and its avoidance available but 
there were other information sources available to consult or information in the history available for prevention of 
the ADR and appropriate action was taken to avoid the ADR. 
 Possibly avoidable: there was no appropriate management plan available to follow but there were other information 
sources or information in the history available to prevent the ADR and these were not followed. 
 Definitely avoidable: there were known preventative strategies or an appropriate management plan was available with 
information about the avoidance of the ADR but the strategies and or management plan were not followed. 
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Guide to questions in the avoidability tool 
Is there sufficient information available about the case and the treatment to allow assessment?  
If  the answer is ‘yes’ there is sufficient information available about the case and the treatment then the assessor can proceed 
to the next question if the answer is ‘no’ either due to lack of information or conflicting information the case becomes 
‘unassessable’ (this category may not be assigned until the case has been reviewed and guideline/information sought).  
Was the reaction predictable on the basis of the known pharmacology of the drug(s)? 
This question relates to whether the ADR is predictable on the basis of known pharmacology as there is lots of ‘unknown’ 
pharmacology. If the answer is ‘no’ then you proceed to the question asking if there was a known history of a previous similar 
reaction. If the answer is ‘yes’ then you proceed down the left hand side of the flow diagram where you are asked questions 
regarding availability of appropriate management plans and if they were followed. 
Was there a known history of allergy or previous similar reaction to the drug? 
The purpose of this question is to establish if the patient has experienced a similar reaction in the past and by answering ‘no’ 
to the question takes you to ‘not avoidable’ as for unpredictable reactions where the patient has no previous history of it 
occurring the reaction could not have been prevented on this occasion. In theory this reaction could be avoided in the future. 
Were other information sources, or information in the history available for prevention of the ADR which could have been 
followed? 
This is an important question to establish if there was something else which could have been done to avoid the ADR either by 
consulting a more senior clinician for advice or looking in another reference source; examples include but are not limited to 
BNFC (British National Formulary for children), SmPC (Summary of Product Characteristics), consulting the parents or 
conducting a quick search for journal article etc. if the answer is ‘no’ to this question then the reaction is categorised as ‘not 
avoidable’ if the answer is ‘yes’ you proceed to the next question. 
Was appropriate action taken to avoid the ADR?  
This question allows the reaction to be categorised as ‘not avoidable’ if appropriate action was taken to avoid the ADR but it 
occurred anyway and for cases where other information sources were available but the appropriate action was not taken i.e. 
answering ‘no’ to the question categorises the ADR as ‘possibly avoidable’.   
Were there known preventative strategies and/or appropriate management plan(s), with information about the ADR and 
its avoidance, available?  
This question is designed to establish if there was an appropriate treatment guideline available. This could include any local, 
national or international guideline available to the clinical team when the child was seen e.g. hospital guidelines, NICE 
(National Institute for Health and Clinical Excellence), SIGN (Scottish Intercollegiate Guidelines Network), BTS (British thoracic 
society), WHO (World health organisation). If there was information available on the management of the condition but the 
guidance makes no reference to the ADR or its prevention then by answering ‘no’ to the question you are directed to answer 
the question about whether other information sources were available. This allows for the application of other measures. If the 
answer is ‘yes’ to this question you proceed to the next question below. 
Were the strategies and/or management plan(s) followed? 
If there was an appropriate management plan available and it contained information about the avoidance of the ADR but it 
was not followed this would mean by answering ‘no’ to this question categorises the ADR as ‘definitely avoidable’ if the 
answer is ‘yes’ the drug(s) was used in accordance with the management plan then the ADR is categorised as ‘not avoidable’.  
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Appendix 3 Sample participant information sheets and a copy of the 
consent form 
 
 
 
Participant Information Sheet:  The Development and Testing of the Liverpool Adverse Drug Reaction 
Avoidability Assessment Tool 
 
Thank you for taking time to read this information sheet. You are being invited to take part in a research study. 
Please ask us if there is anything that is not clear in this information sheet or if you would like more information.  
 
Why are we doing this study? 
The aim of this study is to test a new way of determining whether adverse drug reactions are avoidable. The 
Liverpool avoidability assessment tool (LAAT) was developed through the Adverse Drug Reactions in Children 
(ADRIC) research programme. 
 
Why have I been invited? 
You have been invited to participate because you are a clinician (nurse, pharmacist, doctor) working at Alder 
Hey Children’s NHS Foundation Trust.  
 
Do I have to take part? 
No it is your decision entirely. If you decide to take part, you will be given this information sheet to keep and will 
be asked to sign a consent form. You are still free to withdraw from the study at any time and without giving a 
reason.  
 
 
What will taking part involve? 
If you have agreed to take part you will be assigned to either one of the three consensus groups (A/B/C) or to 
the individual assessment group (where reviewers will independently assess the cases). Each consensus group 
will be made up of a multidisciplinary team (nurse, pharmacist, doctor). You will either be required to attend a 
consensus group meeting or to assess the same set of case reports individually.  
 
The consensus meetings will last approximately 2-2.5 hours; during which the group will be asked to look 
through a series of 15 – 20 case reports of adverse drug reactions. The group will be asked to use the LAAT to 
decide whether each adverse drug reaction was avoidable or not. The meetings will be audio-recorded and 
transcribed but all identifiable details will be removed or anonymised.   
 
All participants will also be invited to take part in short interviews (15-20 minutes) after the consensus meetings 
have taken place. The purpose of the interviews is to explore reviewers’ accounts of the consensus meetings. 
The interviews will be conducted by Louise Bracken who will ask you about your experiences of the consensus 
meetings and how useful you found it. If there are any questions you do not want to answer just tell the 
interviewer and she will move to the next topic. You can also stop the interview at any point.  
 
With your agreement we would like to audio-record the interviews.  We will transcribe the interviews and 
anonymise them by removing all identifying details.   
 
 
Do I have to take part?  
No – it is your decision entirely. If you decide to take part, you will be given this information sheet to keep and 
will be asked to sign a consent form. You are still free to withdraw from the study at any time and without giving 
a reason.  
Version 1.2 17/10/13 
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If I am assigned to a consensus group do I have to take part in the post-meeting interviews? 
No –it is your decision entirely. You can choose to only take part in the consensus meetings. If you decide to 
take part   
 
How long will it take? 
We estimate that the consensus group meetings will no more than 2-2.5 hours. There will also be an optional 
debrief session lasting 20 minutes at the end of the meeting. We estimate that the individual assessment of the 
ADR case reports will also take no more than 2.5 hours.  
 
What are the benefits of taking part? 
By taking part, you will help us to assess the utility of the LAAT and if it is useful, the best way use the tool. You 
will have the opportunity to undertake some structured assessments of a series of ADR cases which have 
relevance to paediatric practice. If you would like some feedback about the assessment of ADRs in children this 
will be available during the optional debrief. 
 
How will the data collected about me be stored and used?  
All data collected for this study will be kept safely and securely on computer and on transcribed paper records. 
Dr Mark Turner will be the custodian of all study data. With your permission, study records will be archived and 
stored at Alder Hey Children’s Hospital NHS Foundation Trust for up to 5 years after the end of this study for 
research review purposes. If you do not wish your records to be stored they will be destroyed at the end of the 
current study.       
 
After all identifying details have been removed from the transcribed records of audio-recordings, these will be 
analysed by the study team. The results will be published in reports and scientific journals, but it will not be 
possible to identify any individuals from these reports. We will send you a summary of the results at the end of 
the study if you would like one. 
 
 
What should I do if I am unhappy about the research at any time? If you are unhappy, or if there is a problem, 
please contact Dr Mark Turner by email at mark.turner@liverpool.ac.uk  and he will try to help. If you remain 
unhappy or have a complaint which you feel you cannot bring to us, then you should contact the Research 
Governance Officer on 0151 794 8290 (ethics@liv.ac.uk).  
 
Who can I contact for further information? 
You can contact Louise Bracken by email at louise.bracken@alderhey.nhs.uk  or by phone at 0151 236 4751 or 
alternatively, Dr Mark Turner by email at mark.turner@liverpool.ac.uk  or by phone at 0151 795 9558. 
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PARTICIPANT CONSENT FORM (version 1.2 17/10/13)  
          
        Participant Name                           Date                    Signature 
  
                 
      Name of Investigator                                      Date                   Signature 
 
Supervisor:      Student Researcher: 
Name: Dr Mark Turner     Name: Louise Bracken 
Work Address: Liverpool Women's Hospital   Work Address: Alder Hey Children’s Hospital 
Work telephone: 0151 795 9558    Work telephone: 0151 282 4751   
Work email: mark.turner@liverpool.ac.uk   Work email: louise.bracken@alderhey.nhs.uk 
Title of Research Project:  
The development and testing of the Liverpool adverse drug reaction avoidability 
assessment tool 
 
  
 
 
 
 
Please 
initial 
box 
 
Researcher(s): 
 
1. I confirm that I have read and have understood the information sheet dated 
17/10/13 (version 1.2) for the above study. I have had the opportunity to consider 
the information, ask questions and have had these answered satisfactorily. 
  
 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my rights being affected.   
 
3. I understand that the group consensus meetings will be audio-recorded and  
transcribed and I am aware of and consent to your use of these recordings for the 
following purposes:  brief quotations from the meetings may be included in study 
reports. I understand that nobody will be able to identify any participants in these 
reports. 
 
4. I agree to study records (including transcripts of the consensus meetings and 
interviews) being stored at Alder Hey Children's NHS Trust after the end of this 
study. I understand that these will be held securely and marked with a number 
only.  
 
 
 
 
   
 
5. I understand that, under the Data Protection Act,  I can at any time ask for access 
to the information I provide and I can also request the destruction of that 
information if I wish. 
 
6. I understand that if I am assigned to the consenus group and agree to take part in 
a post-meeting interview that it will be audio-recorded and transcribed  and that 
brief quotations from some interviews may be included in study reports. I 
understand that nobody will be able to identify any participants in these reports 
 
 
 
 
 
7. I agree to take part in the above study.    
 
 
 
 
 
 
208 
 
 
Appendix 4 Feedback Survey- Testing of the Liverpool ADR avoidability 
assessment tool (LAAT) 
 
Please circle your answers. 
 
What is your role?  
 
1. Nurse 
2. Doctor 
3. Pharmacist 
            
   
                       Strongly Agree          Agree   Undecided              Disagree        Strongly Disagree 
================================================================================== 
1. The LAAT was easy    1           2             3               4                           5 
to use. 
 
2. Some questions were                 1         2             3                   4            5 
harder to answer. 
 
3. I would have been able to  1            2              3                   4                           5 
answer all the questions 
by myself ? (n/a to individual  
assessors please skip to  
question  4)    
   
4. It may have been easier to    1           2               3                   4          5 
assess the cases in a group  
setting. (n/a to those  
involved in consensus groups 
please skip to question 5).    
 
 
5. The tool could potentially 1  2             3                   4          5 
have some utility in  
the future .    
 
6. If you have any additional comments to add please write them in the box below. 
 
  
 
 
 
 
 
Thank you for taking part in the study and for completing the feedback survey your contribution is 
much appreciated. 
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  Strongly 
Agree     Agree   Undecided               Disagree 
Strongly 
Disagree  
Doctor 1           
The LAAT was easy to use. 
 
x 
   I found some questions harder to answer (for some questions it was difficult to decide 
between a positive and negative response) x 
    
In some cases it was difficult to judge whether guidelines or information were available 
 
x 
   It may have been easier to assess the cases in a group setting 
   
x 
 The tool could potentially have some utility in the future x 
    Additional comments: none 
     
Doctor 2           
The LAAT was easy to use. 
   
x 
 
I found some questions harder to answer (for some questions it was difficult to decide 
between a positive and negative response) 
 
x 
   
In some cases it was difficult to judge whether guidelines or information were available 
 
x 
   It may have been easier to assess the cases in a group setting 
 
x 
   The tool could potentially have some utility in the future 
  
x 
  
Additional comments: Not always easy to judge if other sources of info are available 
     
Doctor 3           
The LAAT was easy to use. 
 
x 
   
I found some questions harder to answer (for some questions it was difficult to decide 
between a positive and negative response) 
 
x 
   
In some cases it was difficult to judge whether guidelines or information were available 
 
x 
   It may have been easier to assess the cases in a group setting 
  
x 
   x 
    
Appendix 5 Results from the Likert scales- individuals and groups 
Results from the Individuals 
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Results from the Individuals (continued) 
 
Strongly 
Agree     Agree   Undecided               Disagree 
Strongly 
Disagree  
Additional comments: none 
     
Nurse 1           
The LAAT was easy to use. 
 
x 
   I found some questions harder to answer (for some questions it was difficult to decide 
between a positive and negative response) 
 
x 
   In some cases it was difficult to judge whether guidelines or information were available x 
    It may have been easier to assess the cases in a group setting x 
    The tool could potentially have some utility in the future 
 
x 
   Additional comments: none 
     
Nurse 2           
The LAAT was easy to use. 
 
x 
   I found some questions harder to answer (for some questions it was difficult to decide 
between a positive and negative response) 
 
x 
   The tool could potentially have some utility in the future x 
    It may have been easier to assess the cases in a group setting 
  
x 
  The tool could potentially have some utility in the future x 
    Additional comments: none 
     
Nurse 3           
The LAAT was easy to use. 
 
x 
   I found some questions harder to answer (for some questions it was difficult to decide 
between a positive and negative response) x 
    In some cases it was difficult to judge whether guidelines or information were available 
  
x 
  It may have been easier to assess the cases in a group setting x 
    The tool could potentially have some utility in the future x 
    Additional comments: I had to use BNFC, nurse's dictionary & google for clarification of 
drugs and conditions 
     
Pharmacist 1           
The LAAT was easy to use. 
  
x 
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Results from the Individuals (continued) 
 
Strongly 
Agree     Agree   Undecided               Disagree 
Strongly 
Disagree  
I found some questions harder to answer (for some questions it was difficult to decide 
between a positive and negative response) 
 
x 
   
In some cases it was difficult to judge whether guidelines or information were available 
 
x 
   It may have been easier to assess the cases in a group setting x 
    The tool could potentially have some utility in the future 
 
x 
   Additional comments: none 
     Pharmacist 2           
The LAAT was easy to use. x 
    I found some questions harder to answer (for some questions it was difficult to decide 
between a positive and negative response) 
 
x 
   In some cases it was difficult to judge whether guidelines or information were available 
 
x 
   It may have been easier to assess the cases in a group setting 
   
x 
 The tool could potentially have some utility in the future x 
    Additional comments: none 
     Pharmacist 3           
The LAAT was easy to use. x 
    I found some questions harder to answer (for some questions it was difficult to decide 
between a positive and negative response) 
   
x 
 In some cases it was difficult to judge whether guidelines or information were available 
   
x 
 It may have been easier to assess the cases in a group setting 
  
x 
  The tool could potentially have some utility in the future 
 
x 
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Result from the Likert scale – Consensus groups 
 
  
Strongly 
Agree     Agree   Undecided               Disagree 
Strongly 
Disagree  
Pharmacist 04/02           
The LAAT was easy to use 
 
x 
   I found some questions harder to answer (for some questions it was difficult to decide between a positive and 
negative response) x 
    In some cases it was difficult to judge whether guidelines or information were available 
 
x 
   I would have been able to answer all the questions by myself 
 
x 
   The tool could potentially have some utility in the future 
 
x 
   Other comments: Sometimes difficult to assess if a 'management plan' was adhered to! 
     Pharmacist 10/02      
The LAAT was easy to use 
 
x 
   I found some questions harder to answer (for some questions it was difficult to decide between a positive and 
negative response) 
 
x 
   In some cases it was difficult to judge whether guidelines or information were available 
 
x 
   I would have been able to answer all the questions by myself 
  
x 
  The tool could potentially have some utility in the future x 
    Other comments: none 
     Pharmacist 26/02           
The LAAT was easy to use 
  
x 
  I found some questions harder to answer (for some questions it was difficult to decide between a positive and 
negative response) 
 
x 
   In some cases it was difficult to judge whether guidelines or information were available 
 
x 
   I would have been able to answer all the questions by myself 
   
x 
 The tool could potentially have some utility in the future 
  
x 
  Other comments: Perhaps the tool would have future potential value with modification to include 
consideration of ADR and deliberate decision to proceed in a certain cause of action. 
     Nurse 04/02      
The LAAT was easy to use 
 
x 
   I found some questions harder to answer (for some questions it was difficult to decide between a positive and 
negative response) x 
    In some cases it was difficult to judge whether guidelines or information were available 
 
x 
   I would have been able to answer all the questions by myself 
  
x 
  The tool could potentially have some utility in the future 
 
x 
   Other comments: none 
     Nurse 10/02      
The LAAT was easy to use 
 
x 
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Results from the Groups (continued) 
Strongly 
Agree     Agree   Undecided               Disagree 
Strongly 
Disagree  
In some cases it was difficult to judge whether guidelines or information were available 
 
x 
   I would have been able to answer all the questions by myself 
  
x 
  The tool could potentially have some utility in the future x 
    Other comments: none 
     Nurse 26/02      
The LAAT was easy to use 
  
x 
  I found some questions harder to answer (for some questions it was difficult to decide between a positive and 
negative response) 
 
x 
   
In some cases it was difficult to judge whether guidelines or information were available 
 
x 
   I would have been able to answer all the questions by myself 
   
x 
 The tool could potentially have some utility in the future 
 
x 
   Other comments:  with some ADRs it was difficult to decide as there could be more than one route. 
     Doctor 04/02      
The LAAT was easy to use 
 
x 
   I found some questions harder to answer (for some questions it was difficult to decide between a positive and 
negative response) 
 
x 
   In some cases it was difficult to judge whether guidelines or information were available 
 
x 
   I would have been able to answer all the questions by myself 
 
x 
   The tool could potentially have some utility in the future x 
    Other comments: Useful tool 
     Doctor 10/02           
The LAAT was easy to use 
 
x 
   I found some questions harder to answer (for some questions it was difficult to decide between a positive and 
negative response) 
 
x 
   In some cases it was difficult to judge whether guidelines or information were available 
   
x 
 I would have been able to answer all the questions by myself 
   
x 
 The tool could potentially have some utility in the future 
 
x 
   Other comments: none 
     Doctor 26/02           
The LAAT was easy to use 
 
x 
   I found some questions harder to answer (for some questions it was difficult to decide between a positive and 
negative response) x 
    In some cases it was difficult to judge whether guidelines or information were available x 
    I would have been able to answer all the questions by myself 
  
x 
  The tool could potentially have some utility in the future x 
    Other comments: Was appropriate action taken box- should include addendum to detail that side effect/ADR 
was considered but that benefit to patient outweighed risk. Were there known preventative strategies box 
should include footnote to list considerable guidance e.g. protocols/NICE guidance/Journal 
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Appendix 6 Interview topic guide 
 
1. General professional background 
 Role 
 Grade  
 How long since registration? 
 How long have you been working in paediatrics? 
 Any specialty? 
2. Could you describe what you understand by avoidability of ADRs?  
3. What is your understanding of an ADR?  
 Could you describe an ADR? (prompt question could be how do you think ADRs are 
different from Adverse drug events or errors?) 
May not need to ask next question depending on answer to question 3 
What is your experience of ADRs in children? 
 Prompt question: could you give me a general example of an ADR? 
4. What is your first impression of the LAAT after using it (today/yesterday etc.)? 
5. How did you find being part of a group? 
6. Were there any advantages of being in a group, if yes what were these? 
7. Were there any disadvantages of being in a group, if yes what were these? 
8. Do you think you would have reached the same conclusions on your own? 
9. Would you feel confident doing the ADR assessments on your own? 
10. How do you think the tool could be used in the future? 
11. Is there anything we haven’t spoken about in the interview that you’d like to add? 
Other useful questions if want more information: can you expand on that please? 
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Appendix 7 Coding Framework 
 
Broad themes for qualitative analysis 
Conceptual awareness 
 Terminology 
 Use and application of terms such as errors/ADEs/ADRs 
 Use and application of terms such as avoidability, prevention, risk etc. 
 
Clinical knowledge 
 Knowledge and experience of ADRs 
 Examples of ADRs 
 Any reference to specific medicines, ADRs, ADEs etc. 
 
Perceptions of groups versus individuals 
 Perceived values of groups 
 Confidence/reassurance 
 Areas of expertise/specialty  
 Advantages/disadvantages 
 Power 
 MDT 
 Information sources 
 
Perceptions of the tool 
 Ease of use 
 Initial impression 
 Possible applications 
 
Engagement with the tool 
 Evidence of  engagement with the tool e.g. through unprompted  reference to 
aspects of the  tool; giving examples of application or perceived value or future use 
of the tool;  ability to converse with the researcher about the tool and demonstrate 
an awareness key aspects of the tool. 
 Compare characteristics seniority/ profession etc. 
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Coding framework 
Participants’ data analysis 
 
Participants   
Nurses (n=3) 
Doctors (n=3) 
Pharmacists (n=2) 
 
Initial/open coding  Emerging themes Final coding and themes 
Participant’s knowledge 
about ADRs/clinical 
knowledge  
 Drawing on own knowledge and 
experience of ADRs 
 Refer back to examples of ADRs 
 Makes references to specific 
medicines  
 Clinicians don’t always use 
guidelines. Guidelines - using 
them/finding them 
Rely on own tacit knowledge. 
Reluctant to search for and use 
existing guidelines.  
Rely on personal previous 
experience of ADRs. 
Perceptions rooted in personal 
clinical experience.  
Awareness and familiarity 
with terminology 
Conceptual awareness 
 Interchangeable use and 
application of terms such as 
errors/ADEs 
 Interchangeable use and 
application of terms such as 
avoidability, prevention and risk 
Confusion about terminology.  
 
Groups/MDT appreciation 
of other members 
expertise and contribution 
to the process 
 Perceived values of groups 
 Confidence/reassurance 
 Dependency 
 Areas of expertise/specialty 
 Advantages/disadvantages 
 Power 
 MDT 
 Judgement – appraising 
judgement 
 Information sources 
Perceptions of groups versus 
individuals.  
Clinicians were generally 
positive about assessing cases 
within a group and could see a 
number of advantages to 
working within an MDT.   
Clinicians especially valued 
access to expertise. 
They felt working as an MDT 
speeded up decision making 
and promoted more balanced 
decisions.  
Reduced feelings of blame and 
judgement. 
 
How clinicians perceive 
the tool 
 Ease of use 
 Initial impression 
 Possible applications 
 Context specific 
Perceptions of the tool. 
Clinicians were generally 
positive about the tool and 
could see how it could be used 
in practice. 
One clinician commented that 
the tool could promote self-
reflective practice. 
How clinicians engaged 
with the tool 
 Future use and perceived value 
 Compare characteristics 
seniority/profession etc. 
 
Engagement with the tool 
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Appendix 8 Final version of the Liverpool ADR avoidability assessment 
tool glossary 
 
 Known preventative strategies: prophylactic or concomitant medicines or any necessary monitoring. 
 
 Appropriate management plan(s): a plan that would be recognised as appropriate by a reasonable body of 
opinion. This could refer to any local, national or international guideline that could be available to the 
prescriber e.g. hospital guidelines, National Institute for Health and Care Excellence (NICE), Scottish 
Intercollegiate Guidelines Network (SIGN), British thoracic society (BTS), the British society for paediatric 
and adolescent rheumatology (BSPAR) or World health organisation (WHO) or a ‘personalised management 
plan’. 
For example in the case of post-operative nausea and vomiting; examples of appropriate management 
plans could include: Alder Hey Children's NHS Trust guideline on post-operative nausea and vomiting or the 
association of paediatric anaesthetists of Great Britain and Ireland (APA) guideline on the prevention of 
post-operative vomiting in children. 
 
 Information about the ADR and its avoidance: does the management plan mention any preventative 
measures to be taken to avoid the ADR including medicines to be given prophylactically or concomitantly 
or any necessary monitoring etc. (electrolytes, FBC or BP)? A management plan may or may not contain 
information regarding prevention of ADRs but more often than not they contain no information regarding 
the prevention of ADRs. 
 
 Other information sources: examples include the BNFC (British National Formulary for children), SmPC 
(Summary of Product Characteristics), advice from colleagues, history from the parents/patients or 
information from a journal article etc. (if the prescriber could reasonably be expected to use these sources) 
 
 Unassessable: the case could not be assessed due to lack of information about the case and/or treatment; 
or due to conflicting information. 
 
 Not avoidable: the ADR was unavoidable based on the information available at the time of the reaction.  
There are four scenarios which lead to an ADR being categorised as “not avoidable”  
1. If the reaction was unpredictable and there was no known history of previous similar reaction or 
allergy to the drug. 
2. If there was an appropriate management plan with information about the ADR and its avoidance and 
it was followed. 
3. If there was no appropriate management plan, with information about the ADR and its avoidance 
available, there were no other information sources available to consult and there was no information 
in the history available for prevention of the ADR. 
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4. If there was no appropriate management plan, with information about the ADR and its avoidance 
available but there were other information sources available to consult or information in the history 
available for prevention of the ADR and appropriate action was taken to avoid the ADR. 
 Possibly avoidable: there was no appropriate management plan available to follow but there were other 
information sources or information in the history available to prevent the ADR and these were not 
followed. 
 
 Definitely avoidable: there were known preventative strategies or an appropriate management plan was 
available with information about the avoidance of the ADR but the strategies and or management plan 
were not followed. 
 
Guide to questions in the avoidability tool 
Is there sufficient information available about the case and the treatment to allow assessment?  
If  the answer is ‘yes’ there is sufficient information available about the case and the treatment then the 
assessor can proceed to the next question if the answer is ‘no’ either due to lack of information or conflicting 
information the case becomes ‘unassessable’ (this category may not be assigned until the case has been 
reviewed and guideline/information sought).  
 
Was the reaction predictable on the basis of the known pharmacology of the drug(s)? 
This question relates to whether the ADR is predictable on the basis of known pharmacology as there is lots of 
‘unknown’ pharmacology. If the answer is ‘no’ then you proceed to the question asking if there was a known 
history of a previous similar reaction. If the answer is ‘yes’ then you proceed down the left hand side of the flow 
diagram where you are asked questions regarding availability of appropriate management plans and if they 
were followed. 
 
Was there a known history of allergy or previous similar reaction to the drug? 
The purpose of this question is to establish if the patient has experienced a similar reaction in the past and by 
answering ‘no’ to the question takes you to ‘not avoidable’ as for unpredictable reactions where the patient has 
no previous history of it occurring the reaction could not have been prevented on this occasion. In theory this 
reaction could be avoided in the future. 
 
Were other information sources, or information in the history available for prevention of the ADR which 
could have been followed? 
This is an important question to establish if there was something else which could have been done to avoid the 
ADR either by consulting a more senior clinician for advice or looking in another reference source; examples 
include but are not limited to BNFC (British National Formulary for children), SmPC (Summary of Product 
Characteristics), consulting the parents or conducting a quick search for journal article etc. if the answer is ‘no’ 
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to this question then the reaction is categorised as ‘not avoidable’ if the answer is ‘yes’ you proceed to the next 
question. 
Was appropriate action taken to avoid the ADR?  
This question allows the reaction to be categorised as ‘not avoidable’ if appropriate action was taken to avoid 
the ADR but it occurred anyway and for cases where other information sources were available but the 
appropriate action was not taken i.e. answering ‘no’ to the question categorises the ADR as ‘possibly avoidable’.   
 
 
Were there known preventative strategies and/or appropriate management plan(s), with information about 
the ADR and its avoidance, available?  
This question is designed to establish if there was an appropriate treatment guideline available. This could 
include any local, national or international guideline available to the clinical team when the child was seen e.g. 
hospital guidelines, NICE (National Institute for Health and Clinical Excellence), SIGN (Scottish Intercollegiate 
Guidelines Network), BTS (British thoracic society), WHO (World health organisation). If there was information 
available on the management of the condition but the guidance makes no reference to the ADR or its 
prevention then by answering ‘no’ to the question you are directed to answer the question about whether 
other information sources were available. This allows for the application of other measures. If the answer is 
‘yes’ to this question you proceed to the next question below. 
Were the strategies and/or management plan(s) followed? 
If there was an appropriate management plan available and it contained information about the avoidance of the 
ADR but it was not followed this would mean by answering ‘no’ to this question categorises the ADR as 
‘definitely avoidable’ if the answer is ‘yes’ the drug(s) was used in accordance with the management plan then 
the ADR is categorised as ‘not avoidable’. 
 
 
 
 
 
 
 
 
 
 
 
